



US 20060292670A1

(19) **United States**

(12) **Patent Application Publication**
Ting et al.

(10) **Pub. No.: US 2006/0292670 A1**

(43) **Pub. Date: Dec. 28, 2006**

(54) **NELL PEPTIDE EXPRESSION SYSTEMS
AND BONE FORMATION ACTIVITY OF
NELL PEPTIDE**

Related U.S. Application Data

(60) Provisional application No. 60/445,672, filed on Feb. 7, 2003.

(75) Inventors: **Kang Ting**, Beverly Hills, CA (US);
Shunichi Kuroda, Osaka (JP); **Ben
Wu**, Los Angeles, CA (US)

(30) **Foreign Application Priority Data**

Sep. 9, 2003 (WO)..... PCT/US03/28281

Correspondence Address:
SQUIRE, SANDERS & DEMPSEY L.L.P.
1 MARITIME PLAZA, SUITE 300
SAN FRANCISCO, CA 94111 (US)

Publication Classification

(51) **Int. Cl.**
C12P 21/06 (2006.01)
C07K 14/705 (2006.01)
C07H 21/04 (2006.01)
C12N 5/06 (2006.01)
(52) **U.S. Cl.** **435/69.1**; 435/455; 435/348;
530/350; 536/23.5

(73) Assignee: **THE REGENTS OF THE UNIVER-
SITY OF CALIFORNIA**, Oakland, CA
(US)

(57) **ABSTRACT**

The invention generally relates to a bone growth factor, and more particularly to compositions including NELL1, articles of manufacture including NELL1 and methods of using NELL1 to induce bone formation. This invention also provides methods for the expression and purification of NELL1 and NELL2 peptides.

(21) Appl. No.: **10/544,553**

(22) PCT Filed: **Feb. 9, 2004**

(86) PCT No.: **PCT/US04/03808**

atg ccg atg gat ttg att tta gtt gtg tgg ttc tgt gtg tgc act gcc	48
Met Pro Met Asp Leu Ile Leu Val Val Trp Phe Cys Val Cys Thr Ala	
1 5 10 15	
agg aca gtg gtg ggc ttt ggg atg gac cct gac ctt cag atg gat atc	96
Arg Thr Val Val Gly Phe Gly Met Asp Pro Asp Leu Gln Met Asp Ile	
20 25 30	
gtc acc gag ctt gac ctt gtg aac acc acc ctt gga gtt gct cag gtg	144
Val Thr Glu Leu Asp Leu Val Asn Thr Thr Leu Gly Val Ala Gln Val	
35 40 45	
tct gga atg cac aat gcc agc aaa gca ttt tta ttt caa gac ata gaa	192
Ser Gly Met His Asn Ala Ser Lys Ala Phe Leu Phe Gln Asp Ile Glu	
50 55 60	
aga gag atc cat gca gct cct cat gtg agt gag aaa tta att cag ctg	240
Arg Glu Ile His Ala Ala Pro His Val Ser Glu Lys Leu Ile Gln Leu	
65 70 75 80	
ttc cag aac aag agt gaa ttc acc att ttg gcc act gta cag cag aag	288
Phe Gln Asn Lys Ser Glu Phe Thr Ile Leu Ala Thr Val Gln Gln Lys	
85 90 95	
cca tcc act tca gga gtg ata ctg tcc att cga gaa ctg gag cac agc	336
Pro Ser Thr Ser Gly Val Ile Leu Ser Ile Arg Glu Leu Glu His Ser	
100 105 110	
tat ttt gaa ctg gag agc agt ggc ctg agg gat gag att cgg tat cac	384
Tyr Phe Glu Leu Glu Ser Ser Gly Leu Arg Asp Glu Ile Arg Tyr His	
115 120 125	
tac ata cac aat ggg aag cca agg aca gag gca ctt cct tac cgc atg	432
Tyr Ile His Asn Gly Lys Pro Arg Thr Glu Ala Leu Pro Tyr Arg Met	
130 135 140	
gca gat gga caa tgg cac aag gtt gca ctg tca gtt agc gcc tct cat	480
Ala Asp Gly Gln Trp His Lys Val Ala Leu Ser Val Ser Ala Ser His	
145 150 155 160	
ctc ctg ctc cat gtc gac tgt aac agg att tat gag cgt gtg ata gac	528
Leu Leu Leu His Val Asp Cys Asn Arg Ile Tyr Glu Arg Val Ile Asp	
165 170 175	
cct cca gat acc aac ctt ccc cca gga atc aat tta tgg ctt ggc cag	576
Pro Pro Asp Thr Asn Leu Pro Pro Gly Ile Asn Leu Trp Leu Gly Gln	
180 185 190	
cgc aac caa aag cat ggc tta ttc aaa ggg atc atc caa gat ggg aag	624
Arg Asn Gln Lys His Gly Leu Phe Lys Gly Ile Ile Gln Asp Gly Lys	
195 200 205	
atc atc ttt atg ccg aat gga tat ata aca cag tgt cca aat cta aat	672
Ile Ile Phe Met Pro Asn Gly Tyr Ile Thr Gln Cys Pro Asn Leu Asn	
210 215 220	

FIGURE 1A

cac act tgc cca acc tgc agt gat ttc tta agc ctg gtg caa gga ata	720
His Thr Cys Pro Thr Cys Ser Asp Phe Leu Ser Leu Val Gln Gly Ile	
225 230 235 240	
atg gat tta caa gag ctt ttg gcc aag atg act gca aaa cta aat tat	768
Met Asp Leu Gln Glu Leu Leu Ala Lys Met Thr Ala Lys Leu Asn Tyr	
245 250 255	
gca gag aca aga ctt agt caa ttg gaa aac tgt cat tgt gag aag act	816
Ala Glu Thr Arg Leu Ser Gln Leu Glu Asn Cys His Cys Glu Lys Thr	
260 265 270	
tgt caa gtg agt gga ctg ctc tat cga gat caa gac tct tgg gta gat	864
Cys Gln Val Ser Gly Leu Leu Tyr Arg Asp Gln Asp Ser Trp Val Asp	
275 280 285	
ggt gac cat tgc agg aac tgc act tgc aaa agt ggt gcc gtg gaa tgc	912
Gly Asp His Cys Arg Asn Cys Thr Cys Lys Ser Gly Ala Val Glu Cys	
290 295 300	
cga agg atg tcc tgt ccc cct ctc aat tgc tcc cca gac tcc ctc cca	960
Arg Arg Met Ser Cys Pro Pro Leu Asn Cys Ser Pro Asp Ser Leu Pro	
305 310 315 320	
gta cac att gct ggc cag tgc tgt aag gtc tgc cga cca aaa tgt atc	1008
Val His Ile Ala Gly Gln Cys Cys Lys Val Cys Arg Pro Lys Cys Ile	
325 330 335	
tat gga gga aaa gtt ctt gca gaa ggc cag cgg att tta acc aag agc	1056
Tyr Gly Gly Lys Val Leu Ala Glu Gly Gln Arg Ile Leu Thr Lys Ser	
340 345 350	
tgt cgg gaa tgc cga ggt gga gtt tta gta aaa att aca gaa atg tgt	1104
Cys Arg Glu Cys Arg Gly Gly Val Leu Val Lys Ile Thr Glu Met Cys	
355 360 365	
cct cct ttg aac tgc tca gaa aag gat cac att ctt cct gag aat cag	1152
Pro Pro Leu Asn Cys Ser Glu Lys Asp His Ile Leu Pro Glu Asn Gln	
370 375 380	
tgc tgc cgt gtc tgt aga ggt cat aac ttt tgt gca gaa gga cct aaa	1200
Cys Cys Arg Val Cys Arg Gly His Asn Phe Cys Ala Glu Gly Pro Lys	
385 390 395 400	
tgt ggt gaa aac tca gag tgc aaa aac tgg aat aca aaa gct act tgt	1248
Cys Gly Glu Asn Ser Glu Cys Lys Asn Trp Asn Thr Lys Ala Thr Cys	
405 410 415	
gag tgc aag agt ggt tac atc tct gtc cag gga gac tct gcc tac tgt	1296
Glu Cys Lys Ser Gly Tyr Ile Ser Val Gln Gly Asp Ser Ala Tyr Cys	
420 425 430	
gaa gat att gat gag tgt gca gct aag atg cat tac tgt cat gcc aat	1344
Glu Asp Ile Asp Glu Cys Ala Ala Lys Met His Tyr Cys His Ala Asn	
435 440 445	

FIGURE 1B

act	gtg	tgt	gtc	aac	ctt	cct	ggg	tta	tat	cgc	tgt	gac	tgt	gtc	cca	1392
Thr	Val	Cys	Val	Asn	Leu	Pro	Gly	Leu	Tyr	Arg	Cys	Asp	Cys	Val	Pro	
450						455					460					
gga	tac	att	cgt	gtg	gat	gac	ttc	tct	tgt	aca	gaa	cac	gat	gaa	tgt	1440
Gly	Tyr	Ile	Arg	Val	Asp	Asp	Phe	Ser	Cys	Thr	Glu	His	Asp	Glu	Cys	
465					470					475					480	
ggc	agc	ggc	cag	cac	aac	tgt	gat	gag	aat	gcc	atc	tgc	acc	aac	act	1488
Gly	Ser	Gly	Gln	His	Asn	Cys	Asp	Glu	Asn	Ala	Ile	Cys	Thr	Asn	Thr	
				485					490					495		
gtc	cag	gga	cac	agc	tgc	acc	tgc	aaa	ccg	ggc	tac	gtg	ggg	aac	ggg	1536
Val	Gln	Gly	His	Ser	Cys	Thr	Cys	Lys	Pro	Gly	Tyr	Val	Gly	Asn	Gly	
			500					505					510			
acc	atc	tgc	aga	gct	ttc	tgt	gaa	gag	ggc	tgc	aga	tac	ggt	gga	acg	1584
Thr	Ile	Cys	Arg	Ala	Phe	Cys	Glu	Glu	Gly	Cys	Arg	Tyr	Gly	Gly	Thr	
		515					520					525				
tgt	gtg	gct	ccc	aac	aaa	tgt	gtc	tgt	cca	tct	gga	ttc	aca	gga	agc	1632
Cys	Val	Ala	Pro	Asn	Lys	Cys	Val	Cys	Pro	Ser	Gly	Phe	Thr	Gly	Ser	
	530					535					540					
cac	tgc	gag	aaa	gat	att	gat	gaa	tgt	tca	gag	gga	atc	att	gag	tgc	1680
His	Cys	Glu	Lys	Asp	Ile	Asp	Glu	Cys	Ser	Glu	Gly	Ile	Ile	Glu	Cys	
545					550					555					560	
cac	aac	cat	tcc	cgc	tgc	ggt	aac	ctg	cca	ggg	tgg	tac	cac	tgt	gag	1728
His	Asn	His	Ser	Arg	Cys	Val	Asn	Leu	Pro	Gly	Trp	Tyr	His	Cys	Glu	
				565					570					575		
tgc	aga	agc	ggt	ttc	cat	gac	gat	ggg	acc	tat	tca	ctg	tcc	ggg	gag	1776
Cys	Arg	Ser	Gly	Phe	His	Asp	Asp	Gly	Thr	Tyr	Ser	Leu	Ser	Gly	Glu	
			580					585					590			
tcc	tgt	att	gac	att	gat	gaa	tgt	gcc	tta	aga	act	cac	acc	tgt	tgg	1824
Ser	Cys	Ile	Asp	Ile	Asp	Glu	Cys	Ala	Leu	Arg	Thr	His	Thr	Cys	Trp	
		595				600						605				
aac	gat	tct	gcc	tgc	atc	aac	ctg	gca	ggg	ggt	ttt	gac	tgt	ctc	tgc	1872
Asn	Asp	Ser	Ala	Cys	Ile	Asn	Leu	Ala	Gly	Gly	Phe	Asp	Cys	Leu	Cys	
	610					615					620					
ccc	tct	ggg	ccc	tcc	tgc	tct	ggt	gac	tgt	cct	cat	gaa	ggg	ggg	ctg	1920
Pro	Ser	Gly	Pro	Ser	Cys	Ser	Gly	Asp	Cys	Pro	His	Glu	Gly	Gly	Leu	
625					630					635					640	
aag	cac	aat	ggc	cag	gtg	tgg	acc	ttg	aaa	gaa	gac	agg	tgt	tct	gtc	1968
Lys	His	Asn	Gly	Gln	Val	Trp	Thr	Leu	Lys	Glu	Asp	Arg	Cys	Ser	Val	
				645					650					655		
tgc	tcc	tgc	aag	gat	ggc	aag	ata	ttc	tgc	cga	cgg	aca	gct	tgt	gat	2016
Cys	Ser	Cys	Lys	Asp	Gly	Lys	Ile	Phe	Cys	Arg	Arg	Thr	Ala	Cys	Asp	
			660					665					670			

FIGURE 1C

aga gtc aca agt caa tgt tta gac caa aat ggt cac aag ctg tat cga	2112
Arg Val Thr Ser Gln Cys Leu Asp Gln Asn Gly His Lys Leu Tyr Arg	
690 695 700	
agt gga gac aat tgg acc cat agc tgt cag cag tgt cgg tgt ctg gaa	2160
Ser Gly Asp Asn Trp Thr His Ser Cys Gln Gln Cys Arg Cys Leu Glu	
705 710 715 720	
gga gag gta gat tgc tgg cca ctc act tgc ccc aac ttg agc tgt gag	2208
Gly Glu Val Asp Cys Trp Pro Leu Thr Cys Pro Asn Leu Ser Cys Glu	
725 730 735	
tat aca gct atc tta gaa ggg gaa tgt tgt ccc cgc tgt gtc agt gac	2256
Tyr Thr Ala Ile Leu Glu Gly Glu Cys Cys Pro Arg Cys Val Ser Asp	
740 745 750	
ccc tgc cta gct gat aac atc acc tat gac atc aga aaa act tgc ctg	2304
Pro Cys Leu Ala Asp Asn Ile Thr Tyr Asp Ile Arg Lys Thr Cys Leu	
755 760 765	
gac agc tat ggt gtt tca cgg ctt agt ggc tca gtg tgg acg atg gct	2352
Asp Ser Tyr Gly Val Ser Arg Leu Ser Gly Ser Val Trp Thr Met Ala	
770 775 780	
gga tct ccc tgc aca acc tgt aaa tgc aag aat gga aga gtc tgt tgt	2400
Gly Ser Pro Cys Thr Thr Cys Lys Cys Lys Asn Gly Arg Val Cys Cys	
785 790 795 800	
tct gtg gat ttt gag tgt ctt caa aat aat tga	2433
Ser Val Asp Phe Glu Cys Leu Gln Asn Asn *	
805 810	

FIGURE 1D

Met Pro Met Asp Leu Ile Leu Val Val Trp Phe Cys Val Cys Thr Ala
 1 5 10 15
 Arg Thr Val Val Gly Phe Gly Met Asp Pro Asp Leu Gln Met Asp Ile
 20 25 30
 Val Thr Glu Leu Asp Leu Val Asn Thr Thr Leu Gly Val Ala Gln Val
 35 40 45
 Ser Gly Met His Asn Ala Ser Lys Ala Phe Leu Phe Gln Asp Ile Glu
 50 55 60
 Arg Glu Ile His Ala Ala Pro His Val Ser Glu Lys Leu Ile Gln Leu
 65 70 75 80
 Phe Gln Asn Lys Ser Glu Phe Thr Ile Leu Ala Thr Val Gln Gln Lys
 85 90 95
 Pro Ser Thr Ser Gly Val Ile Leu Ser Ile Arg Glu Leu Glu His Ser
 100 105 110
 Tyr Phe Glu Leu Glu Ser Ser Gly Leu Arg Asp Glu Ile Arg Tyr His
 115 120 125
 Tyr Ile His Asn Gly Lys Pro Arg Thr Glu Ala Leu Pro Tyr Arg Met
 130 135 140
 Ala Asp Gly Gln Trp His Lys Val Ala Leu Ser Val Ser Ala Ser His
 145 150 155 160
 Leu Leu Leu His Val Asp Cys Asn Arg Ile Tyr Glu Arg Val Ile Asp
 165 170 175
 Pro Pro Asp Thr Asn Leu Pro Pro Gly Ile Asn Leu Trp Leu Gly Gln
 180 185 190
 Arg Asn Gln Lys His Gly Leu Phe Lys Gly Ile Ile Gln Asp Gly Lys
 195 200 205
 Ile Ile Phe Met Pro Asn Gly Tyr Ile Thr Gln Cys Pro Asn Leu Asn
 210 215 220
 His Thr Cys Pro Thr Cys Ser Asp Phe Leu Ser Leu Val Gln Gly Ile
 225 230 235 240
 Met Asp Leu Gln Glu Leu Leu Ala Lys Met Thr Ala Lys Leu Asn Tyr
 245 250 255
 Ala Glu Thr Arg Leu Ser Gln Leu Glu Asn Cys His Cys Glu Lys Thr
 260 265 270
 Cys Gln Val Ser Gly Leu Leu Tyr Arg Asp Gln Asp Ser Trp Val Asp
 275 280 285
 Gly Asp His Cys Arg Asn Cys Thr Cys Lys Ser Gly Ala Val Glu Cys
 290 295 300
 Arg Arg Met Ser Cys Pro Pro Leu Asn Cys Ser Pro Asp Ser Leu Pro
 305 310 315 320
 Val His Ile Ala Gly Gln Cys Cys Lys Val Cys Arg Pro Lys Cys Ile
 325 330 335
 Tyr Gly Gly Lys Val Leu Ala Glu Gly Gln Arg Ile Leu Thr Lys Ser
 340 345 350
 Cys Arg Glu Cys Arg Gly Gly Val Leu Val Lys Ile Thr Glu Met Cys
 355 360 365
 Pro Pro Leu Asn Cys Ser Glu Lys Asp His Ile Leu Pro Glu Asn Gln
 370 375 380
 Cys Cys Arg Val Cys Arg Gly His Asn Phe Cys Ala Glu Gly Pro Lys
 385 390 395 400
 Cys Gly Glu Asn Ser Glu Cys Lys Asn Trp Asn Thr Lys Ala Thr Cys
 405 410 415
 Glu Cys Lys Ser Gly Tyr Ile Ser Val Gln Gly Asp Ser Ala Tyr Cys
 420 425 430
 Glu Asp Ile Asp Glu Cys Ala Ala Lys Met His Tyr Cys His Ala Asn
 435 440 445
 Thr Val Cys Val Asn Leu Pro Gly Leu Tyr Arg Cys Asp Cys Val Pro
 450 455 460

FIGURE 2A

Gly	Tyr	Ile	Arg	Val	Asp	Asp	Phe	Ser	Cys	Thr	Glu	His	Asp	Glu	Cys
465					470					475					480
Gly	Ser	Gly	Gln	His	Asn	Cys	Asp	Glu	Asn	Ala	Ile	Cys	Thr	Asn	Thr
				485					490						495
Val	Gln	Gly	His	Ser	Cys	Thr	Cys	Lys	Pro	Gly	Tyr	Val	Gly	Asn	Gly
			500					505						510	
Thr	Ile	Cys	Arg	Ala	Phe	Cys	Glu	Glu	Gly	Cys	Arg	Tyr	Gly	Gly	Thr
		515					520						525		
Cys	Val	Ala	Pro	Asn	Lys	Cys	Val	Cys	Pro	Ser	Gly	Phe	Thr	Gly	Ser
	530					535					540				
His	Cys	Glu	Lys	Asp	Ile	Asp	Glu	Cys	Ser	Glu	Gly	Ile	Ile	Glu	Cys
545					550					555					560
His	Asn	His	Ser	Arg	Cys	Val	Asn	Leu	Pro	Gly	Trp	Tyr	His	Cys	Glu
				565					570						575
Cys	Arg	Ser	Gly	Phe	His	Asp	Asp	Gly	Thr	Tyr	Ser	Leu	Ser	Gly	Glu
			580					585						590	
Ser	Cys	Ile	Asp	Ile	Asp	Glu	Cys	Ala	Leu	Arg	Thr	His	Thr	Cys	Trp
		595				600							605		
Asn	Asp	Ser	Ala	Cys	Ile	Asn	Leu	Ala	Gly	Gly	Phe	Asp	Cys	Leu	Cys
	610					615					620				
Pro	Ser	Gly	Pro	Ser	Cys	Ser	Gly	Asp	Cys	Pro	His	Glu	Gly	Gly	Leu
625					630					635					640
Lys	His	Asn	Gly	Gln	Val	Trp	Thr	Leu	Lys	Glu	Asp	Arg	Cys	Ser	Val
				645						650					655
Cys	Ser	Cys	Lys	Asp	Gly	Lys	Ile	Phe	Cys	Arg	Arg	Thr	Ala	Cys	Asp
			660					665						670	
Cys	Gln	Asn	Pro	Ser	Ala	Asp	Leu	Phe	Cys	Cys	Pro	Glu	Cys	Asp	Thr
		675					680						685		
Arg	Val	Thr	Ser	Gln	Cys	Leu	Asp	Gln	Asn	Gly	His	Lys	Leu	Tyr	Arg
	690					695						700			
Ser	Gly	Asp	Asn	Trp	Thr	His	Ser	Cys	Gln	Gln	Cys	Arg	Cys	Leu	Glu
705					710						715				720
Gly	Glu	Val	Asp	Cys	Trp	Pro	Leu	Thr	Cys	Pro	Asn	Leu	Ser	Cys	Glu
				725					730					735	
Tyr	Thr	Ala	Ile	Leu	Glu	Gly	Glu	Cys	Cys	Pro	Arg	Cys	Val	Ser	Asp
			740					745						750	
Pro	Cys	Leu	Ala	Asp	Asn	Ile	Thr	Tyr	Asp	Ile	Arg	Lys	Thr	Cys	Leu
		755					760						765		
Asp	Ser	Tyr	Gly	Val	Ser	Arg	Leu	Ser	Gly	Ser	Val	Trp	Thr	Met	Ala
	770					775						780			
Gly	Ser	Pro	Cys	Thr	Thr	Cys	Lys	Cys	Lys	Asn	Gly	Arg	Val	Cys	Cys
785					790					795					800
Ser	Val	Asp	Phe	Glu	Cys	Leu	Gln	Asn	Asn						
				805					810						

FIGURE 2B

atg	ccg	atg	gat	gtg	att	tta	gtt	ttg	tgg	ttc	tgt	gta	tgc	acc	gcc	48
Met	Pro	Met	Asp	Val	Ile	Leu	Val	Leu	Trp	Phe	Cys	Val	Cys	Thr	Ala	
1				5				10						15		
agg	aca	gtg	ttg	ggc	ttt	ggg	atg	gac	cct	gac	ctt	cag	ctg	gac	atc	96
Arg	Thr	Val	Leu	Gly	Phe	Gly	Met	Asp	Pro	Asp	Leu	Gln	Leu	Asp	Ile	
			20					25						30		
atc	tca	gag	ctc	gac	ctg	gtg	aac	acc	acc	ctg	gga	gtc	acg	cag	gtg	144
Ile	Ser	Glu	Leu	Asp	Leu	Val	Asn	Thr	Thr	Leu	Gly	Val	Thr	Gln	Val	
		35					40					45				
gct	gga	ctg	cac	aac	gcc	agt	aaa	gca	ttt	cta	ttt	caa	gat	gta	cag	192
Ala	Gly	Leu	His	Asn	Ala	Ser	Lys	Ala	Phe	Leu	Phe	Gln	Asp	Val	Gln	
	50					55						60				
aga	gag	atc	cat	tcg	gcc	cct	cac	gtg	agt	gag	aag	ctg	atc	cag	cta	240
Arg	Glu	Ile	His	Ser	Ala	Pro	His	Val	Ser	Glu	Lys	Leu	Ile	Gln	Leu	
	65				70					75					80	
ttc	cgg	aat	aag	agc	gag	ttc	acc	ttt	ttg	gct	aca	gtg	cag	cag	aaa	288
Phe	Arg	Asn	Lys	Ser	Glu	Phe	Thr	Phe	Leu	Ala	Thr	Val	Gln	Gln	Lys	
				85					90						95	
cca	tcc	acc	tca	ggg	gtg	ata	ctg	tcc	atc	cgg	gag	ctg	gag	cac	agc	336
Pro	Ser	Thr	Ser	Gly	Val	Ile	Leu	Ser	Ile	Arg	Glu	Leu	Glu	His	Ser	
			100					105						110		
tat	ttt	gaa	ctg	gag	agc	agt	ggc	cca	aga	gaa	gag	ata	cgc	tac	cat	384
Tyr	Phe	Glu	Leu	Glu	Ser	Ser	Gly	Pro	Arg	Glu	Glu	Ile	Arg	Tyr	His	
		115					120						125			
tac	ata	cat	ggt	gga	aag	ccc	agg	act	gag	gcc	ctt	ccc	tac	cgc	atg	432
Tyr	Ile	His	Gly	Gly	Lys	Pro	Arg	Thr	Glu	Ala	Leu	Pro	Tyr	Arg	Met	
	130					135						140				
gca	gac	gga	caa	tgg	cac	aag	gtc	gcg	ctg	tca	gtg	agc	gcc	tct	cac	480
Ala	Asp	Gly	Gln	Trp	His	Lys	Val	Ala	Leu	Ser	Val	Ser	Ala	Ser	His	
	145				150					155					160	
ctc	ctg	ctc	cac	atc	gac	tgc	aat	agg	att	tac	gag	cgt	gtg	ata	gac	528
Leu	Leu	Leu	His	Ile	Asp	Cys	Asn	Arg	Ile	Tyr	Glu	Arg	Val	Ile	Asp	
				165					170						175	
cct	ccg	gag	acc	aac	ctt	cct	cca	gga	agc	aat	ctg	tgg	ctt	ggg	caa	576
Pro	Pro	Glu	Thr	Asn	Leu	Pro	Pro	Gly	Ser	Asn	Leu	Trp	Leu	Gly	Gln	
			180					185						190		
cgt	aac	caa	aag	cat	ggc	ttt	ttc	aaa	gga	atc	atc	caa	gat	ggt	aag	624
Arg	Asn	Gln	Lys	His	Gly	Phe	Phe	Lys	Gly	Ile	Ile	Gln	Asp	Gly	Lys	
		195					200						205			
atc	atc	ttc	atg	ccg	aat	ggt	ttc	atc	aca	cag	tgt	ccc	aac	ctc	aat	672
Ile	Ile	Phe	Met	Pro	Asn	Gly	Phe	Ile	Thr	Gln	Cys	Pro	Asn	Leu	Asn	
		210				215						220				
cgc	act	tgc	cca	aca	tgc	agt	gac	ttc	ctg	agc	ctg	ggt	caa	gga	ata	720
Arg	Thr	Cys	Pro	Thr	Cys	Ser	Asp	Phe	Leu	Ser	Leu	Val	Gln	Gly	Ile	
	225				230					235					240	

FIGURE 3A

atg gat ttg caa gag ctt ttg gcc aag atg act gca aaa ctg aat tat	768
Met Asp Leu Gln Glu Leu Leu Ala Lys Met Thr Ala Lys Leu Asn Tyr	
245 250 255	
gca gag acg aga ctt ggt caa ctg gaa aat tgc cac tgt gag aag acc	816
Ala Glu Thr Arg Leu Gly Gln Leu Glu Asn Cys His Cys Glu Lys Thr	
260 265 270	
tgc caa gtg agt ggg ctg ctc tac agg gac caa gac tcc tgg gtg gat	864
Cys Gln Val Ser Gly Leu Leu Tyr Arg Asp Gln Asp Ser Trp Val Asp	
275 280 285	
ggt gac aac tgt ggg aac tgc acg tgc aaa agt ggt gcc gtg gag tgc	912
Gly Asp Asn Cys Gly Asn Cys Thr Cys Lys Ser Gly Ala Val Glu Cys	
290 295 300	
cgc agg atg tcc tgt ccc ccg ctc aac tgt tcc ccg gac tca ctt cct	960
Arg Arg Met Ser Cys Pro Pro Leu Asn Cys Ser Pro Asp Ser Leu Pro	
305 310 315 320	
gtg cac att tcc ggc cag tgt tgt aaa gtt tgc aga cca aaa tgt atc	1008
Val His Ile Ser Gly Gln Cys Cys Lys Val Cys Arg Pro Lys Cys Ile	
325 330 335	
tat gga gga aaa gtt ctt gct gag ggc cag cgg att tta acc aag acc	1056
Tyr Gly Gly Lys Val Leu Ala Glu Gly Gln Arg Ile Leu Thr Lys Thr	
340 345 350	
tgc cgg gaa tgt cga ggt gga gtc ttg gta aaa atc aca gaa gct tgc	1104
Cys Arg Glu Cys Arg Gly Gly Val Leu Val Lys Ile Thr Glu Ala Cys	
355 360 365	
cct cct ttg aac tgc tca gca aag gat cat att ctt cca gag aat cag	1152
Pro Pro Leu Asn Cys Ser Ala Lys Asp His Ile Leu Pro Glu Asn Gln	
370 375 380	
tgc tgc agg gtc tgc cca ggt cat aac ttc tgt gca gaa gca cct aag	1200
Cys Cys Arg Val Cys Pro Gly His Asn Phe Cys Ala Glu Ala Pro Lys	
385 390 395 400	
tgc gga gaa aac tcg gaa tgc aaa aat tgg aat aca aaa gca acc tgt	1248
Cys Gly Glu Asn Ser Glu Cys Lys Asn Trp Asn Thr Lys Ala Thr Cys	
405 410 415	
gag tgc aag aat gga tac atc tct gtc cag ggc aac tct gca tac tgt	1296
Glu Cys Lys Asn Gly Tyr Ile Ser Val Gln Gly Asn Ser Ala Tyr Cys	
420 425 430	
gaa gat att gat gag tgt gca gct aaa atg cac tat tgt cat gcc aac	1344
Glu Asp Ile Asp Glu Cys Ala Ala Lys Met His Tyr Cys His Ala Asn	
435 440 445	
acc gtg tgt gtc aac ttg ccg ggg ttg tat cgc tgt gac tgc gtc cca	1392
Thr Val Cys Val Asn Leu Pro Gly Leu Tyr Arg Cys Asp Cys Val Pro	
450 455 460	

FIGURE 3B

ggg tac atc cgt gtg gat gac ttc tct tgt acg gag cat gat gat tgt Gly Tyr Ile Arg Val Asp Asp Phe Ser Cys Thr Glu His Asp Asp Cys 465 470 475 480	1440
ggc agc gga caa cac aac tgc gac aaa aat gcc atc tgt acc aac aca Gly Ser Gly Gln His Asn Cys Asp Lys Asn Ala Ile Cys Thr Asn Thr 485 490 495	1488
gtc cag gga cac agc tgc acc tgc cag ccg ggt tac gtg gga aat ggc Val Gln Gly His Ser Cys Thr Cys Gln Pro Gly Tyr Val Gly Asn Gly 500 505 510	1536
acc atc tgc aaa gca ttc tgt gaa gag ggt tgc aga tac gga ggt acc Thr Ile Cys Lys Ala Phe Cys Glu Glu Gly Cys Arg Tyr Gly Gly Thr 515 520 525	1584
tgt gtg gct cct aac aag tgt gtc tgt cct tct gga ttc acg gga agc Cys Val Ala Pro Asn Lys Cys Val Cys Pro Ser Gly Phe Thr Gly Ser 530 535 540	1632
cac tgt gag aaa gat att gat gaa tgc gca gag gga ttc gtt gaa tgc His Cys Glu Lys Asp Ile Asp Glu Cys Ala Glu Gly Phe Val Glu Cys 545 550 555 560	1680
cac aac tac tcc cgc tgt gtt aac ctg cca ggg tgg tac cac tgt gag His Asn Tyr Ser Arg Cys Val Asn Leu Pro Gly Trp Tyr His Cys Glu 565 570 575	1728
tgc aga agc ggt ttc cat gac gat ggg acc tac tca ctg tcc ggg gag Cys Arg Ser Gly Phe His Asp Asp Gly Thr Tyr Ser Leu Ser Gly Glu 580 585 590	1776
tcc tgc att gat atc gat gaa tgt gcc tta/aga act cac act tgt tgg Ser Cys Ile Asp Ile Asp Glu Cys Ala Leu Arg Thr His Thr Cys Trp 595 600 605	1824
aat gac tct gcc tgc atc aac tta gca gga gga ttt gac tgc ctg tgt Asn Asp Ser Ala Cys Ile Asn Leu Ala Gly Gly Phe Asp Cys Leu Cys 610 615 620	1872
ccc tct ggg ccc tcc tgc tct ggt gac tgt ccc cac gaa gga ggg ctg Pro Ser Gly Pro Ser Cys Ser Gly Asp Cys Pro His Glu Gly Gly Leu 625 630 635 640	1920
aag cat aat ggg cag gtg tgg att ctg aga gaa gac agg tgt tca gtc Lys His Asn Gly Gln Val Trp Ile Leu Arg Glu Asp Arg Cys Ser Val 645 650 655	1968
tgt tcc tgc aag gat ggg aag ata ttc tgc cgg cgg aca gct tgt gat Cys Ser Cys Lys Asp Gly Lys Ile Phe Cys Arg Arg Thr Ala Cys Asp 660 665 670	2016
tgc cag aat cca aat gtt gac ctt ttt tgc tgc cca gag tgc gat acc Cys Gln Asn Pro Asn Val Asp Leu Phe Cys Cys Pro Glu Cys Asp Thr 675 680 685	2064
agg gtc acc agc caa tgt tta gat caa agt gga cag aag ctc tat cga Arg Val Thr Ser Gln Cys Leu Asp Gln Ser Gly Gln Lys Leu Tyr Arg 690 695 700	2112

FIGURE 3C

agt gga gac aac tgg acc cac agc tgc cag cag tgc cga tgt ctg gaa	2160
Ser Gly Asp Asn Trp Thr His Ser Cys Gln Gln Cys Arg Cys Leu Glu	
705 710 715 720	
gga gag gca gac tgc tgg cct ctg gct tgc cct agt ttg ggc tgt gaa	2208
Gly Glu Ala Asp Cys Trp Pro Leu Ala Cys Pro Ser Leu Gly Cys Glu	
725 730 735	
tac aca gcc atg ttt gaa ggg gag tgt tgt ccc cga tgt gtc agt gac	2256
Tyr Thr Ala Met Phe Glu Gly Glu Cys Cys Pro Arg Cys Val Ser Asp	
740 745 750	
ccc tgc ctg gct ggt aat att gcc tat gac atc aga aaa act tgc ctg	2304
Pro Cys Leu Ala Gly Asn Ile Ala Tyr Asp Ile Arg Lys Thr Cys Leu	
755 760 765	
gac agc ttt ggt gtt tcg agg ctg agc gga gcc gtg tgg aca atg gct	2352
Asp Ser Phe Gly Val Ser Arg Leu Ser Gly Ala Val Trp Thr Met Ala	
770 775 780	
gga tct cct tgt aca acc tgc aaa tgc aag aat ggg aga gtc tgc tgc	2400
Gly Ser Pro Cys Thr Thr Cys Lys Cys Lys Asn Gly Arg Val Cys Cys	
785 790 795 800	
tct gtg gat ctg gag tgt att gag aat aac tga	2433
Ser Val Asp Leu Glu Cys Ile Glu Asn Asn *	
805 810	

FIGURE 3D

Met	Pro	Met	Asp	Val	Ile	Leu	Val	Leu	Trp	Phe	Cys	Val	Cys	Thr	Ala
1				5					10					15	
Arg	Thr	Val	Leu	Gly	Phe	Gly	Met	Asp	Pro	Asp	Leu	Gln	Leu	Asp	Ile
			20					25						30	
Ile	Ser	Glu	Leu	Asp	Leu	Val	Asn	Thr	Thr	Leu	Gly	Val	Thr	Gln	Val
		35					40					45			
Ala	Gly	Leu	His	Asn	Ala	Ser	Lys	Ala	Phe	Leu	Phe	Gln	Asp	Val	Gln
		50				55					60				
Arg	Glu	Ile	His	Ser	Ala	Pro	His	Val	Ser	Glu	Lys	Leu	Ile	Gln	Leu
65					70					75					80
Phe	Arg	Asn	Lys	Ser	Glu	Phe	Thr	Phe	Leu	Ala	Thr	Val	Gln	Gln	Lys
			85					90						95	
Pro	Ser	Thr	Ser	Gly	Val	Ile	Leu	Ser	Ile	Arg	Glu	Leu	Glu	His	Ser
			100					105						110	
Tyr	Phe	Glu	Leu	Glu	Ser	Ser	Gly	Pro	Arg	Glu	Glu	Ile	Arg	Tyr	His
		115					120						125		
Tyr	Ile	His	Gly	Gly	Lys	Pro	Arg	Thr	Glu	Ala	Leu	Pro	Tyr	Arg	Met
		130				135					140				
Ala	Asp	Gly	Gln	Trp	His	Lys	Val	Ala	Leu	Ser	Val	Ser	Ala	Ser	His
145					150					155					160
Leu	Leu	Leu	His	Ile	Asp	Cys	Asn	Arg	Ile	Tyr	Glu	Arg	Val	Ile	Asp
				165				170						175	
Pro	Pro	Glu	Thr	Asn	Leu	Pro	Pro	Gly	Ser	Asn	Leu	Trp	Leu	Gly	Gln
			180					185						190	
Arg	Asn	Gln	Lys	His	Gly	Phe	Phe	Lys	Gly	Ile	Ile	Gln	Asp	Gly	Lys
		195					200						205		
Ile	Ile	Phe	Met	Pro	Asn	Gly	Phe	Ile	Thr	Gln	Cys	Pro	Asn	Leu	Asn
		210				215					220				
Arg	Thr	Cys	Pro	Thr	Cys	Ser	Asp	Phe	Leu	Ser	Leu	Val	Gln	Gly	Ile
225					230					235					240
Met	Asp	Leu	Gln	Glu	Leu	Leu	Ala	Lys	Met	Thr	Ala	Lys	Leu	Asn	Tyr
				245				250						255	
Ala	Glu	Thr	Arg	Leu	Gly	Gln	Leu	Glu	Asn	Cys	His	Cys	Glu	Lys	Thr
			260					265						270	
Cys	Gln	Val	Ser	Gly	Leu	Leu	Tyr	Arg	Asp	Gln	Asp	Ser	Trp	Val	Asp
		275					280					285			
Gly	Asp	Asn	Cys	Gly	Asn	Cys	Thr	Cys	Lys	Ser	Gly	Ala	Val	Glu	Cys
	290					295					300				
Arg	Arg	Met	Ser	Cys	Pro	Pro	Leu	Asn	Cys	Ser	Pro	Asp	Ser	Leu	Pro
305					310					315					320
Val	His	Ile	Ser	Gly	Gln	Cys	Cys	Lys	Val	Cys	Arg	Pro	Lys	Cys	Ile
				325					330					335	
Tyr	Gly	Gly	Lys	Val	Leu	Ala	Glu	Gly	Gln	Arg	Ile	Leu	Thr	Lys	Thr
			340					345						350	
Cys	Arg	Glu	Cys	Arg	Gly	Gly	Val	Leu	Val	Lys	Ile	Thr	Glu	Ala	Cys
		355					360					365			
Pro	Pro	Leu	Asn	Cys	Ser	Ala	Lys	Asp	His	Ile	Leu	Pro	Glu	Asn	Gln
		370				375					380				
Cys	Cys	Arg	Val	Cys	Pro	Gly	His	Asn	Phe	Cys	Ala	Glu	Ala	Pro	Lys
385					390					395					400
Cys	Gly	Glu	Asn	Ser	Glu	Cys	Lys	Asn	Trp	Asn	Thr	Lys	Ala	Thr	Cys
			405						410					415	
Glu	Cys	Lys	Asn	Gly	Tyr	Ile	Ser	Val	Gln	Gly	Asn	Ser	Ala	Tyr	Cys
			420					425					430		
Glu	Asp	Ile	Asp	Glu	Cys	Ala	Ala	Lys	Met	His	Tyr	Cys	His	Ala	Asn
		435					440					445			
Thr	Val	Cys	Val	Asn	Leu	Pro	Gly	Leu	Tyr	Arg	Cys	Asp	Cys	Val	Pro
		450				455					460				

FIGURE 4A

Gly	Tyr	Ile	Arg	Val	Asp	Asp	Phe	Ser	Cys	Thr	Glu	His	Asp	Asp	Cys
465					470					475					480
Gly	Ser	Gly	Gln	His	Asn	Cys	Asp	Lys	Asn	Ala	Ile	Cys	Thr	Asn	Thr
				485					490					495	
Val	Gln	Gly	His	Ser	Cys	Thr	Cys	Gln	Pro	Gly	Tyr	Val	Gly	Asn	Gly
			500					505					510		
Thr	Ile	Cys	Lys	Ala	Phe	Cys	Glu	Glu	Gly	Cys	Arg	Tyr	Gly	Gly	Thr
		515					520					525			
Cys	Val	Ala	Pro	Asn	Lys	Cys	Val	Cys	Pro	Ser	Gly	Phe	Thr	Gly	Ser
	530					535					540				
His	Cys	Glu	Lys	Asp	Ile	Asp	Glu	Cys	Ala	Glu	Gly	Phe	Val	Glu	Cys
545				550					555						560
His	Asn	Tyr	Ser	Arg	Cys	Val	Asn	Leu	Pro	Gly	Trp	Tyr	His	Cys	Glu
				565				570						575	
Cys	Arg	Ser	Gly	Phe	His	Asp	Asp	Gly	Thr	Tyr	Ser	Leu	Ser	Gly	Glu
			580					585					590		
Ser	Cys	Ile	Asp	Ile	Asp	Glu	Cys	Ala	Leu	Arg	Thr	His	Thr	Cys	Trp
		595				600						605			
Asn	Asp	Ser	Ala	Cys	Ile	Asn	Leu	Ala	Gly	Gly	Phe	Asp	Cys	Leu	Cys
	610					615					620				
Pro	Ser	Gly	Pro	Ser	Cys	Ser	Gly	Asp	Cys	Pro	His	Glu	Gly	Gly	Leu
625					630					635					640
Lys	His	Asn	Gly	Gln	Val	Trp	Ile	Leu	Arg	Glu	Asp	Arg	Cys	Ser	Val
				645					650					655	
Cys	Ser	Cys	Lys	Asp	Gly	Lys	Ile	Phe	Cys	Arg	Arg	Thr	Ala	Cys	Asp
			660					665					670		
Cys	Gln	Asn	Pro	Asn	Val	Asp	Leu	Phe	Cys	Cys	Pro	Glu	Cys	Asp	Thr
		675				680						685			
Arg	Val	Thr	Ser	Gln	Cys	Leu	Asp	Gln	Ser	Gly	Gln	Lys	Leu	Tyr	Arg
	690					695						700			
Ser	Gly	Asp	Asn	Trp	Thr	His	Ser	Cys	Gln	Gln	Cys	Arg	Cys	Leu	Glu
705					710					715					720
Gly	Glu	Ala	Asp	Cys	Trp	Pro	Leu	Ala	Cys	Pro	Ser	Leu	Gly	Cys	Glu
				725					730					735	
Tyr	Thr	Ala	Met	Phe	Glu	Gly	Glu	Cys	Cys	Pro	Arg	Cys	Val	Ser	Asp
			740					745					750		
Pro	Cys	Leu	Ala	Gly	Asn	Ile	Ala	Tyr	Asp	Ile	Arg	Lys	Thr	Cys	Leu
		755					760					765			
Asp	Ser	Phe	Gly	Val	Ser	Arg	Leu	Ser	Gly	Ala	Val	Trp	Thr	Met	Ala
	770					775						780			
Gly	Ser	Pro	Cys	Thr	Thr	Cys	Lys	Cys	Lys	Asn	Gly	Arg	Val	Cys	Cys
785					790					795					800
Ser	Val	Asp	Leu	Glu	Cys	Ile	Glu	Asn	Asn						
				805					810						

FIGURE 4B

atg ccg atg gat gtg att tta gtt ttg tgg ttc tgt gtg tgc acc gcc	48
Met Pro Met Asp Val Ile Leu Val Leu Trp Phe Cys Val Cys Thr Ala	
1 5 10 15	
cag gac agt ggt ggg ctt tgg gat gga ccc tga cct tca gat gga cat	96
Gln Asp Ser Gly Gly Leu Trp Asp Gly Pro * Pro Ser Asp Gly His	
20 25 30	
cat cac tga act tga cct tgt gaa cac cag ccc tgg gcg tca ctc agg	144
His His * Thr * Pro Cys Glu His Gln Pro Trp Ala Ser Leu Arg	
35 40 45	
tgg gtg gac tac aca atg cca gta agg cat ttc tgt ttc aag atg tac	192
Trp Val Asp Tyr Thr Met Pro Val Arg His Phe Cys Phe Lys Met Tyr	
50 55 60	
aga gag aga tcc act cag ccc ctc atg tga gtg aga agc tga tcc agc	240
Arg Glu Arg Ser Thr Gln Pro Leu Met * Val Arg Ser * Ser Ser	
65 70 75	
tat tcc gga ata aga gtg agt tta cct ttt tgg cta cag tgc agc aga	288
Tyr Ser Gly Ile Arg Val Ser Leu Pro Phe Trp Leu Gln Cys Ser Arg	
80 85 90	
agc cgt cca cct cag ggg tga tac tgt cga tcc ggg agc tgg aac aca	336
Ser Arg Pro Pro Gln Gly * Tyr Cys Arg Ser Gly Ser Trp Asn Thr	
95 100 105	
gct att ttg aac tgg aga gca gtg gcc caa gag aag aga tac gct atc	384
Ala Ile Leu Asn Trp Arg Ala Val Ala Gln Glu Lys Arg Tyr Ala Ile	
110 115 120	
att aca tcc atg gcg gca agc cca gga ctg agg ccc ttc cct acc gca	432
Ile Thr Ser Met Ala Ala Ser Pro Gly Leu Arg Pro Phe Pro Thr Ala	
125 130 135	
tgg ccg atg gac agt ggc aca agg tcg cgc tgt ctg tga gcg cct ctc	480
Trp Pro Met Asp Ser Gly Thr Arg Ser Arg Cys Leu * Ala Pro Leu	
140 145 150	
acc tcc tac tcc atg tcg act gca ata gga ttt atg agc gtg tga tag	528
Thr Ser Tyr Ser Met Ser Thr Ala Ile Gly Phe Met Ser Val * *	
155 160 165	
atc ctc cgg aga cca acc ttc ctc cag gaa gca atc tat ggc ttg ggc	576
Ile Leu Arg Arg Pro Thr Phe Leu Gln Glu Ala Ile Tyr Gly Leu Gly	
170 175 180	
aac gta atc aaa agc atg gct ttt tca aag gaa tca tcc aag atg gca	624
Asn Val Ile Lys Ser Met Ala Phe Ser Lys Glu Ser Ser Lys Met Ala	
185 190 195	
aga tca tct tca tgc cga acg gct tca tca cac agt gcc cca acc taa	672
Arg Ser Ser Ser Cys Arg Thr Ala Ser Ser His Ser Ala Pro Thr *	
200 205 210	
atc gca ctt gcc caa cat gca gtg att tcc tga gcc tgg ttc aag gaa	720
Ile Ala Leu Ala Gln His Ala Val Ile Ser * Ala Trp Phe Lys Glu	
215 220 225	

FIGURE 5A

taa tgg att tgc aag agc ttt tgg cca aga tga ctg caa aac tga att	768
* Trp Ile Cys Lys Ser Phe Trp Pro Arg * Leu Gln Asn * Ile	
230 235 240	
atg cag aga cga gac ttg gtc aac tgg aaa att gcc act gtg aga aga	816
Met Gln Arg Arg Asp Leu Val Asn Trp Lys Ile Ala Thr Val Arg Arg	
245 250 255	
cct gcc aag tga gtg ggc tgc tct aca ggg acc aag act cct ggg tag	864
Pro Ala Lys * Val Gly Cys Ser Thr Gly Thr Lys Thr Pro Gly *	
260 265 270	
atg gtg aca act gca gga act gca cat gca aaa gtg gtg ctg tgg agt	912
Met Val Thr Thr Ala Gly Thr Ala His Ala Lys Val Val Leu Trp Ser	
275 280 285	
gcc gaa gga tgt cct gtc ccc cac tca act gtt ccc cag act cac ttc	960
Ala Glu Gly Cys Pro Val Pro His Ser Thr Val Pro Gln Thr His Phe	
290 295 300	
ctg tgc ata ttt ctg gcc aat gtt gta aag ttt gca gac caa aat gta	1008
Leu Cys Ile Phe Leu Ala Asn Val Val Lys Phe Ala Asp Gln Asn Val	
305 310 315 320	
tct atg gag gaa aag ttc ttg ctg agg gcc agc gga ttt taa cca aga	1056
Ser Met Glu Glu Lys Phe Leu Leu Arg Ala Ser Gly Phe * Pro Arg	
325 330 335	
cct gcc ggg aat gtc gag gtg gag tct tgg taa aaa tca cag aag ctt	1104
Pro Ala Gly Asn Val Glu Val Glu Ser Trp * Lys Ser Gln Lys Leu	
340 345 350	
gcc ctc ctt tga act gct cag aga agg atc ata ttc ttc cgg aga acc	1152
Ala Leu Leu * Thr Ala Gln Arg Arg Ile Ile Phe Phe Arg Arg Thr	
355 360 365	
agt gct ggg gtc tgc cga ggt cat aac ttc tgt gca gaa gca cct aag	1200
Ser Ala Gly Val Cys Arg Gly His Asn Phe Cys Ala Glu Ala Pro Lys	
370 375 380	
tgt gga gaa aac tcg gaa tgc aaa aat tgg aat aca aaa gcg act tgt	1248
Cys Gly Glu Asn Ser Glu Cys Lys Asn Trp Asn Thr Lys Ala Thr Cys	
385 390 395	
gag tgc aag aat gga tac atc tct gtc cag ggc aac tct gca tac tgt	1296
Glu Cys Lys Asn Gly Tyr Ile Ser Val Gln Gly Asn Ser Ala Tyr Cys	
400 405 410	
gaa gat atc gat gag tgt gca gca aag atg cac tac tgt cat gcc aac	1344
Glu Asp Ile Asp Glu Cys Ala Ala Lys Met His Tyr Cys His Ala Asn	
415 420 425	
acg gtg tgt gtc aac ttg ccg ggg tta tat cgc tgt gac tgc atc cca	1392
Thr Val Cys Val Asn Leu Pro Gly Leu Tyr Arg Cys Asp Cys Ile Pro	
430 435 440 445	
gga tac atc cgt gtg gat gac ttc tct tgt acg gag cat gat gat tgt	1440
Gly Tyr Ile Arg Val Asp Asp Phe Ser Cys Thr Glu His Asp Asp Cys	
450 455 460	

FIGURE 5B

ggc agc gga caa cac aac tgt gac aaa aat gcc atc tgt acc aac aca Gly Ser Gly Gln His Asn Cys Asp Lys Asn Ala Ile Cys Thr Asn Thr 465 470 475	1488
gtc cag gga cac agc tgt acc tgc cag cca gcc tac gtg gga aat ggt Val Gln Gly His Ser Cys Thr Cys Gln Pro Gly Tyr Val Gly Asn Gly 480 485 490	1536
act gtc tgc aaa gca ttc tgt gaa gag ggt tgc aga tac gga ggt acc Thr Val Cys Lys Ala Phe Cys Glu Glu Gly Cys Arg Tyr Gly Gly Thr 495 500 505	1584
tgt gtg gcc cct aac aaa tgt gtc tgt cct tct gga ttc aca gga agc Cys Val Ala Pro Asn Lys Cys Val Cys Pro Ser Gly Phe Thr Gly Ser 510 515 520 525	1632
cac tgt gag aaa gat att gat gaa tgt gca gag gga ttc gtt gag tgc His Cys Glu Lys Asp Ile Asp Glu Cys Ala Glu Gly Phe Val Glu Cys 530 535 540	1680
cac aac cac tcc cgc tgc gtt aac ctt cca ggg tgg tac cac tgt gag His Asn His Ser Arg Cys Val Asn Leu Pro Gly Trp Tyr His Cys Glu 545 550 555	1728
tgc aga agc ggt ttc cat gac gat ggg acc tat tca ctg tcc ggg gag Cys Arg Ser Gly Phe His Asp Asp Gly Thr Tyr Ser Leu Ser Gly Glu 560 565 570	1776
tcc tgc att gat att gat gaa tgt gcc tta aga act cac act tgt tgg Ser Cys Ile Asp Ile Asp Glu Cys Ala Leu Arg Thr His Thr Cys Trp 575 580 585	1824
aat gac tct gcc tgc atc aac tta gca gga gga ttt gac tgc ctg tgt Asn Asp Ser Ala Cys Ile Asn Leu Ala Gly Gly Phe Asp Cys Leu Cys 590 595 600 605	1872
ccc tct ggg ccc tcc tgc tct ggt gac tgt ccc cac gaa ggg ggg ctg Pro Ser Gly Pro Ser Cys Ser Gly Asp Cys Pro His Glu Gly Gly Leu 610 615 620	1920
aag cat aat ggg cag gtg tgg att ctg aga gaa gac agg tgt tca gtc Lys His Asn Gly Gln Val Trp Ile Leu Arg Glu Asp Arg Cys Ser Val 625 630 635	1968
tgt tcc tgt aag gat ggg aag ata ttc tgc cgg cgg aca gct tgt gat Cys Ser Cys Lys Asp Gly Lys Ile Phe Cys Arg Arg Thr Ala Cys Asp 640 645 650	2016
tgc cag aat cca aat gtt gac ctt ttc tgc tgc cca gag tgt gac acc Cys Gln Asn Pro Asn Val Asp Leu Phe Cys Cys Pro Glu Cys Asp Thr 655 660 665	2064
agg gtc act agc caa tgt tta gat caa agc gga cag aag ctc tat cga Arg Val Thr Ser Gln Cys Leu Asp Gln Ser Gly Gln Lys Leu Tyr Arg 670 675 680 685	2112
agt gga gac aac tgg acc cac agc tgc cag cag tgc cga tgt ctg gaa Ser Gly Asp Asn Trp Thr His Ser Cys Gln Gln Cys Arg Cys Leu Glu 690 695 700	2160

FIGURE 5C

gga gag gca gac tgc tgg cct cta gct tgc cct agt ttg agc tgt gaa	2208
Gly Glu Ala Asp Cys Trp Pro Leu Ala Cys Pro Ser Leu Ser Cys Glu	
705 710 715	
tac aca gcc atc ttt gaa gga gag tgt tgt ccc cgc tgt gtc agt gac	2256
Tyr Thr Ala Ile Phe Glu Gly Glu Cys Cys Pro Arg Cys Val Ser Asp	
720 725 730	
ccc tgc ctg gct gat aat att gcc tat gac atc aga aaa act tgc ctg	2304
Pro Cys Leu Ala Asp Asn Ile Ala Tyr Asp Ile Arg Lys Thr Cys Leu	
735 740 745	
gac agc tct ggt att tcg agg ctg agc ggc gca gtg tgg aca atg gct	2352
Asp Ser Ser Gly Ile Ser Arg Leu Ser Gly Ala Val Trp Thr Met Ala	
750 755 760 765	
gga tct ccc tgt aca acc tgt caa tgc aag aat ggg aga gtc tgc tgc	2400
Gly Ser Pro Cys Thr Thr Cys Gln Cys Lys Asn Gly Arg Val Cys Cys	
770 775 780	
tct gtg gat ctg gtg tgt ctt gag aat aac tga	2433
Ser Val Asp Leu Val Cys Leu Glu Asn Asn *	
785 790	

FIGURE 6A

Met	Pro	Met	Asp	Val	Ile	Leu	Val	Leu	Trp	Phe	Cys	Val	Cys	Thr	Ala
1				5					10					15	
Gln	Asp	Ser	Gly	Gly	Leu	Trp	Asp	Gly	Pro	Pro	Ser	Asp	Gly	His	His
			20					25					30		
His	Thr	Pro	Cys	Glu	His	Gln	Pro	Trp	Ala	Ser	Leu	Arg	Trp	Val	Asp
		35					40					45			
Tyr	Thr	Met	Pro	Val	Arg	His	Phe	Cys	Phe	Lys	Met	Tyr	Arg	Glu	Arg
	50					55					60				
Ser	Thr	Gln	Pro	Leu	Met	Val	Arg	Ser	Ser	Ser	Tyr	Ser	Gly	Ile	Arg
65					70					75					80
Val	Ser	Leu	Pro	Phe	Trp	Leu	Gln	Cys	Ser	Arg	Ser	Arg	Pro	Pro	Gln
				85					90					95	
Gly	Tyr	Cys	Arg	Ser	Gly	Ser	Trp	Asn	Thr	Ala	Ile	Leu	Asn	Trp	Arg
			100					105					110		
Ala	Val	Ala	Gln	Glu	Lys	Arg	Tyr	Ala	Ile	Ile	Thr	Ser	Met	Ala	Ala
		115					120					125			
Ser	Pro	Gly	Leu	Arg	Pro	Phe	Pro	Thr	Ala	Trp	Pro	Met	Asp	Ser	Gly
	130					135						140			
Thr	Arg	Ser	Arg	Cys	Leu	Ala	Pro	Leu	Thr	Ser	Tyr	Ser	Met	Ser	Thr
145					150					155					160
Ala	Ile	Gly	Phe	Met	Ser	Val	Ile	Leu	Arg	Arg	Pro	Thr	Phe	Leu	Gln
				165					170					175	
Glu	Ala	Ile	Tyr	Gly	Leu	Gly	Asn	Val	Ile	Lys	Ser	Met	Ala	Phe	Ser
			180					185					190		
Lys	Glu	Ser	Ser	Lys	Met	Ala	Arg	Ser	Ser	Ser	Cys	Arg	Thr	Ala	Ser
	195						200					205			
Ser	His	Ser	Ala	Pro	Thr	Ile	Ala	Leu	Ala	Gln	His	Ala	Val	Ile	Ser
	210					215						220			
Ala	Trp	Phe	Lys	Glu	Trp	Ile	Cys	Lys	Ser	Phe	Trp	Pro	Arg	Leu	Gln
225					230					235					240
Asn	Ile	Met	Gln	Arg	Arg	Asp	Leu	Val	Asn	Trp	Lys	Ile	Ala	Thr	Val
				245					250					255	
Arg	Arg	Pro	Ala	Lys	Val	Gly	Cys	Ser	Thr	Gly	Thr	Lys	Thr	Pro	Gly
			260					265						270	
Met	Val	Thr	Thr	Ala	Gly	Thr	Ala	His	Ala	Lys	Val	Val	Leu	Trp	Ser
		275					280						285		
Ala	Glu	Gly	Cys	Pro	Val	Pro	His	Ser	Thr	Val	Pro	Gln	Thr	His	Phe
	290					295					300				
Leu	Cys	Ile	Phe	Leu	Ala	Asn	Val	Val	Lys	Phe	Ala	Asp	Gln	Asn	Val
305					310					315					320
Ser	Met	Glu	Glu	Lys	Phe	Leu	Leu	Arg	Ala	Ser	Gly	Phe	Pro	Arg	Pro
				325					330					335	
Ala	Gly	Asn	Val	Glu	Val	Glu	Ser	Trp	Lys	Ser	Gln	Lys	Leu	Ala	Leu
			340					345					350		
Leu	Thr	Ala	Gln	Arg	Arg	Ile	Ile	Phe	Phe	Arg	Arg	Thr	Ser	Ala	Gly
		355					360					365			
Val	Cys	Arg	Gly	His	Asn	Phe	Cys	Ala	Glu	Ala	Pro	Lys	Cys	Gly	Glu
	370					375					380				
Asn	Ser	Glu	Cys	Lys	Asn	Trp	Asn	Thr	Lys	Ala	Thr	Cys	Glu	Cys	Lys
385					390					395					400
Asn	Gly	Tyr	Ile	Ser	Val	Gln	Gly	Asn	Ser	Ala	Tyr	Cys	Glu	Asp	Ile
				405					410					415	
Asp	Glu	Cys	Ala	Ala	Lys	Met	His	Tyr	Cys	His	Ala	Asn	Thr	Val	Cys
			420					425					430		
Val	Asn	Leu	Pro	Gly	Leu	Tyr	Arg	Cys	Asp	Cys	Ile	Pro	Gly	Tyr	Ile
	435						440					445			
Arg	Val	Asp	Asp	Phe	Ser	Cys	Thr	Glu	His	Asp	Asp	Cys	Gly	Ser	Gly
	450					455						460			

FIGURE 6B

Gln	His	Asn	Cys	Asp	Lys	Asn	Ala	Ile	Cys	Thr	Asn	Thr	Val	Gln	Gly
465					470				475						480
His	Ser	Cys	Thr	Cys	Gln	Pro	Gly	Tyr	Val	Gly	Asn	Gly	Thr	Val	Cys
			485					490						495	
Lys	Ala	Phe	Cys	Glu	Glu	Gly	Cys	Arg	Tyr	Gly	Gly	Thr	Cys	Val	Ala
			500				505						510		
Pro	Asn	Lys	Cys	Val	Cys	Pro	Ser	Gly	Phe	Thr	Gly	Ser	His	Cys	Glu
		515				520						525			
Lys	Asp	Ile	Asp	Glu	Cys	Ala	Glu	Gly	Phe	Val	Glu	Cys	His	Asn	His
	530					535					540				
Ser	Arg	Cys	Val	Asn	Leu	Pro	Gly	Trp	Tyr	His	Cys	Glu	Cys	Arg	Ser
545					550					555					560
Gly	Phe	His	Asp	Asp	Gly	Thr	Tyr	Ser	Leu	Ser	Gly	Glu	Ser	Cys	Ile
				565					570					575	
Asp	Ile	Asp	Glu	Cys	Ala	Leu	Arg	Thr	His	Thr	Cys	Trp	Asn	Asp	Ser
			580					585					590		
Ala	Cys	Ile	Asn	Leu	Ala	Gly	Gly	Phe	Asp	Cys	Leu	Cys	Pro	Ser	Gly
		595					600					605			
Pro	Ser	Cys	Ser	Gly	Asp	Cys	Pro	His	Glu	Gly	Gly	Leu	Lys	His	Asn
	610					615					620				
Gly	Gln	Val	Trp	Ile	Leu	Arg	Glu	Asp	Arg	Cys	Ser	Val	Cys	Ser	Cys
625					630					635					640
Lys	Asp	Gly	Lys	Ile	Phe	Cys	Arg	Arg	Thr	Ala	Cys	Asp	Cys	Gln	Asn
				645					650					655	
Pro	Asn	Val	Asp	Leu	Phe	Cys	Cys	Pro	Glu	Cys	Asp	Thr	Arg	Val	Thr
			660					665						670	
Ser	Gln	Cys	Leu	Asp	Gln	Ser	Gly	Gln	Lys	Leu	Tyr	Arg	Ser	Gly	Asp
		675					680					685			
Asn	Trp	Thr	His	Ser	Cys	Gln	Gln	Cys	Arg	Cys	Leu	Glu	Gly	Glu	Ala
	690					695					700				
Asp	Cys	Trp	Pro	Leu	Ala	Cys	Pro	Ser	Leu	Ser	Cys	Glu	Tyr	Thr	Ala
705					710						715				720
Ile	Phe	Glu	Gly	Glu	Cys	Cys	Pro	Arg	Cys	Val	Ser	Asp	Pro	Cys	Leu
				725					730					735	
Ala	Asp	Asn	Ile	Ala	Tyr	Asp	Ile	Arg	Lys	Thr	Cys	Leu	Asp	Ser	Ser
			740					745						750	
Gly	Ile	Ser	Arg	Leu	Ser	Gly	Ala	Val	Trp	Thr	Met	Ala	Gly	Ser	Pro
		755					760						765		
Cys	Thr	Thr	Cys	Gln	Cys	Lys	Asn	Gly	Arg	Val	Cys	Cys	Ser	Val	Asp
	770					775					780				
Leu	Val	Cys	Leu	Glu	Asn	Asn									
785					790										

FIGURE 6C

atg gag tct cgg gtc tta ctg aga aca ttc tgt ttg atc ttc ggt ctc Met Glu Ser Arg Val Leu Leu Arg Thr Phe Cys Leu Ile Phe Gly Leu 1 5 10 15	48
gga gca gtt tgg ggg ctt ggt gtg gac cct tcc cta cag att gac gtc Gly Ala Val Trp Gly Leu Gly Val Asp Pro Ser Leu Gln Ile Asp Val 20 25 30	96
tta aca gag tta gaa ctt ggg gag tcc acg acc gga gtg cgt cag gtc Leu Thr Glu Leu Glu Leu Gly Glu Ser Thr Thr Gly Val Arg Gln Val 35 40 45	144
ccg ggg ctg cat aat ggg acg aaa gcc ttt ctc ttt caa gat act ccc Pro Gly Leu His Asn Gly Thr Lys Ala Phe Leu Phe Gln Asp Thr Pro 50 55 60	192
aga agc ata aaa gca tcc act gct aca gct gaa cag ttt ttt cag aag Arg Ser Ile Lys Ala Ser Thr Ala Thr Ala Glu Gln Phe Phe Gln Lys 65 70 75 80	240
ctg aga aat aaa cat gaa ttt act att ttg gtg acc cta aaa cag acc Leu Arg Asn Lys His Glu Phe Thr Ile Leu Val Thr Leu Lys Gln Thr 85 90 95	288
cac tta aat tca gga gtt att ctc tca att cac cac ttg gat cac agg His Leu Asn Ser Gly Val Ile Leu Ser Ile His His Leu Asp His Arg 100 105 110	336
tac ctg gaa ctg gaa agt agt ggc cat cgg aat gaa gtc aga ctg cat Tyr Leu Glu Leu Glu Ser Ser Gly His Arg Asn Glu Val Arg Leu His 115 120 125	384
tac cgc tca ggc agt cac cgc cct cac aca gaa gtg ttt cct tac att Tyr Arg Ser Gly Ser His Arg Pro His Thr Glu Val Phe Pro Tyr Ile 130 135 140	432
ttg gct gat gac aag tgg cac aag ctc tcc tta gcc atc agt gct tcc Leu Ala Asp Asp Lys Trp His Lys Leu Ser Leu Ala Ile Ser Ala Ser 145 150 155 160	480
cat ttg att tta cac att gac tgc aat aaa att tat gaa agg gta gta His Leu Ile Leu His Ile Asp Cys Asn Lys Ile Tyr Glu Arg Val Val 165 170 175	528
gaa aag ccc tcc aca gac ttg cct cta ggc aca aca ttt tgg cta gga Glu Lys Pro Ser Thr Asp Leu Pro Leu Gly Thr Thr Phe Trp Leu Gly 180 185 190	576
cag aga aat aat gcg cat gga tat ttt aag ggt ata atg caa gat gtc Gln Arg Asn Asn Ala His Gly Tyr Phe Lys Gly Ile Met Gln Asp Val 195 200 205	624
caa tta ctt gtc atg ccc cag gga ttt att gct cag tgc cca gat ctt Gln Leu Leu Val Met Pro Gln Gly Phe Ile Ala Gln Cys Pro Asp Leu 210 215 220	672
aat cgc acc tgt cca act tgc aat gac ttc cat gga ctt gtg cag aaa Asn Arg Thr Cys Pro Thr Cys Asn Asp Phe His Gly Leu Val Gln Lys 225 230 235 240	720

FIGURE 7A

atc atg gag cta cag gat att. tta gcc aaa aca tca gcc aag ctg tct	768
Ile Met Glu Leu Gln Asp Ile Leu Ala Lys Thr Ser Ala Lys Leu Ser	
245 250 255	
cga gct gaa cag cga atg aat aga ttg gat cag tgc tat tgt gaa agg	816
Arg Ala Glu Gln Arg Met Asn Arg Leu Asp Gln Cys Tyr Cys Glu Arg	
260 265 270	
act tgc acc atg aag gga acc acc tac cga gaa ttt gag tcc tgg ata	864
Thr Cys Thr Met Lys Gly Thr Thr Tyr Arg Glu Phe Glu Ser Trp Ile	
275 280 285	
gac ggc tgt aag aac tgc aca tgc ctg aat gga acc atc cag tgt gaa	912
Asp Gly Cys Lys Asn Cys Thr Cys Leu Asn Gly Thr Ile Gln Cys Glu	
290 295 300	
act cta atc tgc cca aat cct gac tgc cca ctt aag tcg gct ctt gcg	960
Thr Leu Ile Cys Pro Asn Pro Asp Cys Pro Leu Lys Ser Ala Leu Ala	
305 310 315 320	
tat gtg gat ggc aaa tgc tgt aag gaa tgc aaa tcg ata tgc caa ttt	1008
Tyr Val Asp Gly Lys Cys Cys Lys Glu Cys Lys Ser Ile Cys Gln Phe	
325 330 335	
caa gga cga acc tac ttt gaa gga gaa aga aat aca gtc tat tcc tct	1056
Gln Gly Arg Thr Tyr Phe Glu Gly Glu Arg Asn Thr Val Tyr Ser Ser	
340 345 350	
tct gga gta tgt gtt ctc tat gag tgc aag gac cag acc atg aaa ctt	1104
Ser Gly Val Cys Val Leu Tyr Glu Cys Lys Asp Gln Thr Met Lys Leu	
355 360 365	
gtt gag agt tca ggc tgt cca gct ttg gat tgt cca gag tct cat cag	1152
Val Glu Ser Ser Gly Cys Pro Ala Leu Asp Cys Pro Glu Ser His Gln	
370 375 380	
ata acc ttg tct cac agc tgt tgc aaa gtt tgt aaa ggt tat gac ttt	1200
Ile Thr Leu Ser His Ser Cys Cys Lys Val Cys Lys Gly Tyr Asp Phe	
385 390 395 400	
tgt tct gaa agg cat aac tgc atg gag aat tcc atc tgc aga aat ctg	1248
Cys Ser Glu Arg His Asn Cys Met Glu Asn Ser Ile Cys Arg Asn Leu	
405 410 415	
aat gac agg gct gtt tgt agc tgt cga gat ggt ttt agg gct ctt cga	1296
Asn Asp Arg Ala Val Cys Ser Cys Arg Asp Gly Phe Arg Ala Leu Arg	
420 425 430	
gag gat aat gcc tac tgt gaa gac atc gat gag tgt gct gaa ggg cgc	1344
Glu Asp Asn Ala Tyr Cys Glu Asp Ile Asp Glu Cys Ala Glu Gly Arg	
435 440 445	
cat tac tgt cgt gaa aat aca atg tgt gtc aac acc ccg ggt tct ttt	1392
His Tyr Cys Arg Glu Asn Thr Met Cys Val Asn Thr Pro Gly Ser Phe	
450 455 460	
atg tgc atc tgc aaa act gga tac atc aga att gat gat tat tca tgt	1440
Met Cys Ile Cys Lys Thr Gly Tyr Ile Arg Ile Asp Asp Tyr Ser Cys	
465 470 475 480	

FIGURE 7B

aca gaa cat gat gag tgt atc aca aat cag cac aac tgt gat gaa aat	1488
Thr Glu His Asp Glu Cys Ile Thr Asn Gln His Asn Cys Asp Glu Asn	
485 490 495	
gct tta tgc ttc aac act gtt gga gga cac aac tgt gtt tgc aag ccg	1536
Ala Leu Cys Phe Asn Thr Val Gly Gly His Asn Cys Val Cys Lys Pro	
500 505 510	
ggc tat aca ggg aat gga acg aca tgc aaa gca ttt tgc aaa gat ggc	1584
Gly Tyr Thr Gly Asn Gly Thr Thr Cys Lys Ala Phe Cys Lys Asp Gly	
515 520 525	
tgt agg aat gga gga gcc tgt att gcc gct aat gtg tgt gcc tgc cca	1632
Cys Arg Asn Gly Gly Ala Cys Ile Ala Ala Asn Val Cys Ala Cys Pro	
530 535 540	
caa ggc ttc act gga ccc agc tgt gaa acg gac att gat gaa tgc tct	1680
Gln Gly Phe Thr Gly Pro Ser Cys Glu Thr Asp Ile Asp Glu Cys Ser	
545 550 555 560	
gat ggt ttt gtt caa tgt gac agt cgt gct aat tgc att aac ctg cct	1728
Asp Gly Phe Val Gln Cys Asp Ser Arg Ala Asn Cys Ile Asn Leu Pro	
565 570 575	
gga tgg tac cac tgt gag tgc aga gat ggc tac cat gac aat ggg atg	1776
Gly Trp Tyr His Cys Glu Cys Arg Asp Gly Tyr His Asp Asn Gly Met	
580 585 590	
ttt tca cca agt gga gaa tcg tgt gaa gat att gat gag tgt ggg acc	1824
Phe Ser Pro Ser Gly Glu Ser Cys Glu Asp Ile Asp Glu Cys Gly Thr	
595 600 605	
ggg agg cac agc tgt gcc aat gat acc att tgc ttc aat ttg gat ggc	1872
Gly Arg His Ser Cys Ala Asn Asp Thr Ile Cys Phe Asn Leu Asp Gly	
610 615 620	
gga tat gat tgt cga tgt cct cat gga aag aat tgc aca ggg gac tgc	1920
Gly Tyr Asp Cys Arg Cys Pro His Gly Lys Asn Cys Thr Gly Asp Cys	
625 630 635 640	
atc cat gat gga aaa gtt aag cac aat ggt cag att tgg gtg ttg gaa	1968
Ile His Asp Gly Lys Val Lys His Asn Gly Gln Ile Trp Val Leu Glu	
645 650 655	
aat gac agg tgc tct gtg tgc tca tgt cag aat gga ttc gtt atg tgt	2016
Asn Asp Arg Cys Ser Val Cys Ser Cys Gln Asn Gly Phe Val Met Cys	
660 665 670	
cga cgg atg gtc tgt gac tgt gag aat ccc aca gtt gat ctt ttt tgc	2064
Arg Arg Met Val Cys Asp Cys Glu Asn Pro Thr Val Asp Leu Phe Cys	
675 680 685	
tgc cct gaa tgt gac cca agg ctt agt agt cag tgc ctc cat caa aat	2112
Cys Pro Glu Cys Asp Pro Arg Leu Ser Ser Gln Cys Leu His Gln Asn	
690 695 700	

FIGURE 7C

ggg gaa act ttg tat aac agt ggt gac acc tgg gtc cag aat tgt 'caa	2160
Gly Glu Thr Leu Tyr Asn Ser Gly Asp Thr Trp Val Gln Asn Cys Gln	
705 710 715 720	
cag tgc cgc tgc ttg caa ggg gaa gtt gat tgt tgg ccc ctg cct tgc	2208
Gln Cys Arg Cys Leu Gln Gly Glu Val Asp Cys Trp Pro Leu Pro Cys	
725 730 735	
cca gat gtg gag tgt gaa ttc agc att ctc cca gag aat gag tgc tgc	2256
Pro Asp Val Glu Cys Glu Phe Ser Ile Leu Pro Glu Asn Glu Cys Cys	
740 745 750	
ccg cgc tgt gtc aca gac cct tgc cag gct gac acc atc cgc aat gac	2304
Pro Arg Cys Val Thr Asp Pro Cys Gln Ala Asp Thr Ile Arg Asn Asp	
755 760 765	
atc acc aag act tgc ctg gac gaa atg aat gtg gtt cgc ttc acc ggg	2352
Ile Thr Lys Thr Cys Leu Asp Glu Met Asn Val Val Arg Phe Thr Gly	
770 775 780	
tcc tct tgg atc aaa cat ggc act gag tgt act ctc tgc cag tgc aag	2400
Ser Ser Trp Ile Lys His Gly Thr Glu Cys Thr Leu Cys Gln Cys Lys	
785 790 795 800	
aat ggc cac atc tgt tgc tca gtg gat cca cag tgc ctt cag gaa ctg	2448
Asn Gly His Ile Cys Cys Ser Val Asp Pro Gln Cys Leu Gln Glu Leu	
805 810 815	
tga	2451
*	

FIGURE 7D

Met	Glu	Ser	Arg	Val	Leu	Leu	Arg	Thr	Phe	Cys	Leu	Ile	Phe	Gly	Leu
1				5					10					15	
Gly	Ala	Val	Trp	Gly	Leu	Gly	Val	Asp	Pro	Ser	Leu	Gln	Ile	Asp	Val
			20					25					30		
Leu	Thr	Glu	Leu	Glu	Leu	Gly	Glu	Ser	Thr	Thr	Gly	Val	Arg	Gln	Val
		35					40					45			
Pro	Gly	Leu	His	Asn	Gly	Thr	Lys	Ala	Phe	Leu	Phe	Gln	Asp	Thr	Pro
	50					55					60				
Arg	Ser	Ile	Lys	Ala	Ser	Thr	Ala	Thr	Ala	Glu	Gln	Phe	Phe	Gln	Lys
65					70					75					80
Leu	Arg	Asn	Lys	His	Glu	Phe	Thr	Ile	Leu	Val	Thr	Leu	Lys	Gln	Thr
				85					90					95	
His	Leu	Asn	Ser	Gly	Val	Ile	Leu	Ser	Ile	His	His	Leu	Asp	His	Arg
			100					105					110		
Tyr	Leu	Glu	Leu	Glu	Ser	Ser	Gly	His	Arg	Asn	Glu	Val	Arg	Leu	His
		115					120					125			
Tyr	Arg	Ser	Gly	Ser	His	Arg	Pro	His	Thr	Glu	Val	Phe	Pro	Tyr	Ile
	130					135					140				
Leu	Ala	Asp	Asp	Lys	Trp	His	Lys	Leu	Ser	Leu	Ala	Ile	Ser	Ala	Ser
145					150					155					160
His	Leu	Ile	Leu	His	Ile	Asp	Cys	Asn	Lys	Ile	Tyr	Glu	Arg	Val	Val
				165				170						175	
Glu	Lys	Pro	Ser	Thr	Asp	Leu	Pro	Leu	Gly	Thr	Thr	Phe	Trp	Leu	Gly
			180					185					190		
Gln	Arg	Asn	Asn	Ala	His	Gly	Tyr	Phe	Lys	Gly	Ile	Met	Gln	Asp	Val
		195					200						205		
Gln	Leu	Leu	Val	Met	Pro	Gln	Gly	Phe	Ile	Ala	Gln	Cys	Pro	Asp	Leu
	210					215					220				
Asn	Arg	Thr	Cys	Pro	Thr	Cys	Asn	Asp	Phe	His	Gly	Leu	Val	Gln	Lys
225					230					235					240
Ile	Met	Glu	Leu	Gln	Asp	Ile	Leu	Ala	Lys	Thr	Ser	Ala	Lys	Leu	Ser
				245					250					255	
Arg	Ala	Glu	Gln	Arg	Met	Asn	Arg	Leu	Asp	Gln	Cys	Tyr	Cys	Glu	Arg
			260					265					270		
Thr	Cys	Thr	Met	Lys	Gly	Thr	Thr	Tyr	Arg	Glu	Phe	Glu	Ser	Trp	Ile
		275					280					285			
Asp	Gly	Cys	Lys	Asn	Cys	Thr	Cys	Leu	Asn	Gly	Thr	Ile	Gln	Cys	Glu
290					295						300				
Thr	Leu	Ile	Cys	Pro	Asn	Pro	Asp	Cys	Pro	Leu	Lys	Ser	Ala	Leu	Ala
305					310					315					320
Tyr	Val	Asp	Gly	Lys	Cys	Cys	Lys	Glu	Cys	Lys	Ser	Ile	Cys	Gln	Phe
			325						330					335	
Gln	Gly	Arg	Thr	Tyr	Phe	Glu	Gly	Glu	Arg	Asn	Thr	Val	Tyr	Ser	Ser
			340					345					350		
Ser	Gly	Val	Cys	Val	Leu	Tyr	Glu	Cys	Lys	Asp	Gln	Thr	Met	Lys	Leu
		355					360					365			
Val	Glu	Ser	Ser	Gly	Cys	Pro	Ala	Leu	Asp	Cys	Pro	Glu	Ser	His	Gln
	370					375					380				
Ile	Thr	Leu	Ser	His	Ser	Cys	Cys	Lys	Val	Cys	Lys	Gly	Tyr	Asp	Phe
385					390					395					400
Cys	Ser	Glu	Arg	His	Asn	Cys	Met	Glu	Asn	Ser	Ile	Cys	Arg	Asn	Leu
				405					410					415	
Asn	Asp	Arg	Ala	Val	Cys	Ser	Cys	Arg	Asp	Gly	Phe	Arg	Ala	Leu	Arg
			420					425					430		
Glu	Asp	Asn	Ala	Tyr	Cys	Glu	Asp	Ile	Asp	Glu	Cys	Ala	Glu	Gly	Arg
		435				440						445			
His	Tyr	Cys	Arg	Glu	Asn	Thr	Met	Cys	Val	Asn	Thr	Pro	Gly	Ser	Phe
	450					455					460				
Met	Cys	Ile	Cys	Lys	Thr	Gly	Tyr	Ile	Arg	Ile	Asp	Asp	Tyr	Ser	Cys
465					470					475					480

FIGURE 8A

Thr	Glu	His	Asp	Glu	Cys	Ile	Thr	Asn	Gln	His	Asn	Cys	Asp	Glu	Asn
				485					490					495	
Ala	Leu	Cys	Phe	Asn	Thr	Val	Gly	Gly	His	Asn	Cys	Val	Cys	Lys	Pro
			500					505					510		
Gly	Tyr	Thr	Gly	Asn	Gly	Thr	Thr	Cys	Lys	Ala	Phe	Cys	Lys	Asp	Gly
		515					520					525			
Cys	Arg	Asn	Gly	Gly	Ala	Cys	Ile	Ala	Ala	Asn	Val	Cys	Ala	Cys	Pro
		530				535					540				
Gln	Gly	Phe	Thr	Gly	Pro	Ser	Cys	Glu	Thr	Asp	Ile	Asp	Glu	Cys	Ser
545					550					555					560
Asp	Gly	Phe	Val	Gln	Cys	Asp	Ser	Arg	Ala	Asn	Cys	Ile	Asn	Leu	Pro
				565					570					575	
Gly	Trp	Tyr	His	Cys	Glu	Cys	Arg	Asp	Gly	Tyr	His	Asp	Asn	Gly	Met
			580					585					590		
Phe	Ser	Pro	Ser	Gly	Glu	Ser	Cys	Glu	Asp	Ile	Asp	Glu	Cys	Gly	Thr
		595					600					605			
Gly	Arg	His	Ser	Cys	Ala	Asn	Asp	Thr	Ile	Cys	Phe	Asn	Leu	Asp	Gly
		610				615						620			
Gly	Tyr	Asp	Cys	Arg	Cys	Pro	His	Gly	Lys	Asn	Cys	Thr	Gly	Asp	Cys
625					630					635					640
Ile	His	Asp	Gly	Lys	Val	Lys	His	Asn	Gly	Gln	Ile	Trp	Val	Leu	Glu
				645					650					655	
Asn	Asp	Arg	Cys	Ser	Val	Cys	Ser	Cys	Gln	Asn	Gly	Phe	Val	Met	Cys
			660					665					670		
Arg	Arg	Met	Val	Cys	Asp	Cys	Glu	Asn	Pro	Thr	Val	Asp	Leu	Phe	Cys
		675					680					685			
Cys	Pro	Glu	Cys	Asp	Pro	Arg	Leu	Ser	Ser	Gln	Cys	Leu	His	Gln	Asn
		690				695					700				
Gly	Glu	Thr	Leu	Tyr	Asn	Ser	Gly	Asp	Thr	Trp	Val	Gln	Asn	Cys	Gln
705					710					715					720
Gln	Cys	Arg	Cys	Leu	Gln	Gly	Glu	Val	Asp	Cys	Trp	Pro	Leu	Pro	Cys
				725					730					735	
Pro	Asp	Val	Glu	Cys	Glu	Phe	Ser	Ile	Leu	Pro	Glu	Asn	Glu	Cys	Cys
			740					745					750		
Pro	Arg	Cys	Val	Thr	Asp	Pro	Cys	Gln	Ala	Asp	Thr	Ile	Arg	Asn	Asp
		755					760					765			
Ile	Thr	Lys	Thr	Cys	Leu	Asp	Glu	Met	Asn	Val	Val	Arg	Phe	Thr	Gly
						775						780			
Ser	Ser	Trp	Ile	Lys	His	Gly	Thr	Glu	Cys	Thr	Leu	Cys	Gln	Cys	Lys
785					790					795					800
Asn	Gly	His	Ile	Cys	Cys	Ser	Val	Asp	Pro	Gln	Cys	Leu	Gln	Glu	Leu
				805					810					815	

FIGURE 8B

atg gaa tcc cgg gta tta ctg aga acg ttc tgc gtg atc ctc ggg ctc	48
Met Glu Ser Arg Val Leu Leu Arg Thr Phe Cys Val Ile Leu Gly Leu	
1 5 10 15	
gaa gcg gtt tgg gga ctt ggt gtg gac ccc tcc cta cag att gac gtc	96
Glu Ala Val Trp Gly Leu Gly Val Asp Pro Ser Leu Gln Ile Asp Val	
20 25 30	
tta tca gag tta gaa ctt ggg gag tcc aca gct gga gtg cgc caa gtc	144
Leu Ser Glu Leu Glu Leu Gly Glu Ser Thr Ala Gly Val Arg Gln Val	
35 40 45	
cca gga ctg cat aat ggg acg aaa gcc ttc ctc ttc caa gat tcc ccc	192
Pro Gly Leu His Asn Gly Thr Lys Ala Phe Leu Phe Gln Asp Ser Pro	
50 55 60	
aga agc ata aaa gca ccc att gct aca gct gag cgg ttt ttc cag aag	240
Arg Ser Ile Lys Ala Pro Ile Ala Thr Ala Glu Arg Phe Phe Gln Lys	
65 70 75 80	
ctg agg aat aaa cac gag ttc aca att ctg gtg acc ctg aaa cag atc	288
Leu Arg Asn Lys His Glu Phe Thr Ile Leu Val Thr Leu Lys Gln Ile	
85 90 95	
cac tta aat tcg gga gtc att ctc tcc atc cac cac ttg gat cac agg	336
His Leu Asn Ser Gly Val Ile Leu Ser Ile His His Leu Asp His Arg	
100 105 110	
tac ctg gaa ctg gaa agc agc ggc cac cgg aat gag atc aga ctg cat	384
Tyr Leu Glu Leu Glu Ser Ser Gly His Arg Asn Glu Ile Arg Leu His	
115 120 125	
tac cgc tct gga act cac cgc ccg cac acg gaa gtg ttt cct tat att	432
Tyr Arg Ser Gly Thr His Arg Pro His Thr Glu Val Phe Pro Tyr Ile	
130 135 140	
ttg gct gat gcc aag tgg cac aag ctc tcc tta gcc ttc agt gcc tcc	480
Leu Ala Asp Ala Lys Trp His Lys Leu Ser Leu Ala Phe Ser Ala Ser	
145 150 155 160	
cac tta att tta cac atc gac tgc aac aag atc tat gaa cga gtg gtg	528
His Leu Ile Leu His Ile Asp Cys Asn Lys Ile Tyr Glu Arg Val Val	
165 170 175	
gaa atg cct tct aca gac ttg cct ctg ggc acc aca ttt tgg ttg gga	576
Glu Met Pro Ser Thr Asp Leu Pro Leu Gly Thr Thr Phe Trp Leu Gly	
180 185 190	
cag aga aat aac gca cac ggg tat ttt aag gga ata atg caa gat gtg	624
Gln Arg Asn Asn Ala His Gly Tyr Phe Lys Gly Ile Met Gln Asp Val	
195 200 205	
caa tta ctt gtc atg ccc cag ggg ttc atc gct cag tgc ccg gat ctt	672
Gln Leu Leu Val Met Pro Gln Gly Phe Ile Ala Gln Cys Pro Asp Leu	
210 215 220	
aat cga acc tgt cca aca tgc aac gac ttc cat ggg ctt gtg cag aaa	720
Asn Arg Thr Cys Pro Thr Cys Asn Asp Phe His Gly Leu Val Gln Lys	
225 230 235 240	

FIGURE 9A

atc atg gag ctg cag gac att tta tgc aag acg tca gcc aag ttg tct Ile Met Glu Leu Gln Asp Ile Leu Ser Lys Thr Ser Ala Lys Leu Ser 245 250 255	768
aga gct gaa caa cga atg aac agg ctg gat cag tgc tac tgt gag cgg Arg Ala Glu Gln Arg Met Asn Arg Leu Asp Gln Cys Tyr Cys Glu Arg 260 265 270	816
acg tgc acc atg aag gga gcc acc tac cgg gag ttc gag tcc tgg aca Thr Cys Thr Met Lys Gly Ala Thr Tyr Arg Glu Phe Glu Ser Trp Thr 275 280 285	864
gac ggc tgc aag aac tgc aca tgc ttg aat ggg acc atc cag tgc gag Asp Gly Cys Lys Asn Cys Thr Cys Leu Asn Gly Thr Ile Gln Cys Glu 290 295 300	912
act ctg gtc tgc cct gct ccc gac tgc ccg gct aaa tgc gct cca gcg Thr Leu Val Cys Pro Ala Pro Asp Cys Pro Ala Lys Ser Ala Pro Ala 305 310 315 320	960
tac gtg gat ggc aag tgc tgt aag gag tgc aag tcc acc tgc cag ttc Tyr Val Asp Gly Lys Cys Cys Lys Glu Cys Lys Ser Thr Cys Gln Phe 325 330 335	1008
cag ggg cgg agc tac ttt gag gga gaa agg agc aca gtc ttc tca gct Gln Gly Arg Ser Tyr Phe Glu Gly Glu Arg Ser Thr Val Phe Ser Ala 340 345 350	1056
tcc gga atg tgc gtc ttg tat gaa tgc aag gat cag acc atg aag ctt Ser Gly Met Cys Val Leu Tyr Glu Cys Lys Asp Gln Thr Met Lys Leu 355 360 365	1104
gtt gag aac gcc ggc tgc ccg gct tta gat tgc ccc gag tct cat cag Val Glu Asn Ala Gly Cys Pro Ala Leu Asp Cys Pro Glu Ser His Gln 370 375 380	1152
atc gcc ttg tct cac agc tgc tgc aag gtt tgc aaa ggt tat gac ttc Ile Ala Leu Ser His Ser Cys Cys Lys Val Cys Lys Gly Tyr Asp Phe 385 390 395 400	1200
tgt tct gag aag cat aca tgc atg gag aac tca gtc tgc agg aac ctg Cys Ser Glu Lys His Thr Cys Met Glu Asn Ser Val Cys Arg Asn Leu 405 410 415	1248
aac gac agg gca gtg tgc agc tgc cgg gat ggt ttc cgg gcc ctc cgg Asn Asp Arg Ala Val Cys Ser Cys Arg Asp Gly Phe Arg Ala Leu Arg 420 425 430	1296
gag gac aat gcc tac tgt gaa gac att gac gag tgt gca gag ggg cgc Glu Asp Asn Ala Tyr Cys Glu Asp Ile Asp Glu Cys Ala Glu Gly Arg 435 440 445	1344
cat tac tgc cgt gag aac acc atg tgt gtg aac aca ccg ggc tct ttc His Tyr Cys Arg Glu Asn Thr Met Cys Val Asn Thr Pro Gly Ser Phe 450 455 460	1392
ctg tgt atc tgc caa aca ggg tac atc aga atc gac gat tac tgc tgt Leu Cys Ile Cys Gln Thr Gly Tyr Ile Arg Ile Asp Asp Tyr Ser Cys 465 470 475 480	1440

FIGURE 9B

acg gaa cat gac gag tgc ctc aca aac cag cac aac tgt gac gag aac Thr Glu His Asp Glu Cys Leu Thr Asn Gln His Asn Cys Asp Glu Asn 485 490 495	1488
gct ttg tgc ttt aac acc gtt gga ggt cac aac tgc gtc tgc aag cct Ala Leu Cys Phe Asn Thr Val Gly Gly His Asn Cys Val Cys Lys Pro 500 505 510	1536
ggg tac act ggg aat gga acc acg tgc aaa gct ttc tgc aaa gac ggc Gly Tyr Thr Gly Asn Gly Thr Thr Cys Lys Ala Phe Cys Lys Asp Gly 515 520 525	1584
tgc aaa aac gga ggt gcc tgc att gct gcc aat gtc tgt gct tgc cca Cys Lys Asn Gly Gly Ala Cys Ile Ala Ala Asn Val Cys Ala Cys Pro 530 535 540	1632
caa ggc ttc acc gga ccc agc tgt gag aca gac att gat gag tgc tct Gln Gly Phe Thr Gly Pro Ser Cys Glu Thr Asp Ile Asp Glu Cys Ser 545 550 555 560	1680
gag ggc ttt gtt cag tgt gac agc cgt gcc aac tgc att aac ctg cct Glu Gly Phe Val Gln Cys Asp Ser Arg Ala Asn Cys Ile Asn Leu Pro 565 570 575	1728
ggg tgg tac cac tgt gag tgc aga gat ggc tac cat gac aat ggg atg Gly Trp Tyr His Cys Glu Cys Arg Asp Gly Tyr His Asp Asn Gly Met 580 585 590	1776
ttt gcg cca ggt gga gaa tcc tgt gaa gat att gat gaa tgt ggg act Phe Ala Pro Gly Gly Glu Ser Cys Glu Asp Ile Asp Glu Cys Gly Thr 595 600 605	1824
ggg agg cac agc tgt gcc aat gac acc att tgc ttc aac ttg gac ggt Gly Arg His Ser Cys Ala Asn Asp Thr Ile Cys Phe Asn Leu Asp Gly 610 615 620	1872
ggc tac gat tgc cgg tgt ccc cat gga aag aac tgc aca ggg gac tgc Gly Tyr Asp Cys Arg Cys Pro His Gly Lys Asn Cys Thr Gly Asp Cys 625 630 635 640	1920
gtg cac gac ggg aaa gtc aaa cac aac ggc cag atc tgg gtg ctg gag Val His Asp Gly Lys Val Lys His Asn Gly Gln Ile Trp Val Leu Glu 645 650 655	1968
aac gac agg tgc tct gtg tgt tcc tgc cag act gga ttt gtt atg tgc Asn Asp Arg Cys Ser Val Cys Ser Cys Gln Thr Gly Phe Val Met Cys 660 665 670	2016
caa cgg atg gtc tgt gac tgc gaa aac ccc aca gtt gac ctc tcc tgc Gln Arg Met Val Cys Asp Cys Glu Asn Pro Thr Val Asp Leu Ser Cys 675 680 685	2064
tgc cct gag tgc gac cca agg ctg agc agc cag tgc ctg cat caa aac Cys Pro Glu Cys Asp Pro Arg Leu Ser Ser Gln Cys Leu His Gln Asn 690 695 700	2112
ggg gaa acc gtg tac aac agc ggt gac acc tgg gcc cag gat tgc cgt Gly Glu Thr Val Tyr Asn Ser Gly Asp Thr Trp Ala Gln Asp Cys Arg 705 710 715 720	2160

FIGURE 9C

cag tgc cgc tgc ttg caa gaa gaa gtt gac tgc tgg ccc ctg gct tgc	2208
Gln Cys Arg Cys Leu Gln Glu Glu Val Asp Cys Trp Pro Leu Ala Cys	
725 730 735	
cca gag gta gag tgt gaa ttt agt gtc ctt cct gag aac gag tgc tgc	2256
Pro Glu Val Glu Cys Glu Phe Ser Val Leu Pro Glu Asn Glu Cys Cys	
740 745 750	
cca cgc tgt gtc acc gat cct tgt cag gct gac acc atc cgc aat gac	2304
Pro Arg Cys Val Thr Asp Pro Cys Gln Ala Asp Thr Ile Arg Asn Asp	
755 760 765	
atc acc aaa acc tgc ctg gac gag atg aac gtg gtt cgc ttc act ggg	2352
Ile Thr Lys Thr Cys Leu Asp Glu Met Asn Val Val Arg Phe Thr Gly	
770 775 780	
tct tcc tgg atc aag cac ggc acg gag tgc acc ctc tgc cag tgc aag	2400
Ser Ser Trp Ile Lys His Gly Thr Glu Cys Thr Leu Cys Gln Cys Lys	
785 790 795 800	
aac ggc cac gtg tgc tgc tca gtg gac cca cag tgc ctc cag gag ctg	2448
Asn Gly His Val Cys Cys Ser Val Asp Pro Gln Cys Leu Gln Glu Leu	
805 810 815	
tga	2451
*	

FIGURE 9D

Met	Glu	Ser	Arg	Val	Leu	Leu	Arg	Thr	Phe	Cys	Val	Ile	Leu	Gly	Leu
1				5					10					15	
Glu	Ala	Val	Trp	Gly	Leu	Gly	Val	Asp	Pro	Ser	Leu	Gln	Ile	Asp	Val
			20					25						30	
Leu	Ser	Glu	Leu	Glu	Leu	Gly	Glu	Ser	Thr	Ala	Gly	Val	Arg	Gln	Val
		35					40					45			
Pro	Gly	Leu	His	Asn	Gly	Thr	Lys	Ala	Phe	Leu	Phe	Gln	Asp	Ser	Pro
	50					55					60				
Arg	Ser	Ile	Lys	Ala	Pro	Ile	Ala	Thr	Ala	Glu	Arg	Phe	Phe	Gln	Lys
65					70					75					80
Leu	Arg	Asn	Lys	His	Glu	Phe	Thr	Ile	Leu	Val	Thr	Leu	Lys	Gln	Ile
				85					90					95	
His	Leu	Asn	Ser	Gly	Val	Ile	Leu	Ser	Ile	His	His	Leu	Asp	His	Arg
			100					105					110		
Tyr	Leu	Glu	Leu	Glu	Ser	Ser	Gly	His	Arg	Asn	Glu	Ile	Arg	Leu	His
		115					120					125			
Tyr	Arg	Ser	Gly	Thr	His	Arg	Pro	His	Thr	Glu	Val	Phe	Pro	Tyr	Ile
	130					135					140				
Leu	Ala	Asp	Ala	Lys	Trp	His	Lys	Leu	Ser	Leu	Ala	Phe	Ser	Ala	Ser
145					150					155					160
His	Leu	Ile	Leu	His	Ile	Asp	Cys	Asn	Lys	Ile	Tyr	Glu	Arg	Val	Val
				165					170					175	
Glu	Met	Pro	Ser	Thr	Asp	Leu	Pro	Leu	Gly	Thr	Thr	Phe	Trp	Leu	Gly
			180					185					190		
Gln	Arg	Asn	Asn	Ala	His	Gly	Tyr	Phe	Lys	Gly	Ile	Met	Gln	Asp	Val
		195					200					205			
Gln	Leu	Leu	Val	Met	Pro	Gln	Gly	Phe	Ile	Ala	Gln	Cys	Pro	Asp	Leu
	210					215					220				
Asn	Arg	Thr	Cys	Pro	Thr	Cys	Asn	Asp	Phe	His	Gly	Leu	Val	Gln	Lys
225					230					235					240
Ile	Met	Glu	Leu	Gln	Asp	Ile	Leu	Ser	Lys	Thr	Ser	Ala	Lys	Leu	Ser
				245					250					255	
Arg	Ala	Glu	Gln	Arg	Met	Asn	Arg	Leu	Asp	Gln	Cys	Tyr	Cys	Glu	Arg
			260					265					270		
Thr	Cys	Thr	Met	Lys	Gly	Ala	Thr	Tyr	Arg	Glu	Phe	Glu	Ser	Trp	Thr
		275					280					285			
Asp	Gly	Cys	Lys	Asn	Cys	Thr	Cys	Leu	Asn	Gly	Thr	Ile	Gln	Cys	Glu
	290					295					300				
Thr	Leu	Val	Cys	Pro	Ala	Pro	Asp	Cys	Pro	Ala	Lys	Ser	Ala	Pro	Ala
305					310					315					320
Tyr	Val	Asp	Gly	Lys	Cys	Cys	Lys	Glu	Cys	Lys	Ser	Thr	Cys	Gln	Phe
				325					330					335	
Gln	Gly	Arg	Ser	Tyr	Phe	Glu	Gly	Glu	Arg	Ser	Thr	Val	Phe	Ser	Ala
			340					345					350		
Ser	Gly	Met	Cys	Val	Leu	Tyr	Glu	Cys	Lys	Asp	Gln	Thr	Met	Lys	Leu
		355					360					365			
Val	Glu	Asn	Ala	Gly	Cys	Pro	Ala	Leu	Asp	Cys	Pro	Glu	Ser	His	Gln
		370				375					380				
Ile	Ala	Leu	Ser	His	Ser	Cys	Cys	Lys	Val	Cys	Lys	Gly	Tyr	Asp	Phe
385					390					395					400
Cys	Ser	Glu	Lys	His	Thr	Cys	Met	Glu	Asn	Ser	Val	Cys	Arg	Asn	Leu
				405					410					415	
Asn	Asp	Arg	Ala	Val	Cys	Ser	Cys	Arg	Asp	Gly	Phe	Arg	Ala	Leu	Arg
			420					425					430		
Glu	Asp	Asn	Ala	Tyr	Cys	Glu	Asp	Ile	Asp	Glu	Cys	Ala	Glu	Gly	Arg
		435					440					445			
His	Tyr	Cys	Arg	Glu	Asn	Thr	Met	Cys	Val	Asn	Thr	Pro	Gly	Ser	Phe
				450			455					460			

FIGURE 10A

Leu	Cys	Ile	Cys	Gln	Thr	Gly	Tyr	Ile	Arg	Ile	Asp	Asp	Tyr	Ser	Cys
465					470					475					480
Thr	Glu	His	Asp	Glu	Cys	Leu	Thr	Asn	Gln	His	Asn	Cys	Asp	Glu	Asn
				485					490					495	
Ala	Leu	Cys	Phe	Asn	Thr	Val	Gly	Gly	His	Asn	Cys	Val	Cys	Lys	Pro
			500					505					510		
Gly	Tyr	Thr	Gly	Asn	Gly	Thr	Thr	Cys	Lys	Ala	Phe	Cys	Lys	Asp	Gly
		515				520						525			
Cys	Lys	Asn	Gly	Gly	Ala	Cys	Ile	Ala	Ala	Asn	Val	Cys	Ala	Cys	Pro
	530					535					540				
Gln	Gly	Phe	Thr	Gly	Pro	Ser	Cys	Glu	Thr	Asp	Ile	Asp	Glu	Cys	Ser
545					550					555					560
Glu	Gly	Phe	Val	Gln	Cys	Asp	Ser	Arg	Ala	Asn	Cys	Ile	Asn	Leu	Pro
				565					570					575	
Gly	Trp	Tyr	His	Cys	Glu	Cys	Arg	Asp	Gly	Tyr	His	Asp	Asn	Gly	Met
			580					585					590		
Phe	Ala	Pro	Gly	Gly	Glu	Ser	Cys	Glu	Asp	Ile	Asp	Glu	Cys	Gly	Thr
		595					600					605			
Gly	Arg	His	Ser	Cys	Ala	Asn	Asp	Thr	Ile	Cys	Phe	Asn	Leu	Asp	Gly
	610					615					620				
Gly	Tyr	Asp	Cys	Arg	Cys	Pro	His	Gly	Lys	Asn	Cys	Thr	Gly	Asp	Cys
625					630					635					640
Val	His	Asp	Gly	Lys	Val	Lys	His	Asn	Gly	Gln	Ile	Trp	Val	Leu	Glu
				645					650					655	
Asn	Asp	Arg	Cys	Ser	Val	Cys	Ser	Cys	Gln	Thr	Gly	Phe	Val	Met	Cys
			660					665					670		
Gln	Arg	Met	Val	Cys	Asp	Cys	Glu	Asn	Pro	Thr	Val	Asp	Leu	Ser	Cys
		675					680					685			
Cys	Pro	Glu	Cys	Asp	Pro	Arg	Leu	Ser	Ser	Gln	Cys	Leu	His	Gln	Asn
	690					695					700				
Gly	Glu	Thr	Val	Tyr	Asn	Ser	Gly	Asp	Thr	Trp	Ala	Gln	Asp	Cys	Arg
705					710					715					720
Gln	Cys	Arg	Cys	Leu	Gln	Glu	Glu	Val	Asp	Cys	Trp	Pro	Leu	Ala	Cys
				725					730					735	
Pro	Glu	Val	Glu	Cys	Glu	Phe	Ser	Val	Leu	Pro	Glu	Asn	Glu	Cys	Cys
			740					745					750		
Pro	Arg	Cys	Val	Thr	Asp	Pro	Cys	Gln	Ala	Asp	Thr	Ile	Arg	Asn	Asp
		755					760						765		
Ile	Thr	Lys	Thr	Cys	Leu	Asp	Glu	Met	Asn	Val	Val	Arg	Phe	Thr	Gly
	770					775						780			
Ser	Ser	Trp	Ile	Lys	His	Gly	Thr	Glu	Cys	Thr	Leu	Cys	Gln	Cys	Lys
785					790					795					800
Asn	Gly	His	Val	Cys	Cys	Ser	Val	Asp	Pro	Gln	Cys	Leu	Gln	Glu	Leu
				805					810					815	

FIGURE 10B

atg cac gcc atg gaa tcc cgg gtg tta ctg aga acg ttc tgc gtg atc	48
Met His Ala Met Glu Ser Arg Val Leu Leu Arg Thr Phe Cys Val Ile	
1 5 10 15	
ctc ggc ctt gga gcg gtt tgg ggg ctt ggt gtg gac ccc tcc cta cag	96
Leu Gly Leu Gly Ala Val Trp Gly Leu Gly Val Asp Pro Ser Leu Gln	
20 25 30	
att gac gtc tta aca gag tta gaa ctt ggg gag tct aca gat gga gtg	144
Ile Asp Val Leu Thr Glu Leu Glu Leu Gly Glu Ser Thr Asp Gly Val	
35 40 45	
cgc caa gtc ccg gga ctg cat aat ggg acg aaa gcc ttc ctc ttc caa	192
Arg Gln Val Pro Gly Leu His Asn Gly Thr Lys Ala Phe Leu Phe Gln	
50 55 60	
gag tcc ccc aga agc ata aag gca tcc act gct aca gct gag cgg ttt	240
Glu Ser Pro Arg Ser Ile Lys Ala Ser Thr Ala Thr Ala Glu Arg Phe	
65 70 75 80	
ctc cag aag ctg aga aat aaa cac gag ttc aca atc ttg gtg acc tta	288
Leu Gln Lys Leu Arg Asn Lys His Glu Phe Thr Ile Leu Val Thr Leu	
85 90 95	
aaa cag atc cac tta aat tcg gga gtt atc ctc tcc atc cac cac ttg	336
Lys Gln Ile His Leu Asn Ser Gly Val Ile Leu Ser Ile His His Leu	
100 105 110	
gat cac agg tac ctg gaa ctg gaa agc agt ggc cat cgg aat gag atc	384
Asp His Arg Tyr Leu Glu Leu Glu Ser Ser Gly His Arg Asn Glu Ile	
115 120 125	
aga ctc cac tac cgc tct ggc act cac cgc ccc cac acg gaa gtg ttt	432
Arg Leu His Tyr Arg Ser Gly Thr His Arg Pro His Thr Glu Val Phe	
130 135 140	
cct tat att ttg gct gat gcc aag tgg cac aag ctc tcc tta gcc ttc	480
Pro Tyr Ile Leu Ala Asp Ala Lys Trp His Lys Leu Ser Leu Ala Phe	
145 150 155 160	
agt gcc tct cac tta att tta cac atc gac tgc aat aag atc tat gaa	528
Ser Ala Ser His Leu Ile Leu His Ile Asp Cys Asn Lys Ile Tyr Glu	
165 170 175	
cga gtg gtg gaa atg ccc ttc aca gac ttg gct ctg ggc aca aca ttt	576
Arg Val Val Glu Met Pro Phe Thr Asp Leu Ala Leu Gly Thr Thr Phe	
180 185 190	
tgg ttg gga cag aga aat aat gca cat ggc tat ttt aag gga ata atg	624
Trp Leu Gly Gln Arg Asn Asn Ala His Gly Tyr Phe Lys Gly Ile Met	
195 200 205	
cag gat gtg cac gtn ctt gtc atg cct cag ggc ttc att gct cag tgc	672
Gln Asp Val His Val Leu Val Met Pro Gln Gly Phe Ile Ala Gln Cys	
210 215 220	
ccg gac ctt aat cga acc tgt cca aca tgc aac gac ttc cat ggg ctt	720
Pro Asp Leu Asn Arg Thr Cys Pro Thr Cys Asn Asp Phe His Gly Leu	
225 230 235 240	

FIGURE 11A

gtg	cag	aaa	atc	atg	gag	ctg	cag	gac	att	tta	tca	aag	acg	tca	gcc	768
Val	Gln	Lys	Ile	Met	Glu	Leu	Gln	Asp	Ile	Leu	Ser	Lys	Thr	Ser	Ala	
				245					250					255		
aag	ctg	tcc	cga	gct	gaa	caa	aga	atg	aac	agg	ctg	gat	cag	tgc	tac	816
Lys	Leu	Ser	Arg	Ala	Glu	Gln	Arg	Met	Asn	Arg	Leu	Asp	Gln	Cys	Tyr	
			260					265					270			
tgt	gag	cgg	aca	tgc	act	gtg	aag	gga	acc	acc	tac	cga	gag	tct	gag	864
Cys	Glu	Arg	Thr	Cys	Thr	Val	Lys	Gly	Thr	Thr	Tyr	Arg	Glu	Ser	Glu	
			275					280					285			
tcc	tgg	aca	gac	ggc	tgt	aag	aac	tgc	aca	tgc	ttg	aac	ggg	acc	atc	912
Ser	Trp	Thr	Asp	Gly	Cys	Lys	Asn	Cys	Thr	Cys	Leu	Asn	Gly	Thr	Ile	
	290							295					300			
cag	tgc	gag	act	ctg	gtc	tgc	cct	gct	cct	gac	tgc	cct	cct	aaa	tcg	960
Gln	Cys	Glu	Thr	Leu	Val	Cys	Pro	Ala	Pro	Asp	Cys	Pro	Pro	Lys	Ser	
	305				310					315					320	
gcc	cct	gcg	tat	gtg	gat	ggc	aag	tgc	tgt	aag	gag	tgc	aaa	tca	acc	1008
Ala	Pro	Ala	Tyr	Val	Asp	Gly	Lys	Cys	Cys	Lys	Glu	Cys	Lys	Ser	Thr	
				325					330					335		
tgc	cag	ttc	cag	gga	cgg	agc	tac	ttt	gag	gga	gaa	agg	aac	acg	gca	1056
Cys	Gln	Phe	Gln	Gly	Arg	Ser	Tyr	Phe	Glu	Gly	Glu	Arg	Asn	Thr	Ala	
			340					345					350			
tac	tca	tct	tct	gga	atg	tgt	gtc	tta	tat	gaa	tgc	aag	gat	cag	acc	1104
Tyr	Ser	Ser	Ser	Gly	Met	Cys	Val	Leu	Tyr	Glu	Cys	Lys	Asp	Gln	Thr	
			355					360					365			
atg	aag	ctt	gtt	gag	aac	att	ggc	tgc	cca	ccc	tta	gat	tgt	ccc	gag	1152
Met	Lys	Leu	Val	Glu	Asn	Ile	Gly	Cys	Pro	Pro	Leu	Asp	Cys	Pro	Glu	
	370					375							380			
tct	cat	cag	att	gcc	ttg	tct	cac	agc	tgc	tgc	aag	gtt	tgt	aaa	ggt	1200
Ser	His	Gln	Ile	Ala	Leu	Ser	His	Ser	Cys	Cys	Lys	Val	Cys	Lys	Gly	
					390						395				400	
tat	gac	ttc	tgt	tct	gag	aag	cat	acc	tgc	atg	gag	aac	tcg	gtc	tgc	1248
Tyr	Asp	Phe	Cys	Ser	Glu	Lys	His	Thr	Cys	Met	Glu	Asn	Ser	Val	Cys	
				405					410					415		
agg	aac	ctg	aac	gac	agg	gtt	gtg	tgc	agc	tgc	agg	gat	ggt	ttt	cgg	1296
Arg	Asn	Leu	Asn	Asp	Arg	Val	Val	Cys	Ser	Cys	Arg	Asp	Gly	Phe	Arg	
			420					425					430			
gct	ctc	cga	gag	gac	aac	gcc	tac	tgt	gaa	gac	att	gac	gag	tgt	gca	1344
Ala	Leu	Arg	Glu	Asp	Asn	Ala	Tyr	Cys	Glu	Asp	Ile	Asp	Glu	Cys	Ala	
			435				440					445				
gaa	ggg	cgc	cat	tac	tgc	cgt	gag	aac	acc	atg	tgt	gtg	aat	aca	cct	1392
Glu	Gly	Arg	His	Tyr	Cys	Arg	Glu	Asn	Thr	Met	Cys	Val	Asn	Thr	Pro	
	450					455					460					
ggt	tct	ttc	atg	tgt	gtc	tgc	aaa	act	ggg	tac	atc	agg	atc	gac	gat	1440
Gly	Ser	Phe	Met	Cys	Val	Cys	Lys	Thr	Gly	Tyr	Ile	Arg	Ile	Asp	Asp	
	465				470					475					480	

FIGURE 11B

tac tca tgt aca gaa cat gat gag tgt ctc aca acc cag cac aat tgt Tyr Ser Cys Thr Glu His Asp Glu Cys Leu Thr Thr Gln His Asn Cys 485 490 495	1488
gat gaa aac gct ttg tgc ttt aac act gtt gga gga cac aac tgt gtc Asp Glu Asn Ala Leu Cys Phe Asn Thr Val Gly Gly His Asn Cys Val 500 505 510	1536
tgc aag cct ggc tac acc ggg aat gga acc acg tgc aaa gct ttc tgc Cys Lys Pro Gly Tyr Thr Gly Asn Gly Thr Thr Cys Lys Ala Phe Cys 515 520 525	1584
aaa gat ggc tgt aga aac gga gga gcg tgc att gct gcc aat gtg tgt Lys Asp Gly Cys Arg Asn Gly Gly Ala Cys Ile Ala Ala Asn Val Cys 530 535 540	1632
gcc tgc cca caa ggc ttc acg gga ccc agc tgt gag aca gac att gac Ala Cys Pro Gln Gly Phe Thr Gly Pro Ser Cys Glu Thr Asp Ile Asp 545 550 555 560	1680
gag tgc tct gag ggc ttt gtt cag tgt gac agc cgt gcc aac tgc atc Glu Cys Ser Glu Gly Phe Val Gln Cys Asp Ser Arg Ala Asn Cys Ile 565 570 575	1728
aac ctg cct ggg tgg tat cac tgt gag tgc aga gac ggc tac cat gac Asn Leu Pro Gly Trp Tyr His Cys Glu Cys Arg Asp Gly Tyr His Asp 580 585 590	1776
aat ggg atg ttt gcg cca ggc gga gaa tcc tgt gaa gat att gac gaa Asn Gly Met Phe Ala Pro Gly Gly Glu Ser Cys Glu Asp Ile Asp Glu 595 600 605	1824
tgc ggg act ggg agg cac agc tgc acc aac gac acc att tgc ttc aac Cys Gly Thr Gly Arg His Ser Cys Thr Asn Asp Thr Ile Cys Phe Asn 610 615 620	1872
ttg gac ggg gga tac gat tgc cgg tgt ccc cat ggg aag aac tgc act Leu Asp Gly Gly Tyr Asp Cys Arg Cys Pro His Gly Lys Asn Cys Thr 625 630 635 640	1920
ggg gac tgc gtg cac gag ggg aaa gtg aag cac acc ggc cag atc tgg Gly Asp Cys Val His Glu Gly Lys Val Lys His Thr Gly Gln Ile Trp 645 650 655	1968
gtg ctg gaa aac gac agg tgc tcc gtg tgt tcc tgg cag act ggg ttt Val Leu Glu Asn Asp Arg Cys Ser Val Cys Ser Trp Gln Thr Gly Phe 660 665 670	2016
gtc atg tgt cga cgg atg gtc tgc gac tgc gaa aac ccc aca gat gac Val Met Cys Arg Arg Met Val Cys Asp Cys Glu Asn Pro Thr Asp Asp 675 680 685	2064
ctt tcc tgc tgc cct gag tgt gac cca agg ctg agc agt cag tgc ctg Leu Ser Cys Cys Pro Glu Cys Asp Pro Arg Leu Ser Ser Gln Cys Leu 690 695 700	2112
cat caa aac ggg gaa acc gtg tac aac agc ggc gac acc tgg gtc cag His Gln Asn Gly Glu Thr Val Tyr Asn Ser Gly Asp Thr Trp Val Gln 705 710 715 720	2160

FIGURE 11C

gat tgc cgt cag tgc cgc tgc ttg caa gga gaa gtt gac tgt tgg ccc	2208
Asp Cys Arg Gln Cys Arg Cys Leu Gln Gly Glu Val Asp Cys Trp Pro	
725 730 735	
ctg gct tgc cca gag gta gaa tgt gaa ttt agc gtc ctt cct gag aac	2256
Leu Ala Cys Pro Glu Val Glu Cys Glu Phe Ser Val Leu Pro Glu Asn	
740 745 750	
gag tgc tgc cca cgc tgt gtc acc gat cct tgt cag gcc gac acc atc	2304
Glu Cys Cys Pro Arg Cys Val Thr Asp Pro Cys Gln Ala Asp Thr Ile	
755 760 765	
cgc aat gac atc acc aaa acc tgc ctg gac gag atg aac gtg gtt cgc	2352
Arg Asn Asp Ile Thr Lys Thr Cys Leu Asp Glu Met Asn Val Val Arg	
770 775 780	
ttc acc ggg tct tcc tgg atc aag cac ggc acg gag tgt acc ctc tgc	2400
Phe Thr Gly Ser Ser Trp Ile Lys His Gly Thr Glu Cys Thr Leu Cys	
785 790 795 800	
cag tgc aag aat ggc cat ttg tgc tgc tca gtg gat cca cag tgc ctt	2448
Gln Cys Lys Asn Gly His Leu Cys Cys Ser Val Asp Pro Gln Cys Leu	
805 810 815	
cag gag ctg tga	2460
Gln Glu Leu *	

FIGURE 11D

Met	His	Ala	Met	Glu	Ser	Arg	Val	Leu	Leu	Arg	Thr	Phe	Cys	Val	Ile
1				5				10						15	
Leu	Gly	Leu	Gly	Ala	Val	Trp	Gly	Leu	Gly	Val	Asp	Pro	Ser	Leu	Gln
			20					25					30		
Ile	Asp	Val	Leu	Thr	Glu	Leu	Glu	Leu	Gly	Glu	Ser	Thr	Asp	Gly	Val
	35						40					45			
Arg	Gln	Val	Pro	Gly	Leu	His	Asn	Gly	Thr	Lys	Ala	Phe	Leu	Phe	Gln
	50					55					60				
Glu	Ser	Pro	Arg	Ser	Ile	Lys	Ala	Ser	Thr	Ala	Thr	Ala	Glu	Arg	Phe
65					70					75					80
Leu	Gln	Lys	Leu	Arg	Asn	Lys	His	Glu	Phe	Thr	Ile	Leu	Val	Thr	Leu
				85					90					95	
Lys	Gln	Ile	His	Leu	Asn	Ser	Gly	Val	Ile	Leu	Ser	Ile	His	His	Leu
			100					105					110		
Asp	His	Arg	Tyr	Leu	Glu	Leu	Glu	Ser	Ser	Gly	His	Arg	Asn	Glu	Ile
		115					120					125			
Arg	Leu	His	Tyr	Arg	Ser	Gly	Thr	His	Arg	Pro	His	Thr	Glu	Val	Phe
	130					135					140				
Pro	Tyr	Ile	Leu	Ala	Asp	Ala	Lys	Trp	His	Lys	Leu	Ser	Leu	Ala	Phe
145					150					155					160
Ser	Ala	Ser	His	Leu	Ile	Leu	His	Ile	Asp	Cys	Asn	Lys	Ile	Tyr	Glu
				165					170					175	
Arg	Val	Val	Glu	Met	Pro	Phe	Thr	Asp	Leu	Ala	Leu	Gly	Thr	Thr	Phe
			180					185					190		
Trp	Leu	Gly	Gln	Arg	Asn	Asn	Ala	His	Gly	Tyr	Phe	Lys	Gly	Ile	Met
		195					200					205			
Gln	Asp	Val	His	Val	Leu	Val	Met	Pro	Gln	Gly	Phe	Ile	Ala	Gln	Cys
	210					215					220				
Pro	Asp	Leu	Asn	Arg	Thr	Cys	Pro	Thr	Cys	Asn	Asp	Phe	His	Gly	Leu
225					230					235					240
Val	Gln	Lys	Ile	Met	Glu	Leu	Gln	Asp	Ile	Leu	Ser	Lys	Thr	Ser	Ala
				245					250					255	
Lys	Leu	Ser	Arg	Ala	Glu	Gln	Arg	Met	Asn	Arg	Leu	Asp	Gln	Cys	Tyr
			260					265					270		
Cys	Glu	Arg	Thr	Cys	Thr	Val	Lys	Gly	Thr	Thr	Tyr	Arg	Glu	Ser	Glu
		275					280					285			
Ser	Trp	Thr	Asp	Gly	Cys	Lys	Asn	Cys	Thr	Cys	Leu	Asn	Gly	Thr	Ile
	290					295					300				
Gln	Cys	Glu	Thr	Leu	Val	Cys	Pro	Ala	Pro	Asp	Cys	Pro	Pro	Lys	Ser
305					310					315					320
Ala	Pro	Ala	Tyr	Val	Asp	Gly	Lys	Cys	Cys	Lys	Glu	Cys	Lys	Ser	Thr
				325						330				335	
Cys	Gln	Phe	Gln	Gly	Arg	Ser	Tyr	Phe	Glu	Gly	Glu	Arg	Asn	Thr	Ala
			340					345					350		
Tyr	Ser	Ser	Ser	Gly	Met	Cys	Val	Leu	Tyr	Glu	Cys	Lys	Asp	Gln	Thr
		355				360						365			
Met	Lys	Leu	Val	Glu	Asn	Ile	Gly	Cys	Pro	Pro	Leu	Asp	Cys	Pro	Glu
	370					375					380				
Ser	His	Gln	Ile	Ala	Leu	Ser	His	Ser	Cys	Cys	Lys	Val	Cys	Lys	Gly
385					390					395					400
Tyr	Asp	Phe	Cys	Ser	Glu	Lys	His	Thr	Cys	Met	Glu	Asn	Ser	Val	Cys
				405					410					415	
Arg	Asn	Leu	Asn	Asp	Arg	Val	Val	Cys	Ser	Cys	Arg	Asp	Gly	Phe	Arg
			420					425					430		
Ala	Leu	Arg	Glu	Asp	Asn	Ala	Tyr	Cys	Glu	Asp	Ile	Asp	Glu	Cys	Ala
		435					440					445			
Glu	Gly	Arg	His	Tyr	Cys	Arg	Glu	Asn	Thr	Met	Cys	Val	Asn	Thr	Pro
	450					455					460				
Gly	Ser	Phe	Met	Cys	Val	Cys	Lys	Thr	Gly	Tyr	Ile	Arg	Ile	Asp	Asp
465					470					475					480

FIGURE 12A

Tyr	Ser	Cys	Thr	Glu	His	Asp	Glu	Cys	Leu	Thr	Thr	Gln	His	Asn	Cys
				485					490					495	
Asp	Glu	Asn	Ala	Leu	Cys	Phe	Asn	Thr	Val	Gly	Gly	His	Asn	Cys	Val
			500					505					510		
Cys	Lys	Pro	Gly	Tyr	Thr	Gly	Asn	Gly	Thr	Thr	Cys	Lys	Ala	Phe	Cys
		515					520					525			
Lys	Asp	Gly	Cys	Arg	Asn	Gly	Gly	Ala	Cys	Ile	Ala	Ala	Asn	Val	Cys
	530					535					540				
Ala	Cys	Pro	Gln	Gly	Phe	Thr	Gly	Pro	Ser	Cys	Glu	Thr	Asp	Ile	Asp
545					550					555				560	
Glu	Cys	Ser	Glu	Gly	Phe	Val	Gln	Cys	Asp	Ser	Arg	Ala	Asn	Cys	Ile
			565						570					575	
Asn	Leu	Pro	Gly	Trp	Tyr	His	Cys	Glu	Cys	Arg	Asp	Gly	Tyr	His	Asp
			580					585					590		
Asn	Gly	Met	Phe	Ala	Pro	Gly	Gly	Glu	Ser	Cys	Glu	Asp	Ile	Asp	Glu
		595					600					605			
Cys	Gly	Thr	Gly	Arg	His	Ser	Cys	Thr	Asn	Asp	Thr	Ile	Cys	Phe	Asn
	610					615					620				
Leu	Asp	Gly	Gly	Tyr	Asp	Cys	Arg	Cys	Pro	His	Gly	Lys	Asn	Cys	Thr
625					630					635					640
Gly	Asp	Cys	Val	His	Glu	Gly	Lys	Val	Lys	His	Thr	Gly	Gln	Ile	Trp
			645						650					655	
Val	Leu	Glu	Asn	Asp	Arg	Cys	Ser	Val	Cys	Ser	Trp	Gln	Thr	Gly	Phe
			660					665					670		
Val	Met	Cys	Arg	Arg	Met	Val	Cys	Asp	Cys	Glu	Asn	Pro	Thr	Asp	Asp
		675					680					685			
Leu	Ser	Cys	Cys	Pro	Glu	Cys	Asp	Pro	Arg	Leu	Ser	Ser	Gln	Cys	Leu
	690					695					700				
His	Gln	Asn	Gly	Glu	Thr	Val	Tyr	Asn	Ser	Gly	Asp	Thr	Trp	Val	Gln
705					710					715					720
Asp	Cys	Arg	Gln	Cys	Arg	Cys	Leu	Gln	Gly	Glu	Val	Asp	Cys	Trp	Pro
			725						730					735	
Leu	Ala	Cys	Pro	Glu	Val	Glu	Cys	Glu	Phe	Ser	Val	Leu	Pro	Glu	Asn
			740					745					750		
Glu	Cys	Cys	Pro	Arg	Cys	Val	Thr	Asp	Pro	Cys	Gln	Ala	Asp	Thr	Ile
		755					760					765			
Arg	Asn	Asp	Ile	Thr	Lys	Thr	Cys	Leu	Asp	Glu	Met	Asn	Val	Val	Arg
	770					775					780				
Phe	Thr	Gly	Ser	Ser	Trp	Ile	Lys	His	Gly	Thr	Glu	Cys	Thr	Leu	Cys
785					790					795					800
Gln	Cys	Lys	Asn	Gly	His	Leu	Cys	Cys	Ser	Val	Asp	Pro	Gln	Cys	Leu
			805						810					815	
Gln	Glu	Leu													

FIGURE 12B

atg gag tcc ggc tgc ggc tta ggc acg ctt tgc ctt ctc ctc tgc ctg Met Glu Ser Gly Cys Gly Leu Gly Thr Leu Cys Leu Leu Leu Cys Leu 1 5 10 15	48
ggg cca gtc gta ggc ttc ggc gtg gac ccc tcg ctg cag atc gac gtg Gly Pro Val Val Gly Phe Gly Val Asp Pro Ser Leu Gln Ile Asp Val 20 25 30	96
ctg tcc gag ctg ggg ctg ccg ggc tac gcg gcg ggc gtg cgc cag gtg Leu Ser Glu Leu Gly Leu Pro Gly Tyr Ala Ala Gly Val Arg Gln Val 35 40 45	144
ccg ggg ctg cac aac ggg agc aaa gcc ttc ctc ttc cca gat act tca Pro Gly Leu His Asn Gly Ser Lys Ala Phe Leu Phe Pro Asp Thr Ser 50 55 60	192
aga agt gta aag gcg tct cca gaa aca gct gaa atc ttt ttt cag aag Arg Ser Val Lys Ala Ser Pro Glu Thr Ala Glu Ile Phe Phe Gln Lys 65 70 75 80	240
ttg aga aat aaa tat gaa ttc aca atc ctg gtg acc tta aaa caa gcc Leu Arg Asn Lys Tyr Glu Phe Thr Ile Leu Val Thr Leu Lys Gln Ala 85 90 95	288
cat tta aat tca ggg gtt att ttc tct att cat cac tta gat cac agg His Leu Asn Ser Gly Val Ile Phe Ser Ile His His Leu Asp His Arg 100 105 110	336
tat ctg gaa ttg gaa agc agc ggt cat cga aat gaa atc agg ttg cat Tyr Leu Glu Leu Glu Ser Ser Gly His Arg Asn Glu Ile Arg Leu His 115 120 125	384
tac cgt aca ggc agt cat cgc tcc cac aca gaa gta ttc cca tac atc Tyr Arg Thr Gly Ser His Arg Ser His Thr Glu Val Phe Pro Tyr Ile 130 135 140	432
ctg gca gac gat aag tgg cac agg ctt tcc tta gca atc agt gcc tct Leu Ala Asp Asp Lys Trp His Arg Leu Ser Leu Ala Ile Ser Ala Ser 145 150 155 160	480
cac ttg att tta cac gtg gac tgc aat aaa atc tat gaa aga gtt gtg His Leu Ile Leu His Val Asp Cys Asn Lys Ile Tyr Glu Arg Val Val 165 170 175	528
gag aag ccc ttc atg gac tta cct gtg ggt aca acc ttt tgg cta gga Glu Lys Pro Phe Met Asp Leu Pro Val Gly Thr Thr Phe Trp Leu Gly 180 185 190	576
cag agg aat aat gca cac ggt tat ttt aag ggc ata atg caa gat gtg Gln Arg Asn Asn Ala His Gly Tyr Phe Lys Gly Ile Met Gln Asp Val 195 200 205	624
caa tta ctt gtc atg cct caa gga ttt att tct cag tgc cca gat ctt Gln Leu Leu Val Met Pro Gln Gly Phe Ile Ser Gln Cys Pro Asp Leu 210 215 220	672
aat cgg aca tgc cca act tgt aat gat ttc cat gga ctt gtg cag aaa Asn Arg Thr Cys Pro Thr Cys Asn Asp Phe His Gly Leu Val Gln Lys 225 230 235 240	720

FIGURE 13A

att atg gaa ctg caa gac att tta gct aaa acg tca gct aag ctg tcg Ile Met Glu Leu Gln Asp Ile Leu Ala Lys Thr Ser Ala Lys Leu Ser 245 250 255	768
caa gct gag cag agg atg aac aag ttg gat cag tgc tat tgt gaa agg Gln Ala Glu Gln Arg Met Asn Lys Leu Asp Gln Cys Tyr Cys Glu Arg 260 265 270	816
acc tgc aca atg aaa ggc atg aca tac aga gaa ttt gaa tcc tgg aca Thr Cys Thr Met Lys Gly Met Thr Tyr Arg Glu Phe Glu Ser Trp Thr 275 280 285	864
gat ggt tgt aag aac tgc act tgc atg aat ggc act gtg cag tgt gaa Asp Gly Cys Lys Asn Cys Thr Cys Met Asn Gly Thr Val Gln Cys Glu 290 295 300	912
gct ttg att tgc tcc ctc tct gac tgt cca cct aat tct gcc ctg tca Ala Leu Ile Cys Ser Leu Ser Asp Cys Pro Pro Asn Ser Ala Leu Ser 305 310 315 320	960
tac gtg gat ggc aag tgc tgc aaa gaa tgt caa tcg gtg tgc ata ttt Tyr Val Asp Gly Lys Cys Cys Lys Glu Cys Gln Ser Val Cys Ile Phe 325 330 335	1008
gaa ggc aga acc tac ttt gaa gga caa aga gaa acg gtg tat tca agc Glu Gly Arg Thr Tyr Phe Glu Gly Gln Arg Glu Thr Val Tyr Ser Ser 340 345 350	1056
tca ggg gac tgt gtt ctg ttt gag tgc aag gac cac aaa atg cag cgt Ser Gly Asp Cys Val Leu Phe Glu Cys Lys Asp His Lys Met Gln Arg 355 360 365	1104
att cca aaa gac agt tgt gca act ttg aac tgc ccg gaa tct caa cag Ile Pro Lys Asp Ser Cys Ala Thr Leu Asn Cys Pro Glu Ser Gln Gln 370 375 380	1152
atc cca tta tct cac agt tgc tgc aaa atc tgt aaa ggc cat gac ttt Ile Pro Leu Ser His Ser Cys Cys Lys Ile Cys Lys Gly His Asp Phe 385 390 395 400	1200
tgc act gaa gga cat aac tgt atg gag cat tct gtc tgc cga aac cta Cys Thr Glu Gly His Asn Cys Met Glu His Ser Val Cys Arg Asn Leu 405 410 415	1248
gat gac aga gct gtc tgt agc tgc cga gat ggc ttc cgg gcc ctt cgg Asp Asp Arg Ala Val Cys Ser Cys Arg Asp Gly Phe Arg Ala Leu Arg 420 425 430	1296
gag gac aat gcc tac tgt gaa gat gtt gat gag tgt gcc gag ggg cag Glu Asp Asn Ala Tyr Cys Glu Asp Val Asp Glu Cys Ala Glu Gly Gln 435 440 445	1344
cac tac tgt cgg gag aac acc atg tgt gta aat aca cca gga tcc ttc His Tyr Cys Arg Glu Asn Thr Met Cys Val Asn Thr Pro Gly Ser Phe 450 455 460	1392
atg tgc atc tgc aaa aca gga tat ata cgc att gat gac tat tca tgt Met Cys Ile Cys Lys Thr Gly Tyr Ile Arg Ile Asp Asp Tyr Ser Cys 465 470 475 480	1440

FIGURE 13B

aca gag cac gat gaa tgt gta aca aac cag cac aac tgt gat gaa aat Thr Glu His Asp Glu Cys Val Thr Asn Gln His Asn Cys Asp Glu Asn 485 490 495	1488
gcg cta tgt ttc aac acg gtg ggt ggg cac aac tgt gtc tgc aag ctg Ala Leu Cys Phe Asn Thr Val Gly Gly His Asn Cys Val Cys Lys Leu 500 505 510	1536
ggg tac aca gga aat ggg acg gtg tgt aaa gca ttt tgc aaa gat ggg Gly Tyr Thr Gly Asn Gly Thr Val Cys Lys Ala Phe Cys Lys Asp Gly 515 520 525	1584
tgc agg aat gga gga gcc tgt att gct tcc aac gtg tgt gcc tgc cca Cys Arg Asn Gly Gly Ala Cys Ile Ala Ser Asn Val Cys Ala Cys Pro 530 535 540	1632
caa ggc ttc act ggc ccc agc tgt gaa act gac att gat gaa tgc tct Gln Gly Phe Thr Gly Pro Ser Cys Glu Thr Asp Ile Asp Glu Cys Ser 545 550 555 560	1680
gat ggc ttt gtg cag tgt gac agc cgt gct aat tgc atc aat ctg cca Asp Gly Phe Val Gln Cys Asp Ser Arg Ala Asn Cys Ile Asn Leu Pro 565 570 575	1728
ggg tgg tac cac tgt gaa tgc agg gat ggc tac cat gac aat ggg atg Gly Trp Tyr His Cys Glu Cys Arg Asp Gly Tyr His Asp Asn Gly Met 580 585 590	1776
ttt tca cca agt gga gaa tcc tgt gaa gac att gat gaa tgt gca act Phe Ser Pro Ser Gly Glu Ser Cys Glu Asp Ile Asp Glu Cys Ala Thr 595 600 605	1824
gga agg cat agc tgt gcc aat gac act gtt tgc ttt aac ctg gat ggt Gly Arg His Ser Cys Ala Asn Asp Thr Val Cys Phe Asn Leu Asp Gly 610 615 620	1872
ggg tat gac tgt cga tgt cca cat ggc aag aac tgc aca gga gac tgt Gly Tyr Asp Cys Arg Cys Pro His Gly Lys Asn Cys Thr Gly Asp Cys 625 630 635 640	1920
atc cat gaa gac aaa atc aag cac aat ggt cag att tgg gtg ctg gag Ile His Glu Asp Lys Ile Lys His Asn Gly Gln Ile Trp Val Leu Glu 645 650 655	1968
aac gac aga tgc tct gtc tgc tca tgc cag agt gga tac gtg atg tgc Asn Asp Arg Cys Ser Val Cys Ser Cys Gln Ser Gly Tyr Val Met Cys 660 665 670	2016
cgg cga atg gtc tgt gac tgt gaa aat ccc act gtt gac ctc ttt tgc Arg Arg Met Val Cys Asp Cys Glu Asn Pro Thr Val Asp Leu Phe Cys 675 680 685	2064
tgt cct gag tgt gac cca agg ctc agc agt caa tgt tta cat cag agt Cys Pro Glu Cys Asp Pro Arg Leu Ser Ser Gln Cys Leu His Gln Ser 690 695 700	2112

FIGURE 13C

ggg gag ctt tcc tac aac agt ggt gac tcc tgg ata caa aac tgt cag	2160
Gly Glu Leu Ser Tyr Asn Ser Gly Asp Ser Trp Ile Gln Asn Cys Gln	
705 710 715 720	
cag tgt cgc tgc ttg caa gga gag gtt gac tgt tgg ccc tta ccg tgc	2208
Gln Cys Arg Cys Leu Gln Gly Glu Val Asp Cys Trp Pro Leu Pro Cys	
725 730 735	
cca gag gta gac tgt gag ttc agt gtc ctc cct gag aat gag tgc tgc	2256
Pro Glu Val Asp Cys Glu Phe Ser Val Leu Pro Glu Asn Glu Cys Cys	
740 745 750	
cca cgc tgt gtc act gac ccc tgc caa gcg gac acc atc cgt aat gac	2304
Pro Arg Cys Val Thr Asp Pro Cys Gln Ala Asp Thr Ile Arg Asn Asp	
755 760 765	
atc acc aaa acc tgc ctg gat gaa acc aat gtt gtt cgc ttc act gga	2352
Ile Thr Lys Thr Cys Leu Asp Glu Thr Asn Val Val Arg Phe Thr Gly	
770 775 780	
tct tct tgg att aag cat ggc aca gag tgc aca ctc tgc caa tgt aag	2400
Ser Ser Trp Ile Lys His Gly Thr Glu Cys Thr Leu Cys Gln Cys Lys	
785 790 795 800	
aat ggc cac gtc tgt tgc tca gtg gat cca cag tgc ctt cag gaa ctg	2448
Asn Gly His Val Cys Cys Ser Val Asp Pro Gln Cys Leu Gln Glu Leu	
805 810 815	
tga ca	2453
*	

FIGURE 13D

Met Glu Ser Gly Cys Gly Leu Gly Thr Leu Cys Leu Leu Leu Cys Leu
 1 5 10 15
 Gly Pro Val Val Gly Phe Gly Val Asp Pro Ser Leu Gln Ile Asp Val
 20 25 30
 Leu Ser Glu Leu Gly Leu Pro Gly Tyr Ala Ala Gly Val Arg Gln Val
 35 40 45
 Pro Gly Leu His Asn Gly Ser Lys Ala Phe Leu Phe Pro Asp Thr Ser
 50 55 60
 Arg Ser Val Lys Ala Ser Pro Glu Thr Ala Glu Ile Phe Phe Gln Lys
 65 70 75 80
 Leu Arg Asn Lys Tyr Glu Phe Thr Ile Leu Val Thr Leu Lys Gln Ala
 85 90 95
 His Leu Asn Ser Gly Val Ile Phe Ser Ile His His Leu Asp His Arg
 100 105 110
 Tyr Leu Glu Leu Glu Ser Ser Gly His Arg Asn Glu Ile Arg Leu His
 115 120 125
 Tyr Arg Thr Gly Ser His Arg Ser His Thr Glu Val Phe Pro Tyr Ile
 130 135 140
 Leu Ala Asp Asp Lys Trp His Arg Leu Ser Leu Ala Ile Ser Ala Ser
 145 150 155 160
 His Leu Ile Leu His Val Asp Cys Asn Lys Ile Tyr Glu Arg Val Val
 165 170 175
 Glu Lys Pro Phe Met Asp Leu Pro Val Gly Thr Thr Phe Trp Leu Gly
 180 185 190
 Gln Arg Asn Asn Ala His Gly Tyr Phe Lys Gly Ile Met Gln Asp Val
 195 200 205
 Gln Leu Leu Val Met Pro Gln Gly Phe Ile Ser Gln Cys Pro Asp Leu
 210 215 220
 Asn Arg Thr Cys Pro Thr Cys Asn Asp Phe His Gly Leu Val Gln Lys
 225 230 235 240
 Ile Met Glu Leu Gln Asp Ile Leu Ala Lys Thr Ser Ala Lys Leu Ser
 245 250 255
 Gln Ala Glu Gln Arg Met Asn Lys Leu Asp Gln Cys Tyr Cys Glu Arg
 260 265 270
 Thr Cys Thr Met Lys Gly Met Thr Tyr Arg Glu Phe Glu Ser Trp Thr
 275 280 285
 Asp Gly Cys Lys Asn Cys Thr Cys Met Asn Gly Thr Val Gln Cys Glu
 290 295 300
 Ala Leu Ile Cys Ser Leu Ser Asp Cys Pro Pro Asn Ser Ala Leu Ser
 305 310 315 320
 Tyr Val Asp Gly Lys Cys Cys Lys Glu Cys Gln Ser Val Cys Ile Phe
 325 330 335
 Glu Gly Arg Thr Tyr Phe Glu Gly Gln Arg Glu Thr Val Tyr Ser Ser
 340 345 350
 Ser Gly Asp Cys Val Leu Phe Glu Cys Lys Asp His Lys Met Gln Arg
 355 360 365
 Ile Pro Lys Asp Ser Cys Ala Thr Leu Asn Cys Pro Glu Ser Gln Gln
 370 375 380
 Ile Pro Leu Ser His Ser Cys Cys Lys Ile Cys Lys Gly His Asp Phe
 385 390 395 400
 Cys Thr Glu Gly His Asn Cys Met Glu His Ser Val Cys Arg Asn Leu
 405 410 415
 Asp Asp Arg Ala Val Cys Ser Cys Arg Asp Gly Phe Arg Ala Leu Arg
 420 425 430
 Glu Asp Asn Ala Tyr Cys Glu Asp Val Asp Glu Cys Ala Glu Gly Gln
 435 440 445
 His Tyr Cys Arg Glu Asn Thr Met Cys Val Asn Thr Pro Gly Ser Phe
 450 455 460
 Met Cys Ile Cys Lys Thr Gly Tyr Ile Arg Ile Asp Asp Tyr Ser Cys
 465 470 475 480

FIGURE 14A

Thr	Glu	His	Asp	Glu	Cys	Val	Thr	Asn	Gln	His	Asn	Cys	Asp	Glu	Asn
				485					490					495	
Ala	Leu	Cys	Phe	Asn	Thr	Val	Gly	Gly	His	Asn	Cys	Val	Cys	Lys	Leu
			500					505					510		
Gly	Tyr	Thr	Gly	Asn	Gly	Thr	Val	Cys	Lys	Ala	Phe	Cys	Lys	Asp	Gly
		515					520					525			
Cys	Arg	Asn	Gly	Gly	Ala	Cys	Ile	Ala	Ser	Asn	Val	Cys	Ala	Cys	Pro
		530				535					540				
Gln	Gly	Phe	Thr	Gly	Pro	Ser	Cys	Glu	Thr	Asp	Ile	Asp	Glu	Cys	Ser
545					550					555					560
Asp	Gly	Phe	Val	Gln	Cys	Asp	Ser	Arg	Ala	Asn	Cys	Ile	Asn	Leu	Pro
				565					570					575	
Gly	Trp	Tyr	His	Cys	Glu	Cys	Arg	Asp	Gly	Tyr	His	Asp	Asn	Gly	Met
			580					585					590		
Phe	Ser	Pro	Ser	Gly	Glu	Ser	Cys	Glu	Asp	Ile	Asp	Glu	Cys	Ala	Thr
		595					600					605			
Gly	Arg	His	Ser	Cys	Ala	Asn	Asp	Thr	Val	Cys	Phe	Asn	Leu	Asp	Gly
		610				615						620			
Gly	Tyr	Asp	Cys	Arg	Cys	Pro	His	Gly	Lys	Asn	Cys	Thr	Gly	Asp	Cys
625					630					635					640
Ile	His	Glu	Asp	Lys	Ile	Lys	His	Asn	Gly	Gln	Ile	Trp	Val	Leu	Glu
				645					650					655	
Asn	Asp	Arg	Cys	Ser	Val	Cys	Ser	Cys	Gln	Ser	Gly	Tyr	Val	Met	Cys
			660					665					670		
Arg	Arg	Met	Val	Cys	Asp	Cys	Glu	Asn	Pro	Thr	Val	Asp	Leu	Phe	Cys
		675					680					685			
Cys	Pro	Glu	Cys	Asp	Pro	Arg	Leu	Ser	Ser	Gln	Cys	Leu	His	Gln	Ser
		690				695					700				
Gly	Glu	Leu	Ser	Tyr	Asn	Ser	Gly	Asp	Ser	Trp	Ile	Gln	Asn	Cys	Gln
705					710					715					720
Gln	Cys	Arg	Cys	Leu	Gln	Gly	Glu	Val	Asp	Cys	Trp	Pro	Leu	Pro	Cys
				725					730					735	
Pro	Glu	Val	Asp	Cys	Glu	Phe	Ser	Val	Leu	Pro	Glu	Asn	Glu	Cys	Cys
			740					745					750		
Pro	Arg	Cys	Val	Thr	Asp	Pro	Cys	Gln	Ala	Asp	Thr	Ile	Arg	Asn	Asp
		755					760					765			
Ile	Thr	Lys	Thr	Cys	Leu	Asp	Glu	Thr	Asn	Val	Val	Arg	Phe	Thr	Gly
		770				775						780			
Ser	Ser	Trp	Ile	Lys	His	Gly	Thr	Glu	Cys	Thr	Leu	Cys	Gln	Cys	Lys
785					790					795					800
Asn	Gly	His	Val	Cys	Cys	Ser	Val	Asp	Pro	Gln	Cys	Leu	Gln	Glu	Leu
				805					810					815	

FIGURE 14B




FIG. 15A




FIG. 15B

gccactagtataaatcttagtcaacgcttgcccttgcttttatggctggtacatttct
M K F L V N V A L V F M V Y I S
70 80 90 100 110 120
tacatctatgcggcccgatccctagacagtgtgggctttgggatggaccctgacctt
Y I Y A A P D P R T V L C F G M D P D L
130 140 150 160 170 180
cagctggacatcatctcagagctcgacctggtgaaccaccacctgggagtcacgcaggtg
Q L D I I S E L D L V N T T L G V T Q V
190 200 210 220 230 240
gctggactgcacaacgccagtaaacgcatcttctattcaagatgtacagggagatccat
A G L H N A S K A F L F Q D V Q R E I H

FIG. 16A

10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220
 K F L V A L W Y S
 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220
 Y I H A P D P R T V L G F C M D P D T
 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340
 Q L D I I S E L D L V N I L E G I O N
 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390 400
 A G L H N A S K A F I F Q D V Q R E I H
 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390 400 410 420 430 440
 S A P H V S E K L I O L F R N K S L F T
 310 320 330 340 350 360 370 380 390 400 410 420 430 440 450 460 470 480 490 500 510
 F L A I V O O K E S T S G V I L L S I R E
 390 400 410 420 430 440 450 460 470 480 490 500 510 520 530 540 550 560 570 580 590 600
 L E H S Y F E L E S S G P P R E I R V H
 430 440 450 460 470 480 490 500 510 520 530 540 550 560 570 580 590 600 610 620 630 640
 Y I H G O K P R I E A I P I R M A D G O
 490 500 510 520 530 540 550 560 570 580 590 600 610 620 630 640 650 660 670 680 690 700
 U H K V A L S V S A S H I L L H I D C N
 550 560 570 580 590 600 610 620 630 640 650 660 670 680 690 700 710 720 730 740 750 760
 K I I V E H A I D P F E I N L I P F S S I L
 610 620 630 640 650 660 670 680 690 700 710 720 730 740 750 760 770 780 790 800 810
 I L G O R H Q K H G E I K C I L Q D G K
 670 680 690 700 710 720 730 740 750 760 770 780 790 800 810 820 830 840 850 860 870 880
 I I F M F N C F I T O C P H L N H I C P
 730 740 750 760 770 780 790 800 810 820 830 840 850 860 870 880 890 900 910 920 930 940
 I C S D F L S L Q S L H D I O E L L A
 790 800 810 820 830 840 850 860 870 880 890 900 910 920 930 940 950 960 970 980 990 1000
 K I T A K L N Y A E I R L G O L E N C H
 850 860 870 880 890 900 910 920 930 940 950 960 970 980 990 1000 1010 1020 1030 1040 1050 1060
 C L K I C Q V S G L L Y F D O S V V D
 910 920 930 940 950 960 970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080 1090 1100 1110
 G D H C F R N C T C K S G A V E C R N I S
 1010 1020 1030 1040 1050 1060 1070 1080 1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200 1210
 C P P L N C S P D S L P Y H I S C Q C C
 1070 1080 1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200 1210 1220 1230 1240 1250 1260 1270
 K C P K C I V G G K V L A E G O P I

FIG. 16B




FIG. 17





FIG. 18

FIG. 17







FIG. 19

FIG. 20






FIG. 21




FIG. 22



FIG. 23A

FIG. 23B

FIG. 23C




FIG. 23D

FIG. 23E



FIG. 24



FIG. 25A

FIG. 25B




FIG. 26




FIG. 27A FIG. 27B FIG. 27C




FIG. 28




FIG. 29




FIG. 30




FIG. 31A







FIG. 31B

FIG. 32





**NELL PEPTIDE EXPRESSION SYSTEMS AND
BONE FORMATION ACTIVITY OF NELL
PEPTIDE**

STATEMENT AS TO RIGHTS TO INVENTIONS
MADE UNDER FEDERALLY SPONSORED
RESEARCH AND DEVELOPMENT

[0001] This work was supported by NIH/NIDR grant number DE9400 and CRC/NIH grant number RR00865. The Government of the United States of America may have certain rights in this invention.

FIELD OF THE INVENTION

[0002] The invention generally relates to a bone growth factor, and more particularly to compositions including NELL1, articles of manufacture including NELL1 and methods of using NELL1 to induce bone formation. This invention also provides methods for the expression and purification of NELL1 and NELL2 peptides.

BACKGROUND OF THE INVENTION

[0003] Growth factors are substances, such as peptides, which affect the growth and differentiation of defined populations of cells in vivo or in vitro.

[0004] Bone formation occurs during development of long bones (endochondral bone formation) and flat bones (intramembraneous bone formation). Further, bone formation occurs during bone remodeling which occurs continuously in adult life in order to preserve the integrity of the skeleton. Finally, bone formation occurs during bone repair, such as when bone wounds occur in a fracture or surgical situation, for example. While separate bone formation mechanisms are thought to be involved in the embryological development of long and flat bones and repair is thought to involve intramembraneous bone formation.

[0005] Bone formation by either mechanism involves the activity of osteoblasts, which are regulated by growth factors. Osteoblasts are derived from a pool of marrow stromal cells (also known as mesenchymal stem cells; MSC). These cells are present in a variety of tissues and are prevalent in bone marrow stroma. MSC are pluripotent and can differentiate into a variety of cell types including osteoblasts, chondrocytes, fibroblasts, myocytes, and adipocytes. Growth factors are thought to impact osteogenic cell proliferation, differentiation and osteoblast mineralization, each of which impacts bone formation.

[0006] Autogenous bone has been used, such to repair bone in patients with craniosynostosis and cleft grafting, for example. Craniosynostosis (CS), the premature closure of cranial sutures, affects 1 in 3,000 infants and therefore is one of the most common human congenital craniofacial deformities. Premature suture closure results in cranial dimorphism, which may need surgical correction. Premature suture closure in human CS may occur by two possibly distinct processes: calvarial overgrowth and bony fusion. Recently, FGF2 and FGFR1 have been implicated in premature cranial suture fusion via CBFA1-mediated pathways (8). Missense mutation of CBFA1 is linked to cleidocranial dysplasia, manifested as delayed suture closure.

[0007] Autologous bone grafting procedures have been performed utilizing autogenous bone, such as from the iliac

crest or calvaria. These donor sites are not without associated morbidity including pain, gait disturbance, thigh paresthesia for iliac crest donor sites, and infection, neurologic deficits, and hematomas for calvarial grafts. Further, donor sites may have limited volume and may contribute to increased surgical time and hospital stay.

[0008] Alloplastic grafting materials have also been utilized, and growth factors have been tested in animal models. For example, bFGF has shown potential for use in bone regeneration and repair. Another family of osteogenic growth factors have been described as bone morphogenic protein (BMP). Specifically, BMP-2 recombinant protein has been demonstrated to regenerate mandibular continuity defects and cleft palate defects with results equal to or better than autogenous particulate bone and marrow. BMPs and other osteogenic factors have been studied for use in clinical applications. However, the cost of using minimally effective dosages of BMP has been a limiting factor in clinical use.

[0009] Spinal fusion is a surgical technique in which one more of the vertebrae of the spine are united together so that motion no longer occurs between them. Indications include: treatment of a fractured (broken) vertebra, correction of deformity, elimination of pain from motion, treatment of instability, and treatment of some cervical disc herniations. The surgery may involve placement of a bone graft between the vertebrae to obtain a solid union between the vertebrae. The procedure also may involve supplemental treatments including the placement of plates, screws, cages, and recently bone morphogenic protein 2 and 7 to assist in stabilizing and healing the bone graft. Autogenous bone grafting has been the clinically preferred method, and yet has about a 30-50% failure rate. Autogenous bone grafting is a separate surgery and also carries significant morbidity.

[0010] Therefore, safe, effective and affordable compositions and methods are desired to induce bone formation in bone development, disorders, or bone trauma.

SUMMARY OF THE INVENTION

[0011] This invention may provide methods for the expression and purification of NELL1 and NELL2 peptides. In one embodiment, the method includes NELL peptides, nucleic acid constructs expressing NELL peptides, and cells expressing NELL peptides which may be useful in producing quantities of NELL peptides. In one embodiment, the nucleic acid constructs expressing NELL peptides may further include nucleic acid sequences encoding signal peptides which may facilitate the protein trafficking and post production modification of the NELL peptides in the host cell. In one embodiment, the signal peptide may facilitate the secretion of the peptide from the host cell. Therefore, this invention is advantageous at least in providing quantities of functional NELL peptides which may be purified for clinical or research use.

[0012] The invention may include compositions and substrates including NELL peptides. In some embodiments, a composition may include NELL1, and may include additional agents which may effect the application, stability, activity, diffusion and/or concentration of the peptide relative to the application site, for example. In some embodiments, a substrate may include cells and/or NELL1 peptide which may facilitate bone repair in the proximity of the implant.

[0013] The invention may include methods of inducing osteogenic differentiation, osteoblastic mineralization and/or bone formation in a variety of clinical applications.

[0014] This invention is advantageous at least in that NELL peptides may provide a greater effect than known growth factors or may enhance the activity of other growth factors. Therefore, lower doses of each growth factor may be used for clinical applications. This is significant at least in that clinical treatments may be more affordable. Further this invention is advantageous at least in that NELL1 enhances osteogenic differentiation, osteoblastic mineralization and bone formation, which may improve the clinical rate and effectiveness of treatment with BMP alone.

Definitions

[0015] The terms “polypeptide”, “peptide” and “protein” may be used interchangeably herein to refer to a polymer of amino acid residues. The terms may apply to amino acid polymers in which one or more amino acid residue is an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers.

[0016] The terms “NELL1 cDNA” may refer to SEQ ID NO:1, 3 and 5 (FIGS. 1, 3 & 5 respectively), and “NELL2 cDNA” may refer to SEQ ID NO:7, 9, 11 and 13 (FIGS. 7, 9, 11 & 13).

[0017] A NELL1 peptide is a protein which may be expressed by the NELL1 gene or cDNA and includes SEQ ID NO: 2, 4, and 6 (FIGS. 2, 4 & 16, respectively). The NELL1 peptide may include a NELL1 peptide fragment that retains the ability to induce osteogenic cell differentiation, osteoblast differentiation or bone formation. A NELL2 peptide is a protein which may be expressed by the NELL2 gene or cDNA and includes SEQ ID NO: 8, 10, 12 and 14 (FIGS. 8, 10, 12 and 14, respectively). The NELL2 peptide may include NELL2 peptide fragments that retain similar activity to the full NELL2 peptide sequence.

[0018] The term “antibody” may include various forms of modified or altered antibodies, such as an intact immunoglobulin, an Fv fragment containing only the light and heavy chain variable regions, an Fv fragment linked by a disulfide bond, a Fab or (Fab)₂ fragment containing the variable regions and parts of the constant regions, a single-chain antibody and the like. An antibody may include intact molecules as well as fragments thereof, such as, Fab and F(ab')₂, and/or single-chain antibodies (e.g. scFv) which may bind an epitopic determinant. An antibody may be of animal (such as mouse or rat) or human origin or may be chimeric or humanized. Antibodies may be polyclonal or monoclonal antibodies (“mAb’s”), such as monoclonal antibodies with specificity for a polypeptide encoded by a NELL1 or NELL 2 protein.

[0019] The term “capture agent” may refer to molecules that specifically bind other molecules to form a binding complex such as antibody-antigen, lectin-carbohydrate, nucleic acid-nucleic acid, biotin-avidin, and the like.

[0020] The term “specifically binds” may refer to a biomolecule (e.g., protein, nucleic acid, antibody, etc.), refers to a binding reaction which is determinative of the presence biomolecule in heterogeneous population of molecules (e.g., proteins and other biologics). Thus, under designated con-

ditions (e.g. immunoassay conditions in the case of an antibody or stringent hybridization conditions in the case of a nucleic acid), the specified ligand or antibody may bind to its particular “target” molecule and may not bind in a significant amount to other molecules present in the sample.

[0021] The terms “nucleic acid” or “oligonucleotide” may refer to at least two nucleotides covalently linked together. A nucleic acid of the present invention may be single-stranded or double stranded and may contain phosphodiester bonds, although in some cases, nucleic acid analogs may be included that may have alternate backbones, comprising, for example, phosphoramidate, phosphorothioate, phosphorodithioate, omethylphosphoroamidite linkages, and/or peptide nucleic acid backbones and linkages. Analog nucleic acids may have positive backbones and/or non-ribose backbones. Nucleic acids may also include one or more carbocyclic sugars. Modifications of the ribose-phosphate backbone may be done to facilitate the addition of additional moieties such as labels, or to increase the stability and half-life of such molecules in physiological environments, for example.

[0022] The term “specific hybridization” may refer to the binding, duplexing, or hybridizing of a nucleic acid molecule preferentially to a particular nucleotide sequence under stringent conditions, including conditions under which a probe may hybridize preferentially to its target subsequence, and may hybridize to a lesser extent to other sequences.

BRIEF DESCRIPTION OF THE DRAWINGS

[0023] FIG. 1 is a nucleic acid sequence encoding human NELL1 cDNA (SEQ ID NO:1).

[0024] FIG. 2 is an amino acid sequence encoding human NELL1 (SEQ ID NO:2).

[0025] FIG. 3 is a nucleic acid sequence encoding rat NELL1 cDNA (SEQ ID NO:3).

[0026] FIG. 4 is an amino acid sequence encoding rat NELL1 (SEQ ID NO:4).

[0027] FIG. 5 is a nucleic acid sequence encoding mouse NELL1 cDNA (SEQ ID NO:5).

[0028] FIG. 6 is an amino acid sequence encoding mouse NELL1 (SEQ ID NO:6).

[0029] FIG. 7 is a nucleic acid sequence encoding human NELL2 cDNA (SEQ ID NO:7).

[0030] FIG. 8 is an amino acid sequence encoding human NELL2 (SEQ ID NO:8).

[0031] FIG. 9 is a nucleic acid sequence encoding rat NELL2 cDNA (SEQ ID NO:9).

[0032] FIG. 10 is an amino acid sequence encoding rat NELL2 (SEQ ID NO:10).

[0033] FIG. 11 is a nucleic acid sequence encoding mouse NELL2 cDNA (SEQ ID NO:11).

[0034] FIG. 12 is an amino acid sequence encoding mouse NELL2 (SEQ ID NO:12).

[0035] FIG. 13 is a nucleic acid sequence encoding chicken NELL2 (SEQ ID NO:13).

[0036] **FIG. 14** is an amino acid sequence encoding chicken NELL2 (SEQ ID NO:14).

[0037] **FIG. 15** is a flow diagram of one method of producing functional NELL peptide.

[0038] **FIG. 16** illustrates a signal peptide-NELL1-FLAG nucleic acid construct Underlined amino acid sequences are derived from melittin signal peptide. The bond between Alanine and Proline is a putative cleavage site for secretion by High Five cells. The residues from RTVLGFG—are derived from the mature protein of rat/human NELL1 protein.

[0039] **FIG. 17** illustrates the products of extracellular expression of NELL1-FLAG **FIG. 17A** is a CBB-stained SDS-PAGE gel of UnoQ-eluate containing purified NELL1 peptide produced from high five cells in serum-free medium (Productivity: ca. 3 mg/L medium); **FIG. 17B** is a Western blotting using anti-FLAG antibody. **FIG. 17C** is a CBB-stained SDS-PAGE gel of UnoQ-eluate containing purified NELL1 peptide produced from COS7 cells in serum-free medium (Productivity: <0.1 mg/L medium); **FIG. 17D** is a Western blotting using anti-FLAG antibody.

[0040] **FIG. 18** is a Western blot illustrating the extracellular expression of NELL2-FLAG peptide by insect cells in serum-free medium.

[0041] **FIG. 19** is a Western blot illustrating the extracellular expression of NELL1 and NELL2-FLAG peptides by high five cells in two types of serum free medium (Express Five SFM and ESF921).

[0042] **FIG. 20** is a bar graph depicting alkaline phosphatase induction in fetal rat calvarial cells exposed to NELL1 peptide (1 ng, 10 ng, 100 ng/ml) and BMP4 (100 ng/ml).

[0043] **FIG. 21A-D** are photomicrographs of osteoblasts treated with NELL1 (A & B 5 ng/ml and C & D 50 ng/ml).

[0044] **FIGS. 22A&B** are photomicrographs of NELL1 MC3T3 micronodules forming micronodules in the absence of ascorbic acid; **FIG. 22B** is stained for alkaline phosphatase.

[0045] **FIGS. 23A-C** are photomicrographs depicting mineralization in A) anti-NELL, B) β -Gal and C) NELL adenoviral constructs; **FIGS. 23D & E** are bar graphs representing osteocalcin and osteopontin levels in each cell group over time.

[0046] **FIG. 24** is a photomicrograph of a NELL1 over expressing transgenic mouse stained to depict mineralization demonstrating calvarial overgrowth.

[0047] **FIGS. 25A & B** are photomicrographs of calvaria stained for mineralization in A) NELL1 over expressing transgenic mouse and B) normal littermate, respectively.

[0048] **FIG. 26** is a reverse transcriptase polymerase chain reaction blot depicting NELL1 gene expression in fetal rat calvarial cells treated with A) Cbfa1 or B) control.

[0049] **FIG. 27A-C** are photographs of skeletal staining of the cranium (top), clavicle (middle) and micro-CT of the cranium of A) wild-type, B) Cbfa1^{+/-}, and C) Cbfa1^{+/-} + NELL1^{overexp} mice, respectively.

[0050] **FIG. 28A&B** are photographs of microCT treated (right) and control (left) calvarial defects; A) BMP2 treated and B) NELL1 treated.

[0051] **FIG. 29** is a photograph of microCT treated NELL1 (right) and BMP (left) calvarial defects.

[0052] **FIG. 30A&B** are photographs of microCT treated NELL1 (right) and control (left) palatal defects.

[0053] **FIG. 31A&B** are photomicrographs of TUNEL stained cartilage in A) NELL1^{overexp} and B) wild type mice.

[0054] **FIG. 32** is a flow diagram of one method of treating a patient to form bone in a selected location.

[0055] **FIG. 33A** is a schematic depicting one embodiment of an implant; **FIG. 33B** is a schematic depicting one embodiment of treating a patient to form bone in a selected location.

DETAILED DESCRIPTION

[0056] The present invention is related to agents and methods for inducing bone formation using NELL1. The present invention also is related to methods for the expression and purification of NELL1 and NELL2 proteins.

[0057] NELL1 was identified by Ting and Watanabe simultaneously. NELL1 is a 810 aa peptide, distributed primarily in bone. In adults, NELL2 is expressed at high levels in craniofacial bone, and lower levels in long bone. Its role in osteoblast differentiation, bone formation and regeneration has been examined. NELL2 was identified by Watanabe in 1996, and it is a 816 peptide, distributed in neural cells and brain.

[0058] Human NELL1 gene includes at least 3 Cbfa1 response elements in the promoter region. Cbfa1 specifically binds to these response elements in the NELL1 promoter. NELL1 expression may be under the control of this transcription factors expressed endogenously at least in preosteoblasts, osteoblasts and hypertrophic chondrocytes in development and in adulthood. Cleidocranial dysostosis is a developmental cranial defect thought to be caused at least in part by Cbfa disruption.

[0059] In order to study the function of NELL1 and NELL2 peptides, attempts were made to produce and purify the peptide. Unfortunately, NELL1 and NELL2 peptides were unable to be expressed in a number of expression systems. Specifically, in *E. coli* direct and *S. cerevisiae* expression systems no expression was detected, in *E. coli* fused and CHO-dhfr expression systems, very low levels of expression occurred. In the baculovirus system, peptides were expressed.

[0060] It was a surprising discovery of this invention that NELL1 and NELL 2 peptides could be expressed at high levels in insect cells, and that the NELL1 and NELL2 peptides expressed in an insect system were functional forms of the protein.

[0061] COS7 cells can be used to produce NELL1 and NELL2 proteins at low levels, such as about 10 micrograms per litter medium, but require serum-containing medium for the expression. Unfortunately, this medium is not suitable for protein production. As for the signal peptides, NELL1 and NELL2 endogenous signal peptides permit peptide low levels of expression in COS7 cells.

[0062] In one embodiment, the invention includes a method of expressing a functional NELL peptide, such as NELL1 or NELL2 peptide, using an insect cell line. In one embodiment, the insect cell may be a high five cell, Sf9 and other Sf cells.

[0063] In one embodiment, the method may include providing a nucleic acid sequence encoding a NELL peptide, such as NELL1 or NELL2 peptide. The nucleic acid sequence may be a cDNA or genomic DNA, encoding at least a functional portion of a NELL peptide. For example, the nucleic acid sequence may be selected from the group including, but not limited to human NELL1 (SEQ ID NO:1), rat NELL1 (SEQ ID NO:3), mouse NELL1 (SEQ ID NO:5), or human NELL2 (SEQ ID NO:7), rat NELL2 (SEQ ID NO:9), mouse NELL2 (SEQ ID NO:11), chicken NELL2 (SEQ ID NO:13). The nucleic acid sequence may also include sequences such as those with substantial sequence similarity, such as sequences having at least about 75% sequence similarity with any portion of the sequences listed above.

[0064] Further the nucleic acid may include an expression vector for expressing the nucleic acid sequence encoding a NELL peptide, such as NELL1 or NELL2 peptide. For example, the expression vector may be pIZTN5-His (Invitrogen), and selective markers may also include blasticidin and neomycin.

[0065] Further, the nucleic acid sequence may also include additional nucleic acids which encode reporter products to monitor levels of gene expression, or encode peptide tags which can be visualized using known methods in the art to monitor levels of peptide expression. Additional sequences may be selected so as to not interfere with the expression of the nucleic acid, or the functionality of the expressed peptide product.

[0066] In one embodiment, the method may include providing a nucleic acid sequence encoding a NELL peptide, such as NELL1 or NELL2 peptide, in frame with a nucleic acid sequence encoding a secretory signal peptide. In one embodiment, the secretory signal peptide may be a secretory signal peptide from a secreted bee protein. For example, the nucleic acid sequence may be selected from the group including, but not limited to a melittin signal sequence, drosophila immunoglobulin-binding protein signal sequence, equine interferon-gamma (eIFN-gamma) signal peptide, snake phospholipase A2 inhibitor signal peptide, human and/or chicken lysozyme signal peptide. For mammalian expression systems, a protrypsin leading sequence may also be used.

[0067] In one embodiment, the method may include transfecting an insect cell line with a nucleic acid construct encoding a NELL peptide; and culturing the insect cell line under conditions that permit expression and/or secretion of the NELL peptide. For example, the cell line may be transfected transiently or stably with the nucleic acid construct encoding a NELL peptide.

[0068] The method may also include collecting secreted NELL peptides and/or purifying NELL peptides for use. Peptide products may be tested for activity in a variety of functional or expression assays. For example in any assay, if a NELL peptide has a significant effect over a control substance on a given parameter, the NELL peptides may be said to be functional to effect the measured parameter.

[0069] In one embodiment, the invention may include a nucleic acid construct for expressing a NELL peptide, such as NELL1 and/or NELL2 peptide in an insect cell. The nucleic acid sequence may be a cDNA or genomic DNA, encoding at least a functional portion of a NELL peptide. For example, the nucleic acid sequence may be selected from the group including, but not limited to human NELL1 (SEQ ID NO:1), rat NELL1 (SEQ ID NO:3), mouse NELL1 (SEQ ID NO:5), or human NELL2 (SEQ ID NO:7), rat NELL2 (SEQ ID NO:9), mouse NELL2 (SEQ ID NO:11), chicken NELL2 (SEQ ID NO:13). The nucleic acid sequence may also include sequences such as those with substantial sequence similarity, such as sequences having at least about 75% sequence similarity with any portion of the sequences listed above.

[0070] The nucleic acid construct may include a nucleic acid sequence encoding a signal peptide. The nucleic acid may include an expression vector for expressing the nucleic acid sequence encoding a NELL peptide. Further, the nucleic acid sequence may include additional nucleic acids which encode reporter products to monitor levels of gene expression, or encode peptide tags which can be visualized using known methods in the art to monitor levels of peptide expression.

[0071] Nucleic acid constructs may comprise expression and cloning vectors should containing a selection gene, also termed a selectable marker, such as a gene that encodes a protein necessary for the survival or growth of a host cell transformed with the vector. The presence of this gene ensures that any host cell which deletes the vector will not obtain an advantage in growth or reproduction over transformed hosts. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate or tetracycline, (b) complement auxotrophic deficiencies.

[0072] Nucleic acid constructs may also include a promoter which is recognized by the host organism and is operably linked to the NELL encoding nucleic acid. Promoters are untranslated sequences located upstream from the start codon of a structural gene (generally within about 100 to 1000 bp) that control the transcription and translation of nucleic acid under their control, including inducible and constitutive promoters. Inducible promoters are promoters that initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, e.g. the presence or absence of a nutrient or a change in temperature. At this time a large number of promoters recognized by a variety of potential host cells are well known.

[0073] A nucleic acid may be operably linked when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein which participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.

[0074] In one embodiment, the invention may include cells that express functional NELL peptides. In one embodiment, the cell may be an insect cell. In one embodiment, the insect cell may be a high five cell.

[0075] In one embodiment, the cell may be transfected with a nucleic acid construct encoding a NELL peptide. For example, the cell line may be transfected transiently or stably with the nucleic acid construct encoding a NELL peptide. In one embodiment, NELL expressing nucleic acids (e.g., cDNA(s)) may be cloned into gene expression vector or viral particles that are competent to transfect cells (such as insect cells).

[0076] The nucleic acid sequence may also include a nucleic acid sequence encoding a NELL peptide, such as NELL1 or NELL2 peptide, in frame with a nucleic acid sequence encoding an insect secretory signal peptide.

[0077] In one embodiment, the invention may include cells that express functional NELL peptides, and may secrete functional proteins.

[0078] In one embodiment, the invention may include a polypeptide (amino acid sequence) comprising a NELL peptide, such as NELL1 or NELL2 peptide, and may include secretory signal peptide.

[0079] For example, the amino acid sequence of the NELL peptide may be selected from the group including, but not limited to human NELL1 (SEQ ID NO:2), rat NELL1 (SEQ ID NO:4), mouse NELL1 (SEQ ID NO:6), or human NELL2 (SEQ ID NO:8), rat NELL2 (SEQ ID NO:10), mouse NELL2 (SEQ ID NO:12), chicken NELL2 (SEQ ID NO:14). The amino acid sequence may also include sequences such as those with substantial similarity, such as sequences having at least about 75% sequence similarity with any portion of the sequences listed above, or contain similar active binding domains as NELL1 peptides.

[0080] In one embodiment, the invention includes a method purifying NELL1 and/or NELL2 peptides secreted into culture media, according to standard peptide purification protocols, including, but not limited to those described below.

[0081] In one embodiment, whether a selected cell expresses a selected nucleic acid sequence to express and/or secrete a NELL peptide may be examined. In one embodiment, the presence, amount or and/or activity of NELL peptides may be examined.

[0082] In one embodiment, NELL peptides detected and quantified by any of a number of methods well known to those of skill in the art. These may include analytic biochemical methods such as electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, and the like, or various immunological methods such as fluid or gel precipitin reactions, immunodiffusion (single or double), immunoelectrophoresis, radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, western blotting, and the like.

[0083] In one embodiment, Western blot (immunoblot) analysis may be used to detect and quantify the presence of NELL peptide(s) in a selected sample. This technique may include separating sample proteins by gel electrophoresis on the basis of molecular weight, transferring the separated proteins to a suitable solid support, (such as a nitrocellulose filter, a nylon filter, or derivatized nylon filter), and incubating the sample with the antibodies that specifically bind a target peptide.

[0084] The assays of this invention may be scored (as positive or negative or quantity of target polypeptide) according to standard methods well known to those of skill in the art. The particular method of scoring may depend on the assay format and choice of label. For example, a Western Blot assay may be scored by visualizing the colored product produced by an enzymatic label. A clearly visible colored band or spot at the correct molecular weight may be scored as a positive result, while the absence of a clearly visible spot or band may be scored as a negative. The intensity of the band or spot may provide a quantitative measure of target polypeptide concentration.

[0085] The NELL1 proteins generated in such expression systems can be used in a manner analogous to the use of bone morphogenic proteins (e.g. BMP-1 through BMP-24). Thus, the NELL1 polypeptide(s) can be used to speed repair of bone fractures or to induce bone repair or replacement under circumstances where natural healing is limited or nonexistent. In addition, the NELL1 polypeptides can be incorporated into bone graft materials. These graft materials can be used in the treatment of fractures or to facilitate the replacement/healing of prostheses or bone transplants and spinal fusion.

[0086] The present invention may also include agents and methods for increasing the degree and/or rate of bone formation. More specifically, the invention may include the systemic and/or local application of agents for increasing bone formation. Clinical indices of a method or agents ability to increase the degree and/or rate of bone formation is evidenced by improvements in bone density at the desired site of bone formation as assessed by DEXA scanning. Enhanced bone formation in a healing fracture is routinely assessed by regular X-ray of the fracture site at selected time intervals. More advanced techniques for determining the above indices such as quantitative CT scanning may be used.

[0087] In one embodiment, the invention may include, a method of increasing osteogenic cell differentiation comprising increasing the concentration of a NELL1 gene product in an osteogenic cell, optionally applying a second agent; and inducing the expression of cellular marker of osteoblastic differentiation.

[0088] The method may include increasing the concentration of a NELL1 gene product by applying a NELL1 peptide to an osteogenic cell, and the NELL1 peptide may be selected from the group comprising: SEQ ID NO:2, SEQ ID NO: 4, or SEQ ID NO:6, or any portion of the NELL peptide which is effective in increasing osteoblastic differentiation. The method may include increasing the concentration of a NELL1 gene product by inducing the expression of an endogenous NELL1 gene, such as by increasing cellular levels of the expression regulating molecule, Cbfa1. The method may include increasing the concentration of a NELL1 gene product by transfecting the osteogenic cell with a nucleic acid construct encoding a NELL1 peptide, and the nucleic acid construct encoding a NELL1 peptide may be selected from the group comprising SEQ ID NO:1, SEQ ID NO: 3, or SEQ ID NO:5.

[0089] Osteogenic cells may include, but are not limited to osteoblasts, mesenchymal cells, fibroblasts, fetal embryonic cells, stem cells, bone marrow cells, dural cells, chondrocytes, chondroblasts and adipose stem cells.

[0090] Osteogenic cells may also include cells that are located within, are in contact with, or migrate towards (i.e.,

“home to”), bone tissue and which cells directly or indirectly stimulate the formation of bone tissue. As such, the osteogenic cells may be cells that ultimately differentiate into mature osteoblasts cells themselves, i.e., cells that “directly” form bone tissue.

[0091] A second agent may include, but is not limited to: TGF- β , BMP2, BMP4, BMP7, bFGF, collagen. The second agent may be selected to have a complimentary or synergistic effect with NELL1 in inducing osteoblastic differentiation.

[0092] Cellular markers of osteoblastic differentiation include, but are not limited to increased levels of alkaline phosphatase activity, osteocalcin and osteoponin mRNA expression, BMP7 expression, decorin expression and laminin B1 expression. However, any cellular marker whose activity or expression changes as a result of osteoblastic differentiation may be used as a marker of such.

[0093] In one embodiment, the method of increasing osteoblastic mineralization may include increasing the concentration of a NELL1 gene product in an osteoblastic cell, optionally applying a second agent; and inducing the expression of cellular marker of mineralization.

[0094] The method may include increasing the concentration of a NELL1 gene product by applying a NELL1 peptide to an osteogenic cell, and the NELL1 peptide may be selected from the group comprising: SEQ ID NO:2, SEQ ID NO: 4, or SEQ ID NO:6, or any portion of the NELL peptide which is effective in increasing osteoblastic mineralization. The second agent may be selected to have a complimentary or synergistic effect with NELL1 in inducing osteoblastic mineralization.

[0095] Cellular markers of osteoblastic mineralization include, but are not limited to increased levels of calcium incorporation. However, any cellular marker whose activity or expression changes as a result of osteoblastic mineralization may be used as a marker of such.

[0096] In one embodiment, a method of increasing intramembraneous bone formation may include increasing the concentration of a NELL1 gene product in a location where bone formation is desired, optionally applying a second agent to approximately the same location region where bone formation is desired; and inducing the formation of intramembraneous bone formation.

[0097] The method may include increasing the concentration of a NELL1 gene product by applying a NELL1 peptide to the location where bone formation is desired, and the NELL1 peptide may be selected from the group comprising: SEQ ID NO:2, SEQ ID NO: 4, or SEQ ID NO:6, or any portion of the NELL peptide which is effective in increasing intramembraneous bone formation.

[0098] The second agent may include, but is not limited to TGF- β , BMP2, BMP4, BMP7, bFGF, collagen, osteogenic cells, bone, bone matrix, tendon matrix, ligament matrix. The second agent may be selected to have a complimentary or synergistic effect with NELL1 in inducing intramembraneous bone formation.

[0099] The formation of intramembraneous bone may be evaluated by microscopic inspection for histology, DEXA scanning, X-ray or CT scanning of bone density in the area where bone formation is desired.

[0100] In one embodiment, a method of increasing endochondral bone formation may include increasing the concentration of a NELL1 gene product in a region where bone formation is desired; optionally applying a second agent to the region where bone formation is desired and at least inducing hypertrophy of chondroblast in the region where bone formation is desired.

[0101] The method may include increasing the concentration of a NELL1 gene product by applying a NELL1 peptide to the location where bone formation is desired, and the NELL1 peptide may be selected from the group comprising: SEQ ID NO:2, SEQ ID NO: 4, or SEQ ID NO:6, or any portion of the NELL peptide which is effective in increasing endochondral bone formation.

[0102] The second agent may include, but is not limited to TGF- β , BMP2, BMP4, BMP7, bFGF, collagen, osteogenic cells, bone, bone matrix, tendon matrix, ligament matrix. The second agent may be selected to have a complimentary or synergistic effect with NELL1 in inducing endochondral bone formation.

[0103] The formation of endochondral bone may be evaluated by chondroblast hypertrophy as viewed by an increase in hypertrophic and apoptotic chondroblasts, elucidated by TUNEL staining.

[0104] In one embodiment, the invention may include a method of incorporating NELL1 in carriers or substrates, and the resulting substrates.

[0105] In one embodiment, a composition for inducing bone formation may include an effective amount of a first agent to induce bone formation selected from the group including but not limited to a NELL1 peptide, and an agent that alters expression of NELL1 peptide, or an agent that alters the activity of a NELL1 peptide; and optionally a carrier.

[0106] The composition may include a NELL1 peptide selected from the group comprising: SEQ ID NO:2, SEQ ID NO: 4, or SEQ ID NO:6, or any fragment which is effective in inducing bone formation.

[0107] The composition may include a second agent including, but not limited to TGF- β , BMP2, BMP4, BMP7, bFGF, collagen, bone, bone matrix, tendon matrix or ligament matrix, osteogenic and/or osteoblastic cells.

[0108] In one embodiment, the carrier may be biodegradable, such as degradable by enzymatic or hydrolytic mechanisms. Examples of carriers include, but are not limited to synthetic absorbable polymers such as but not limited to poly(α -hydroxy acids) such as poly(L-lactide) (PLLA), poly(D, L-lactide) (PDLLA), polyglycolide (PGA), poly(lactide-co-glycolide) (PLGA), poly(-caprolactone), poly(trimethylene carbonate), poly(p-dioxanone), poly(-caprolactone-co-glycolide), poly(glycolide-co-trimethylene carbonate) poly(D, L-lactide-co-trimethylene carbonate), polyarylates, polyhydroxybutyrate (PHB), polyanhydrides, poly(anhydride-co-imide), propylene-co-fumarates, polylactones, polyesters, polycarbonates, polyanionic polymers, polyanhydrides, polyester-amides, poly(amino-acids), homopolypeptides, poly(phosphazenes), poly(glaxanone), polysaccharides, and poly(orthoesters), polyglactin, polyglactic acid, polyaldonic acid, polyacrylic acids, polyalkanoates; copolymers and admixtures thereof, and any

derivatives and modifications. See for example, U.S. Pat. No. 4,563,489, and PCT Int. Appl. # WO/03024316, herein incorporated by reference. Other examples of carriers include cellulosic polymers such as, but not limited to alkylcellulose, hydroxyalkylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, carboxymethylcellulose, and their cationic salts. Other examples of carriers include synthetic and natural bioceramics such as, but not limited to calcium carbonates, calcium phosphates, apatites, bioactive glass materials, and coral-derived apatites. See for example U.S. Patent Application 2002187104; PCT Int. Appl. WO/9731661; and PCT Int. Appl. WO/0071083, herein incorporated by reference.

[0109] In one embodiment, the carrier may further be coated by compositions, including bioglass and or apatites derived from sol-gel techniques, or from immersion techniques such as, but not limited to simulated body fluids with calcium and phosphate concentrations ranging from about 1.5 to 7-fold the natural serum concentration and adjusted by various means to solutions with pH range of about 2.8-7.8 at temperature from about 15-65 degrees C. See, for example, U.S. Pat. Nos. 6,426,114 and 6,013,591; and PCT Int. Appl. WO/9117965 herein incorporated by reference.

[0110] Other examples of carriers include, collagen (e.g. Collastat, Helistat collagen sponges), hyaluronan, fibrin, chitosan, alginate, and gelatin. See for example, PCT Int. Appls. WO/9505846; WO/02085422, herein incorporated by reference.

[0111] In one embodiment, the carrier may include heparin-binding agents; including but not limited to heparin-like polymers e.g. dextran sulfate, chondroitin sulfate, heparin sulfate, fucan, alginate, or their derivatives; and peptide fragments with amino acid modifications to increase heparin affinity. See for example, Journal of Biological Chemistry (2003), 278(44), p. 43229-43235, herein incorporated by reference.

[0112] In one embodiment, the substrate may be in the form of a liquid, solid or gel.

[0113] In one embodiment, the substrate may include a carrier that is in the form of a flowable gel. The gel may be selected so as to be injectable, such as via a syringe at the site where bone formation is desired. The gel may be a chemical gel which may be a chemical gel formed by primary bonds, and controlled by pH, ionic groups, and/or solvent concentration. The gel may also be a physical gel which may be formed by secondary bonds and controlled by temperature and viscosity. Examples of gels include, but are not limited to, pluronics, gelatin, hyaluronan, collagen, polylactide-polyethylene glycol solutions and conjugates, chitosan, citosan & b-glycerophosphate (BST-gel), alginates, agarose, hydroxypropyl cellulose, methyl cellulose, polyethylene oxide, polylactides/glycolides in N-methyl-2-pyrrolidone. See for example, Anatomical Record (2001), 263(4), 342-349, herein incorporated by reference.

[0114] In one embodiment, the carrier may be photopolymerizable, such as by electromagnetic radiation with wavelength of at least about 250 nm. Example of photopolymerizable polymers include polyethylene (PEG) acrylate derivatives, PEG methacrylate derivatives, propylene fumarate-co-ethylene glycol, polyvinyl alcohol derivatives, PEG-

co-poly(-hydroxy acid) diacrylate macromers, and modified polysaccharides such as hyaluronic acid derivatives and dextran methacrylate. See for example, U.S. Pat. No. 5,410,016, herein incorporated by reference.

[0115] In one embodiment, the substrate may include a carrier that is temperature sensitive. Examples include carriers made from N-isopropylacrylamide (NiPAM), or modified NiPAM with lowered lower critical solution temperature (LCST) and enhanced peptide (e.g. NELL1) binding by incorporation of ethyl methacrylate and N-acryloxysuccinimide; or alkyl methacrylates such as butylmethacrylate, hexylmethacrylate and dodecylmethacrylate. PCT Int. Appl. WO/2001070288; U.S. Pat. No. 5,124,151 herein incorporated by reference.

[0116] In one embodiment, where the carrier may have a surface that is decorated and/or immobilized with cell adhesion molecules, adhesion peptides, and adhesion peptide analogs which may promote cell-matrix attachment via receptor mediated mechanisms, and/or molecular moieties which may promote adhesion via non-receptor mediated mechanisms binding such as, but not limited to polycationic polyamino-acid-peptides (e.g. poly-lysine), polyanionic polyamino-acid-peptides, Mefp-class adhesive molecules and other DOPA-rich peptides (e.g. poly-lysine-DOPA), polysaccharides, and proteoglycans. See for example, PCT Int. Appl. WO/2004005421; WO/2003008376; WO/9734016, herein incorporated by reference.

[0117] In one embodiment, the carrier may include comprised of sequestering agents such as, but not limited to, collagen, gelatin, hyaluronic acid, alginate, poly(ethylene glycol), alkylcellulose (including hydroxyalkylcellulose), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, blood, fibrin, polyoxyethylene oxide, calcium sulfate hemihydrate, apatites, carboxyvinyl polymer, and poly(vinyl alcohol). See for example, U.S. Pat. No. 6,620,406, herein incorporated by reference.

[0118] In one embodiment, the carrier may include surfactants to promote NELL1 stability and/or distribution within the carrier materials such as, but not limited to polyoxyester (e.g. polysorbate 80, polysorbate 20 or Pluronic F-68).

[0119] In one embodiment, the carrier may include buffering agents such as, but not limited to glycine, glutamic acid hydrochloride, sodium chloride, guanidine, heparin, glutamic acid hydrochloride, acetic acid, succinic acid, polysorbate, dextran sulfate, sucrose, and amino acids. See for example, U.S. Pat. No. 5,385,887, herein incorporated by reference. In one embodiment, the carrier may include a combination of materials such as those listed above.

[0120] By way of example, the carrier may be a PLGA/collagen carrier membrane. The membrane may be soaked in a solution including NELL1 peptide.

[0121] In one embodiment, an implant for use in the human body may include a substrate including NELL1 in an amount sufficient to induce bone formation proximate to the implant.

[0122] In one embodiment, an implant for use in the human body may include a substrate having a surface

including NELL1 in an amount sufficient to induce bone formation proximate to the implant.

[0123] In one embodiment, an implant for use in the human body may include a substrate having a surface including osteogenic cells, and NELL1 in an amount sufficient to induce bone formation. In one embodiment, the implant may be seeded with cells, including but not limited to autologous cells, osteogenic or osteoblastic cells, cells expressing NELL1 or another osteogenic molecule.

[0124] An implant may include a substrate formed into the shape of a mesh, pin, screw, plate, or prosthetic joint. By way of example, a substrate may be in a form of a dental or orthopedic implant, and NELL1 may be used to enhance integration in bone in proximity to the implant. An implant may include a substrate that is resorbable, such as a substrate including collagen.

[0125] In one example, a composition according to this invention may be contained within a time release tablet.

[0126] The NELL1 peptide may be combined with a acceptable carrier to form a pharmacological composition. Acceptable carriers can contain a physiologically acceptable compound that acts, for example, to stabilize the composition or to increase or decrease the absorption of the agent. Physiologically acceptable compounds can include, for example, carbohydrates, such as glucose, sucrose, or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins, compositions that reduce the clearance or hydrolysis of the anti-mitotic agents, or excipients or other stabilizers and/or buffers.

[0127] Other physiologically acceptable compounds include wetting agents, emulsifying agents, dispersing agents or preservatives which are particularly useful for preventing the growth or action of microorganisms. Various preservatives are well known and include, for example, phenol and ascorbic acid. One skilled in the art would appreciate that the choice of a carrier, including a physiologically acceptable compound depends, for example, on the route of administration.

[0128] The compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable may include powder, tablets, pills, capsules.

[0129] The compositions of this invention may comprise a solution of the NELL1 peptide dissolved in a pharmaceutically acceptable carrier, such as an aqueous carrier for water-soluble peptides. A variety of carriers can be used, e.g., buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like.

[0130] The concentration of NELL1 peptide in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like

in accordance with the particular mode of administration selected and the patient's needs.

[0131] The dosage regimen will be determined by the clinical indication being addressed, as well as by various patient variables (e.g. weight, age, sex) and clinical presentation (e.g. extent of injury, site of injury, etc.).

[0132] However, a therapeutically effective dose of a NELL1 peptide or agent useful in this invention is one which has a positive clinical effect on a patient or desired effect in cells as measured by the ability of the agent to enhance osteoblastic differentiation, mineralization, bone formation, as described above. The therapeutically effective dose of each peptide or agent can be modulated to achieve the desired clinical effect, while minimizing negative side effects. The dosage of the peptide or agent may be selected for an individual patient depending upon the route of administration, severity of the disease, age and weight of the patient, other medications the patient is taking and other factors normally considered by an attending physician, when determining an individual regimen and dose level appropriate for a particular patient.

[0133] Dosage Form. The therapeutically effective dose of an agent included in the dosage form may be selected by considering the type of agent selected and the route of administration. The dosage form may include a agent in combination with other inert ingredients, including adjuncts and pharmaceutically acceptable carriers for the facilitation of dosage to the patient, as is known to those skilled in the pharmaceutical arts.

[0134] In one embodiment, the invention may include a method of treating a patient to induce bone formation, comprising administering NELL1 peptide at a therapeutically effective dose in an effective dosage form at a selected interval to enhance bone formation. The method of may further comprise administering at least one secondary agent in the region where bone formation is desired, including but not limited to TGF- β , BMP2, BMP4, BMP7, bFGF, collagen, bone, bone matrix, tendon matrix or ligament matrix, osteogenic or osteoblastic cells.

[0135] In one embodiment, a method of treating a patient to induce bone formation may include harvesting mammalian osteogenic cells, increasing the concentration of expression of NELL1 peptide in contact with the osteogenic cells and administering the osteogenic cells to a region where bone formation is desired.

[0136] In one embodiment, bone formation to repair to cranial trauma or cranial defects may be desired, such as occurs in fetuses, infants or adults having cleidocranial disostosis, or cleft palate. In one embodiment, bone formation may be desired in a region of a non-healing bone defect (also known as critical size defect where bone fails to regenerate/heal in the defect). Critical size defect models are studied as a stringent test on agent effecting all bone healing, including long bone fracture, since all bone wound healing is believed to be by membranous (also called intramembraneous) bone formation. For example, long bone fracture and calvarial defect both heal by membranous bone formation. In one embodiment, bone formation may be desired in alveolar bone grafts or alveolar ridge augmentation, or periodontal bone defect. In one embodiment, bone formation may be desired to enhance the integration of implants such as joint or dental implants, or cosmetic surgery onplants.

[0137] In one embodiment, bone formation may be used in alternative or in addition to autologous, autogenous or alloplastic materials for bone grafts.

EXAMPLES

[0138] The following examples are offered to illustrate, but not to limit the claimed invention.

Example 1

Expression of Nell Peptides

[0139] A cDNA fragment was ligated into the expression vector pIZT/V5-His (3.4 kb) (EcoRV site, Invitrogen) and included a melittin signal peptide, BamHI-EcoRI cDNA fragment of the mature rat NELL1 and a FLAG tag sequence. **FIG. 16** is a depiction of the nucleic acid sequence of the cDNA construct used in this example, and corresponding predicted peptide sequence.

[0140] The High five cells (BTI-TN-5B1-4) were adapted to serum-free medium, and cells were transfected with the NELL1 peptide expression vector. Cells were treated with zeocin so as to select only cell populations expressing the NELL1 FLAG constructs. Surviving cell populations were confirmed to be stable transformants. Extracellular media was collected and tested for the presence of NELL1 peptide. NELL1 peptide was purified and used in functional assays described below.

[0141] **FIG. 17A** is an illustration of a CBB-stained SDS-PAGE gel of UnoQ-eluate containing purified NELL1 peptide. The medium was applied onto UnoQ column (Bio-Rad) as described herein. **FIG. 4B** is an illustration of a Western blot using anti-FLAG antibody depicting NELL1-FLAG expression in reference to a protein ladder. Peptide: 140 kDa (intracellular precursor), 130 kDa (mature form; 90 kDa peptide), 400 kDa (secreted form, homotrimer). In the example above, the productivity of the expression system was about 3 mg NELL1 peptide/L medium.

[0142] Relative to other expression systems which did not express or secrete peptide at all (such as bacterial expression, including yeast) or whose peptide production was extremely low (e.g., *E. coli* fused peptide system, CHO-dhfr cells, >10 mcg/L) production with the systems described (mammalian and insect cells) was surprisingly and substantially more effective at producing large amounts of functional protein.

[0143] Expression and Purification of Recombinant Rat NELL1 Protein. For production of the C-terminally FLAG-tagged NELL1 peptide by insect cells. A pIZT-NELL1-FLC plasmid was constructed by inserting the rat NELL1 cDNA fused to a FLAG epitope sequence derived from the pTB701-NELL1-FLC plasmid (Kuroda, BBRC) into insect expression vector pIZTN5-His (Invitrogen). Furthermore, NELL1 original secretory signal sequence was replaced to honeybee mellitin signal sequence using PCR methods. High Five cells were purchased from Invitrogen, and were cultured in High Five Serum-Free Medium (Invitrogen). High Five cells were transfected with the pIZT-NELL1-FLC plasmid using FuGene6 (Roche). Forty-eight hours after transfection, cells were selected with 400 mg/ml of Zeocin (Invitrogen). Replace selective medium every 3 to 4 days until the stable expression cell line was established. NELL1

secretion was confirmed using immunoprecipitation and Western blot analyses. High five cells were found to express NELL1 peptides (140-kDa) in the culture medium.

[0144] The recombinant rat NELL1-FLC peptide was purified from the culture medium of Zeocin-resistant High Five cells by anion exchange chromatography using a UNO Q-1 column (Bio-Rad). NELL1 peptide was eluted at 500 mM NaCl.

[0145] For production of the C-terminally FLAG-tagged NELL1 peptide by COS7 cells, a pcDNA3.1-NELL1-FLC plasmid was constructed by inserting the rat NELL1 cDNA linked to a FLAG epitope sequence derived from the pTB701-NELL1-FLC plasmid into mammalian expression vector pcDNA3.1 (Invitrogen). COS7 cells were cultured in DMEM supplemented with 10% FBS. COS7 cells were transfected with the pcDNA3.1-NELL1-FLC using the endogenous NELL signal peptide plasmid and using electroporation method. Forty-eight hours after transfection, culture medium was subjected to immunoprecipitation and Western blot analyses for NELL1 peptide.

[0146] **FIG. 17C** is an illustration of a CBB-stained SDS-PAGE gel of UnoQ-eluate, including NELL1-FLAG. These expression studies showed that COS cells did not express functional NELL peptide, without modifying the N terminal of the NELL to increase secretion efficiency such as including a signal sequence. **FIG. 17D** is an illustration of a Western blot using anti-FLAG antibody depicting NELL1-FLAG expression.

[0147] Expression and Purification of Recombinant Rat NELL2 Protein. For production of the C-terminally FLAG-tagged NELL2 peptide by insect cells. A pIZT-NELL2-FLC plasmid was constructed by inserting the rat NELL2 cDNA fused to a FLAG epitope sequence derived from the pTB701-NELL2-FLC plasmid into insect expression vector pIZTN5-His (Invitrogen). High Five cells were purchased from Invitrogen, and were cultured in High Five Serum-Free Medium (Invitrogen). High Five cells were transfected with the pIZT-NELL2-FLC plasmid using FuGene6 (Roche). Forty-eight hours after transfection, cells were selected with 400 mg/ml of Zeocin (Invitrogen). Selective media was replaced every 3 to 4 days, until the stable expression cell line was established. NELL2 expression was confirmed in culture medium was confirmed using immunoprecipitation and Western blot analyses. High five cells were found to express NELL2 peptides (140-kDa) in the culture medium.

[0148] The recombinant rat NELL2-FLC peptide was purified from the culture medium of Zeocin-resistant High Five cells by anion exchange chromatography using a UNO Q-1 column (Bio-Rad). NELL2-FLC peptide was eluted at 500 mM NaCl.

Example 2

Purification of NELL2 Protein from Culture Medium

[0149] High Five cells carrying pIZT-FLC-NELL2 were cultured for about three days in serum free culture medium (1 L). The culture medium was centrifuged at 3000×g for 5 minutes and the supernatant was collected. PMSF was added to a final concentration of 1 mM. Saturated ammonium sulfate solution (80% saturation (v/v)) was added and the

solution kept at 4 degrees for 1 hour. The solution was centrifuged at 15000×g for 30 min. and precipitate collected. Precipitate was dissolved in 50 ml of 20 mM Tris-HCl (pH 8.0), 1 mM EDTA at 4 degree and applied onto an anion-exchange chromatography UnoQ column (6 ml, Bio-Rad) equilibrated in 20 mM Tris-HCl (pH 8.0), 1 mM EDTA at 4 degree (1 ml/min speed by FPLC (Amersham-Pharmacia). The column was thoroughly washed with the same buffer.

[0150] The binding protein was then eluted by the gradation from 0 M to 1.5 M NaCl in the same buffer. The NELL2-FLAG fractions were identified by Western blotting using anti-Flag M2 (Sigma) Ab. The positive fractions were collected into one tube. Final product was dialyzed in the seamless cellulose tube (Wako, cutoff MW 12000) against 1 L PBS for overnight at 4 degree. The product was stored at -70 degree.

[0151] The purity of the NELL2-FLAG peptide was examined by SDS-PAGE/CBB staining. FIG. 18 is an illustration of a CBB-stained SDS-PAGE gel of UnoQ-eluate containing purified NELL2 peptide. Column A depicts a peptide band at about 130 kDa was isolated from the cell medium. "IP" refers to the Anti-FLAG antibody used for the immunoprecipitation; "WB" refers to the Anti-FLAG antibody used for the Western blotting detection.

[0152] FIG. 19 is a blot illustrating the expression of NELL1 and NELL2 from Five SFM. "ESF921" refers to a commercial name of a serum-free medium; "Five SFM" refers to a commercial name of a medium. The constructs for the expression of both NELL proteins are similar to those described above.

Example 3

[0153] Increases in alkaline phosphatase activity is an early cellular marker of osteoblastic differentiation. In one study, fetal rat calvarial cells were grown in the presence of: NELL1 (1 ng/ml, 10 ng/ml, 10 ng/ml) produced using the methods described herein, or BMP4 (100 ng/ml) for duration of time. Alkaline phosphatase was assayed in each sample by conventional methods.

[0154] FIG. 20 is a bar graph depicting alkaline phosphatase induction as a function of treatment in rat calvarial cell cultures ("OD"=Optic density). Therefore, treatment with NELL1 was more potent than BMP4 in inducing osteoblast differentiation, as measured by alkaline phosphatase induction.

[0155] FIG. 21 are photomicrographs of rat calvarial cell cultures treated with NELL1. Treatment with NELL1 induced alkaline phosphatase activity and cell micronodule formation in the absence of ascorbic acid, which is an indication of osteoblastic differentiation and a precursor to bone formation.

Example 4

[0156] Alkaline phosphatase assay is an early cellular marker of osteoblastic differentiation. In one study, rat calvarial osteoblasts were grown on a 24 well plate. Wells were divided into groups including: NELL1, BMP2, NELL1/BMP2 and control (no peptide). Treatments included the application peptides at 100 ng/ml. Alkaline phosphatase was assayed in each sample by conventional methods.

TABLE 1

Time	NELL1	BMP2	NELL1/BMP	Control
24 hr	134%	159%	210%	100%
3 days	154%	145%	189%	100%

[0157] Therefore, NELL1 and BMP have an additive effect on osteoblast differentiation, as measured by alkaline phosphatase activity relative to control or cells treated with single peptides alone.

Example 5

[0158] To investigate the effect of NELL1 expression on osteoblastic differentiation, bone related gene expression was evaluated in a microarray of MC3T3 cells at 3, 6 and 9 days post-infection with a NELL1 expressing construct relative to cells infected with β -gal expressing constructs.

TABLE 2

Expression levels over control cells.			
	Day 3 post-infection	Day 6 post-infection	Day 9 post-infection
Up regulated	NA	Osteocalcin 2.5 BMP7 2.1	Decorin 2.2 Osteocalcin 2.6 Laminin B1 2.0 BMP7 3.2 Osteopontin 3.5 Cal 15alpha1 2.6

[0159] Several bone related genes in NELL1 transfected cells were expressed at levels at least two fold higher than the β -gal control transfected cells. Therefore, since cellular markers of late osteoblastic differentiation (such as osteocalcin and osteopontin) are up regulated, NELL1 expression and production enhanced osteoblastic differentiation.

Example 6

[0160] Micronodule formation, or the aggregation of a plurality of osteoblasts is an indication of osteoblastic differentiation and a precursor to bone formation. The process is thought to be regulated by ascorbic acid.

[0161] To investigate the effects of NELL1 on micronodule formation, MC3TC cells were transfected with a NELL1 encoding construct, and grown in the absence of ascorbic acid.

[0162] FIGS. 22 A&B are photomicrograph of MC3TC cells expressing NELL1 forming micronodules and stained for alkaline phosphatase (B). NELL1 expression induced alkaline phosphate induction, as well and micronodule formation. Therefore, NELL1 is active in cell micronodule formation, which is a precursor to bone formation, and NELL1 alone is sufficient to induce osteoblast differentiation.

Example 7

[0163] Mineralization, or the intracellular accumulation of calcium is an indication of osteoblastic differentiation and a precursor to bone formation. To investigate the effects of NELL1 mineralization, primary calvarial cells were trans-

ected with an adenoviral NELL1 encoding construct or a control construct encoding β -gal, or an antisense NELL1 virus. Cells were subsequently examined by Von Kassa staining to detect the presence of intracellular calcium accumulation after 3, 6, 9 and 12 days in culture. This demonstrates NELL1 can accelerate bone mineralization.

[0164] FIGS. 23A-C are photomicrographs of calvarial cells treated with the A) antisense NELL1 virus, B) β -gal or C) NELL1. The control cells had a moderate amount of mineralization, NELL1 expressing cells had increased levels of mineralization, and in antisense NELL1 cells mineralization was inhibited. This “knock-out” study shows that NELL1 is required for osteoblast differentiation.

[0165] FIGS. 23 D&E are bar graphs depicting osteocalcin and osteoponin mRNA expression as a ratio relative to control GAPFH, after 3, 6, 9 and 12 days in culture. NELL1 expressing cells expressed significantly elevated levels of osteocalcin and osteoponin mRNA after 12 days. Therefore, NELL1 is active in inducing the expression of late cellular markers of osteoblastic differentiation and mineralization, which is a precursor to bone formation.

Example 8

[0166] Transgenic animal models have been used to examine the effect of NELL1 over expression on bone formation. CMV promoter was linked to NELL1 cDNA and microinjected into fertilized eggs. NELL1 was pan-over-expressed under potent CMV promoter.

[0167] FIG. 24 is a photomicrograph of a NELL1 transgenic mouse tissue, depicting Von Kassa staining. As shown, in FIG. 24 NELL1 transgenic mice had calvarial overgrowth, confirming NELL1’s ability to induce bone growth including membranous bone formation.

[0168] FIG. 25 A&B are photomicrographs depicting Von Kassa staining of calvaria of a NELL1 transgenic mouse (A) and normal littermate (B). As shown in FIG. 25A, NELL1 transgenic mice had enhanced mineralization relative to the normal littermate confirming NELL1’s role in membranous bone formation.

Example 9

[0169] Transgenic animal models have been used to examine the effect of NELL1 expression on Cbfa1 deficiency induced developmental defects.

[0170] To determine whether Cbfa1 may play a role in NELL1 regulation, fetal rat calvarial cells were transfected with plasmid vectors containing mouse Cbfa1.

[0171] FIG. 26 is a blot depicting expression of NELL1 in Cbfa1 transfected cells at 24 and 48 hours relative to control cells. Cbfa1 transfection up regulated NELL1 expression within 24 hours (along either positive control osteocalcin). This shows NELL-1 is downstream of Cbfa1—a key “osteoblast transcription factor”.

[0172] FIG. 27A-C are photographs of skeletal staining (top, middle) and micro-CT (bottom). FIG. 27A depicts the normal skeletal pattern of a wild-type mouse. Typical borders of mineralization are noted (dashed lines), anterior and posterior fontanelles (asterisks), and outline of the right coronal suture can be seen (arrows). Also, a normal clavicle is shown (A-middle). The micro-CT reveals the typical

craniofacial bone morphology. FIG. 27B depicts skeletal defects of a Cbfa1^{+/-} animal. Specifically, defective bone mineralization and bone formation is present in the poorly stained tissue (between the dotted lines) lateral to the midline calvarial defect, and lucency can also be seen in the area of the coronal structure (arrows). A significant degree of clavicle hypoplasia is noted (B-middle). Fig. DC depicts skeletal defects of a Cbfa1^{+/-}+NELL1^{overexp} animal demonstrating significantly increased calvarial bone formation relative to the Cbfa1^{+/-} haploid deficient animal on skeletal staining and micro-CT. Also, a significantly lesser degree of clavicle hypoplasia relative to the Cbfa1^{+/-} haploid deficient animal (middle). Note the restoration of bony overlap at the coronal sutures (arrows). Therefore, NELL1 over expression rescued Cbfa1 deficiency in transgenic mice confirming NELL1’s role in membranous bone formation and endochondral bone formation. Further, NELL 1 can regenerate bone in bone in birth defects.

Example 10

[0173] Critical size defect is an important model for the study of an agents ability to induce intramembraneous bone repair. To investigate the effects of NELL1 on bone repair, right and left calvarial defects (3 mm) were created in wild-type adult CD-1 male mice. Left defects (control) were grafted with a PLGA/collagen carrier membrane only while right defects were grafted with PLGA/collagen carrier membrane soaked in either 200 ng of NELL1 or BMP2 per site. Calvaria were extracted and examined by microCT analysis.

[0174] FIG. 28A is a photograph of control (left) and BMP2 (right) treatment of calvarial defect; is a photograph of control (left) and NELL1 (right) treatment of calvarial defect; FIG. 29 is a photograph of NELL1 (left) and BMP2 (right) treatment of calvarial defect. Significant amount of bone formation was observed in both NELL1 and BMP2 groups. Therefore, NELL1 expression significantly effected bone formation and induce bone regeneration in the critical size defect model confirming NELL1’s role in membranous bone formation.

Example 11

[0175] Rapid Palatal Expansion (RPE) is another model for the study of an agents ability to induce intramembraneous bone repair. To investigate the effects of NELL1 on bone repair, 4-week old Sprague Dawley rats were divided into groups for 1) control expansion, and 2) expansion with NELL1 treatment. The rats were sacrificed and their palates extracted and kept vital in organ culture. The palates were expanded and NELL1 added to the treatment group for 9 days.

[0176] FIG. 30A&B are photographs of expanded palates treated with NELL1 (A) and control (B). Significant amount of bone formation was observed in both NELL1 and BMP2 groups. Therefore, NELL1 treatment significantly effected bone formation in the RPE model confirming NELL1’s role in membranous bone formation.

Example 12

[0177] Endochondral bone formation is the key process in long bone development. It has several stages including: chondroblast proliferation, hypertrophy, apoptosis, invasion

of blood vessel, replacement by osteoblasts. Acceleration of any one of these stages will induce endochondral bone growth.

[0178] FIG. 31A&B are photomicrographs of cartilage with TUNEL staining for apoptotic cells in NELL1 over expressing transgenic mice (A) and wild type mice (B).

[0179] As shown in FIG. 31A, in NELL1 over-expression in mice, cartilage shows hypertrophic chondroblasts and apoptosis (indicated by the brown staining using TUNEL ASSAY for identifying shrinkage of apoptotic nuclei). In FIG. 31B is a normal mouse (wild type) cartilage with TUNEL staining very few apoptotic cells are present and the cells are not hypertrophic. Therefore, NELL1 can induce cartilage hypertrophy and apoptosis, thereby inducing long bone formation and regeneration.

Example 13

NELL Substrate Preparation

[0180] In vitro. Polylactide-co-glycolide (85:15 PLGA; intrinsic viscosity ~0.6 dL/g, Birmingham Polymers, AL) was dissolved in chloroform to prepare 5% solution and poured into glass culture dishes and allowed to slowly evaporate for 24 hours. After solvent extraction, the films were coated according to the 8 groups below: (a) polymer only with no coating; (b) conventional apatite (1×SBF followed by 1.5×SBF); (c) accelerated biomimetic apatite (5×SBF followed by Mg-free and carbonate-free 5×SBF); (d) fibronectin (0.01 mg/ml); (e) poly-L-lysine (0.01 mg/ml); (f) collagen; (g) Mefp-1 (0.01 mg/ml); and (h) mixture of collagen & hyaluronan. Each group was subdivided into NELL1 containing (100 ng) and NELL1-free groups, and cultured in vitro for 7 days with primary osteoblasts in non-differentiation media (no ascorbic acid, no beta glycerol phosphates). For each material, NELL1 groups stimulated higher alkaline phosphatase activity than NELL1 counterparts. Among the materials, accelerated apa-

tites (group c) induced the greatest, and polymer control (group a) induced the least alkaline phosphatase activities.

[0181] In vivo. Polylactide-co-glycolide (85:15 PLGA; intrinsic viscosity ~0.6 dL/g, Birmingham Polymers, AL) was dissolved in chloroform and mixed with porogens (sucrose granules with diameter ~100-300 μm) to produce ~90% porosity PLGA scaffolds after particulate leaching and solvent extraction. Porous scaffolds were argon-plasma-etched, sterilized, coated with aqueous bovine type I collagen mixture containing 200 ng NELL1 peptide, dried, and implanted into calvarial defects of adult male wild-type mice. Positive control (PLGA/collagen/BMP) and negative controls (PLGA/collagen only; no growth factors), were also implanted into similar defects. At 4 week, microCT analysis show that while little or no bone formation was induced by the negative control scaffolds (PLGA/collagen only), NELL1-containing and BMP-containing scaffolds induced rapid and complete mineralization across the defects by week 4. Conventional histology confirmed that the mineralization presents the classic features of mature bone.

[0182] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes. It will be understood that the invention may also comprise any combination of the embodiments described or combination with known methods and compositions.

[0183] Although now having described certain embodiments of NELL peptide expression systems and bone formation activity of NELL peptide, it is to be understood that the concepts implicit in these embodiments may be used in other embodiments as well. In short, the protection of this application is limited solely to the claims that now follow.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 14

<210> SEQ ID NO 1

<211> LENGTH: 2433

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)...(2433)

<400> SEQUENCE: 1

```

atg ccg atg gat ttg att tta gtt gtg tgg ttc tgt gtg tgc act gcc      48
Met Pro Met Asp Leu Ile Leu Val Val Trp Phe Cys Val Cys Thr Ala
  1             5             10             15

agg aca gtg gtg ggc ttt ggg atg gac cct gac ctt cag atg gat atc      96
Arg Thr Val Val Gly Phe Gly Met Asp Pro Asp Leu Gln Met Asp Ile
             20             25             30

gtc acc gag ctt gac ctt gtg aac acc acc ctt gga gtt gct cag gtg     144
Val Thr Glu Leu Asp Leu Val Asn Thr Thr Leu Gly Val Ala Gln Val
             35             40             45

```

-continued

tct gga atg cac aat gcc agc aaa gca ttt tta ttt caa gac ata gaa	192
Ser Gly Met His Asn Ala Ser Lys Ala Phe Leu Phe Gln Asp Ile Glu	
50 55 60	
aga gag atc cat gca gct cct cat gtg agt gag aaa tta att cag ctg	240
Arg Glu Ile His Ala Ala Pro His Val Ser Glu Lys Leu Ile Gln Leu	
65 70 75 80	
ttc cag aac aag agt gaa ttc acc att ttg gcc act gta cag cag aag	288
Phe Gln Asn Lys Ser Glu Phe Thr Ile Leu Ala Thr Val Gln Gln Lys	
85 90 95	
cca tcc act tca gga gtg ata ctg tcc att cga gaa ctg gag cac agc	336
Pro Ser Thr Ser Gly Val Ile Leu Ser Ile Arg Glu Leu Glu His Ser	
100 105 110	
tat ttt gaa ctg gag agc agt ggc ctg agg gat gag att cgg tat cac	384
Tyr Phe Glu Leu Glu Ser Ser Gly Leu Arg Asp Glu Ile Arg Tyr His	
115 120 125	
tac ata cac aat ggg aag cca agg aca gag gca ctt cct tac cgc atg	432
Tyr Ile His Asn Gly Lys Pro Arg Thr Glu Ala Leu Pro Tyr Arg Met	
130 135 140	
gca gat gga caa tgg cac aag gtt gca ctg tca gtt agc gcc tct cat	480
Ala Asp Gly Gln Trp His Lys Val Ala Leu Ser Val Ser Ala Ser His	
145 150 155 160	
ctc ctg ctc cat gtc gac tgt aac agg att tat gag cgt gtg ata gac	528
Leu Leu Leu His Val Asp Cys Asn Arg Ile Tyr Glu Arg Val Ile Asp	
165 170 175	
cct cca gat acc aac ctt ccc cca gga atc aat tta tgg ctt ggc cag	576
Pro Pro Asp Thr Asn Leu Pro Pro Gly Ile Asn Leu Trp Leu Gly Gln	
180 185 190	
cgc aac caa aag cat ggc tta ttc aaa ggg atc atc caa gat ggg aag	624
Arg Asn Gln Lys His Gly Leu Phe Lys Gly Ile Ile Gln Asp Gly Lys	
195 200 205	
atc atc ttt atg ccg aat gga tat ata aca cag tgt cca aat cta aat	672
Ile Ile Phe Met Pro Asn Gly Tyr Ile Thr Gln Cys Pro Asn Leu Asn	
210 215 220	
cac act tgc cca acc tgc agt gat ttc tta agc ctg gtg caa gga ata	720
His Thr Cys Pro Thr Cys Ser Asp Phe Leu Ser Leu Val Gln Gly Ile	
225 230 235 240	
atg gat tta caa gag ctt ttg gcc aag atg act gca aaa cta aat tat	768
Met Asp Leu Gln Glu Leu Leu Ala Lys Met Thr Ala Lys Leu Asn Tyr	
245 250 255	
gca gag aca aga ctt agt caa ttg gaa aac tgt cat tgt gag aag act	816
Ala Glu Thr Arg Leu Ser Gln Leu Glu Asn Cys His Cys Glu Lys Thr	
260 265 270	
tgt caa gtg agt gga ctg ctc tat cga gat caa gac tct tgg gta gat	864
Cys Gln Val Ser Gly Leu Leu Tyr Arg Asp Gln Asp Ser Trp Val Asp	
275 280 285	
ggg gac cat tgc agg aac tgc act tgc aaa agt ggt gcc gtg gaa tgc	912
Gly Asp His Cys Arg Asn Cys Thr Cys Lys Ser Gly Ala Val Glu Cys	
290 295 300	
cga agg atg tcc tgt ccc cct ctc aat tgc tcc cca gac tcc ctc cca	960
Arg Arg Met Ser Cys Pro Pro Leu Asn Cys Ser Pro Asp Ser Leu Pro	
305 310 315 320	
gta cac att gct ggc cag tgc tgt aag gtc tgc cga cca aaa tgt atc	1008
Val His Ile Ala Gly Gln Cys Cys Lys Val Cys Arg Pro Lys Cys Ile	
325 330 335	
tat gga gga aaa gtt ctt gca gaa ggc cag cgg att tta acc aag agc	1056
Tyr Gly Gly Lys Val Leu Ala Glu Gly Gln Arg Ile Leu Thr Lys Ser	
340 345 350	

-continued

tgt cgg gaa tgc cga ggt gga gtt tta gta aaa att aca gaa atg tgt	1104
Cys Arg Glu Cys Arg Gly Gly Val Leu Val Lys Ile Thr Glu Met Cys	
355 360 365	
cct cct ttg aac tgc tca gaa aag gat cac att ctt cct gag aat cag	1152
Pro Pro Leu Asn Cys Ser Glu Lys Asp His Ile Leu Pro Glu Asn Gln	
370 375 380	
tgc tgc cgt gtc tgt aga ggt cat aac ttt tgt gca gaa gga cct aaa	1200
Cys Cys Arg Val Cys Arg Gly His Asn Phe Cys Ala Glu Gly Pro Lys	
385 390 395 400	
tgt ggt gaa aac tca gag tgc aaa aac tgg aat aca aaa gct act tgt	1248
Cys Gly Glu Asn Ser Glu Cys Lys Asn Trp Asn Thr Lys Ala Thr Cys	
405 410 415	
gag tgc aag agt ggt tac atc tct gtc cag gga gac tct gcc tac tgt	1296
Glu Cys Lys Ser Gly Tyr Ile Ser Val Gln Gly Asp Ser Ala Tyr Cys	
420 425 430	
gaa gat att gat gag tgt gca gct aag atg cat tac tgt cat gcc aat	1344
Glu Asp Ile Asp Glu Cys Ala Ala Lys Met His Tyr Cys His Ala Asn	
435 440 445	
act gtg tgt gtc aac ctt cct ggg tta tat cgc tgt gac tgt gtc cca	1392
Thr Val Cys Val Asn Leu Pro Gly Leu Tyr Arg Cys Asp Cys Val Pro	
450 455 460	
gga tac att cgt gtg gat gac ttc tct tgt aca gaa cac gat gaa tgt	1440
Gly Tyr Ile Arg Val Asp Asp Phe Ser Cys Thr Glu His Asp Glu Cys	
465 470 475 480	
ggc agc ggc cag cac aac tgt gat gag aat gcc atc tgc acc aac act	1488
Gly Ser Gly Gln His Asn Cys Asp Glu Asn Ala Ile Cys Thr Asn Thr	
485 490 495	
gtc cag gga cac agc tgc acc tgc aaa ccg ggc tac gtg ggg aac ggg	1536
Val Gln Gly His Ser Cys Thr Cys Lys Pro Gly Tyr Val Gly Asn Gly	
500 505 510	
acc atc tgc aga gct ttc tgt gaa gag ggc tgc aga tac ggt gga acg	1584
Thr Ile Cys Arg Ala Phe Cys Glu Glu Gly Cys Arg Tyr Gly Gly Thr	
515 520 525	
tgt gtg gct ccc aac aaa tgt gtc tgt cca tct gga ttc aca gga agc	1632
Cys Val Ala Pro Asn Lys Cys Val Cys Pro Ser Gly Phe Thr Gly Ser	
530 535 540	
cac tgc gag aaa gat att gat gaa tgt tca gag gga atc att gag tgc	1680
His Cys Glu Lys Asp Ile Asp Glu Cys Ser Glu Gly Ile Ile Glu Cys	
545 550 555 560	
cac aac cat tcc cgc tgc gtt aac ctg cca ggg tgg tac cac tgt gag	1728
His Asn His Ser Arg Cys Val Asn Leu Pro Gly Trp Tyr His Cys Glu	
565 570 575	
tgc aga agc ggt ttc cat gac gat ggg acc tat tca ctg tcc ggg gag	1776
Cys Arg Ser Gly Phe His Asp Asp Gly Thr Tyr Ser Leu Ser Gly Glu	
580 585 590	
tcc tgt att gac att gat gaa tgt gcc tta aga act cac acc tgt tgg	1824
Ser Cys Ile Asp Ile Asp Glu Cys Ala Leu Arg Thr His Thr Cys Trp	
595 600 605	
aac gat tct gcc tgc atc aac ctg gca ggg ggt ttt gac tgt ctc tgc	1872
Asn Asp Ser Ala Cys Ile Asn Leu Ala Gly Gly Phe Asp Cys Leu Cys	
610 615 620	
ccc tct ggg ccc tcc tgc tct ggt gac tgt cct cat gaa ggg ggg ctg	1920
Pro Ser Gly Pro Ser Cys Ser Gly Asp Cys Pro His Glu Gly Gly Leu	
625 630 635 640	
aag cac aat ggc cag gtg tgg acc ttg aaa gaa gac agg tgt tct gtc	1968
Lys His Asn Gly Gln Val Trp Thr Leu Lys Glu Asp Arg Cys Ser Val	
645 650 655	

-continued

tgc tcc tgc aag gat ggc aag ata ttc tgc cga cgg aca gct tgt gat	2016
Cys Ser Cys Lys Asp Gly Lys Ile Phe Cys Arg Arg Thr Ala Cys Asp	
660 665 670	
tgc cag aat cca agt gct gac cta ttc tgt tgc cca gaa tgt gac acc	2064
Cys Gln Asn Pro Ser Ala Asp Leu Phe Cys Cys Pro Glu Cys Asp Thr	
675 680 685	
aga gtc aca agt caa tgt tta gac caa aat ggt cac aag ctg tat cga	2112
Arg Val Thr Ser Gln Cys Leu Asp Gln Asn Gly His Lys Leu Tyr Arg	
690 695 700	
agt gga gac aat tgg acc cat agc tgt cag cag tgt cgg tgt ctg gaa	2160
Ser Gly Asp Asn Trp Thr His Ser Cys Gln Gln Cys Arg Cys Leu Glu	
705 710 715 720	
gga gag gta gat tgc tgg cca ctc act tgc ccc aac ttg agc tgt gag	2208
Gly Glu Val Asp Cys Trp Pro Leu Thr Cys Pro Asn Leu Ser Cys Glu	
725 730 735	
tat aca gct atc tta gaa ggg gaa tgt tgt ccc cgc tgt gtc agt gac	2256
Tyr Thr Ala Ile Leu Glu Gly Glu Cys Cys Pro Arg Cys Val Ser Asp	
740 745 750	
ccc tgc cta gct gat aac atc acc tat gac atc aga aaa act tgc ctg	2304
Pro Cys Leu Ala Asp Asn Ile Thr Tyr Asp Ile Arg Lys Thr Cys Leu	
755 760 765	
gac agc tat ggt gtt tca cgg ctt agt ggc tca gtg tgg acg atg gct	2352
Asp Ser Tyr Gly Val Ser Arg Leu Ser Gly Ser Val Trp Thr Met Ala	
770 775 780	
gga tct ccc tgc aca acc tgt aaa tgc aag aat gga aga gtc tgt tgt	2400
Gly Ser Pro Cys Thr Thr Cys Lys Cys Lys Asn Gly Arg Val Cys Cys	
785 790 795 800	
tct gtg gat ttt gag tgt ctt caa aat aat tga	2433
Ser Val Asp Phe Glu Cys Leu Gln Asn Asn *	
805 810	

<210> SEQ ID NO 2
 <211> LENGTH: 810
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

Met Pro Met Asp Leu Ile Leu Val Val Trp Phe Cys Val Cys Thr Ala	
1 5 10 15	
Arg Thr Val Val Gly Phe Gly Met Asp Pro Asp Leu Gln Met Asp Ile	
20 25 30	
Val Thr Glu Leu Asp Leu Val Asn Thr Thr Leu Gly Val Ala Gln Val	
35 40 45	
Ser Gly Met His Asn Ala Ser Lys Ala Phe Leu Phe Gln Asp Ile Glu	
50 55 60	
Arg Glu Ile His Ala Ala Pro His Val Ser Glu Lys Leu Ile Gln Leu	
65 70 75 80	
Phe Gln Asn Lys Ser Glu Phe Thr Ile Leu Ala Thr Val Gln Gln Lys	
85 90 95	
Pro Ser Thr Ser Gly Val Ile Leu Ser Ile Arg Glu Leu Glu His Ser	
100 105 110	
Tyr Phe Glu Leu Glu Ser Ser Gly Leu Arg Asp Glu Ile Arg Tyr His	
115 120 125	
Tyr Ile His Asn Gly Lys Pro Arg Thr Glu Ala Leu Pro Tyr Arg Met	
130 135 140	
Ala Asp Gly Gln Trp His Lys Val Ala Leu Ser Val Ser Ala Ser His	

-continued

145	150	155	160
Leu Leu Leu His Val Asp Cys Asn Arg Ile Tyr Glu Arg Val Ile Asp 165			175
Pro Pro Asp Thr Asn Leu Pro Pro Gly Ile Asn Leu Trp Leu Gly Gln 180		185	190
Arg Asn Gln Lys His Gly Leu Phe Lys Gly Ile Ile Gln Asp Gly Lys 195		200	205
Ile Ile Phe Met Pro Asn Gly Tyr Ile Thr Gln Cys Pro Asn Leu Asn 210		215	220
His Thr Cys Pro Thr Cys Ser Asp Phe Leu Ser Leu Val Gln Gly Ile 225		230	235
Met Asp Leu Gln Glu Leu Leu Ala Lys Met Thr Ala Lys Leu Asn Tyr 245		250	255
Ala Glu Thr Arg Leu Ser Gln Leu Glu Asn Cys His Cys Glu Lys Thr 260		265	270
Cys Gln Val Ser Gly Leu Leu Tyr Arg Asp Gln Asp Ser Trp Val Asp 275		280	285
Gly Asp His Cys Arg Asn Cys Thr Cys Lys Ser Gly Ala Val Glu Cys 290		295	300
Arg Arg Met Ser Cys Pro Pro Leu Asn Cys Ser Pro Asp Ser Leu Pro 305		310	315
Val His Ile Ala Gly Gln Cys Cys Lys Val Cys Arg Pro Lys Cys Ile 325		330	335
Tyr Gly Gly Lys Val Leu Ala Glu Gly Gln Arg Ile Leu Thr Lys Ser 340		345	350
Cys Arg Glu Cys Arg Gly Gly Val Leu Val Lys Ile Thr Glu Met Cys 355		360	365
Pro Pro Leu Asn Cys Ser Glu Lys Asp His Ile Leu Pro Glu Asn Gln 370		375	380
Cys Cys Arg Val Cys Arg Gly His Asn Phe Cys Ala Glu Gly Pro Lys 385		390	395
Cys Gly Glu Asn Ser Glu Cys Lys Asn Trp Asn Thr Lys Ala Thr Cys 405		410	415
Glu Cys Lys Ser Gly Tyr Ile Ser Val Gln Gly Asp Ser Ala Tyr Cys 420		425	430
Glu Asp Ile Asp Glu Cys Ala Ala Lys Met His Tyr Cys His Ala Asn 435		440	445
Thr Val Cys Val Asn Leu Pro Gly Leu Tyr Arg Cys Asp Cys Val Pro 450		455	460
Gly Tyr Ile Arg Val Asp Asp Phe Ser Cys Thr Glu His Asp Glu Cys 465		470	475
Gly Ser Gly Gln His Asn Cys Asp Glu Asn Ala Ile Cys Thr Asn Thr 485		490	495
Val Gln Gly His Ser Cys Thr Cys Lys Pro Gly Tyr Val Gly Asn Gly 500		505	510
Thr Ile Cys Arg Ala Phe Cys Glu Glu Gly Cys Arg Tyr Gly Gly Thr 515		520	525
Cys Val Ala Pro Asn Lys Cys Val Cys Pro Ser Gly Phe Thr Gly Ser 530		535	540
His Cys Glu Lys Asp Ile Asp Glu Cys Ser Glu Gly Ile Ile Glu Cys 545		550	555
			560

-continued

aga gag atc cat tcg gcc cct cac gtg agt gag aag ctg atc cag cta	240
Arg Glu Ile His Ser Ala Pro His Val Ser Glu Lys Leu Ile Gln Leu	
65 70 75 80	
ttc cgg aat aag agc gag ttc acc ttt ttg gct aca gtg cag cag aaa	288
Phe Arg Asn Lys Ser Glu Phe Thr Phe Leu Ala Thr Val Gln Gln Lys	
85 90 95	
cca tcc acc tca ggg gtg ata ctg tcc atc cgg gag ctg gag cac agc	336
Pro Ser Thr Ser Gly Val Ile Leu Ser Ile Arg Glu Leu Glu His Ser	
100 105 110	
tat ttt gaa ctg gag agc agt ggc cca aga gaa gag ata cgc tac cat	384
Tyr Phe Glu Leu Glu Ser Ser Gly Pro Arg Glu Glu Ile Arg Tyr His	
115 120 125	
tac ata cat ggt gga aag ccc agg act gag gcc ctt ccc tac cgc atg	432
Tyr Ile His Gly Gly Lys Pro Arg Thr Glu Ala Leu Pro Tyr Arg Met	
130 135 140	
gca gac gga caa tgg cac aag gtc gcg ctg tca gtg agc gcc tct cac	480
Ala Asp Gly Gln Trp His Lys Val Ala Leu Ser Val Ser Ala Ser His	
145 150 155 160	
ctc ctg ctc cac atc gac tgc aat agg att tac gag cgt gtg ata gac	528
Leu Leu Leu His Ile Asp Cys Asn Arg Ile Tyr Glu Arg Val Ile Asp	
165 170 175	
cct ccg gag acc aac ctt cct cca gga agc aat ctg tgg ctt ggg caa	576
Pro Pro Glu Thr Asn Leu Pro Pro Gly Ser Asn Leu Trp Leu Gly Gln	
180 185 190	
cgt aac caa aag cat ggc ttt ttc aaa gga atc atc caa gat ggt aag	624
Arg Asn Gln Lys His Gly Phe Phe Lys Gly Ile Ile Gln Asp Gly Lys	
195 200 205	
atc atc ttc atg ccg aat ggt ttc atc aca cag tgt ccc aac ctc aat	672
Ile Ile Phe Met Pro Asn Gly Phe Ile Thr Gln Cys Pro Asn Leu Asn	
210 215 220	
cgc act tgc cca aca tgc agt gac ttc ctg agc ctg gtt caa gga ata	720
Arg Thr Cys Pro Thr Cys Ser Asp Phe Leu Ser Leu Val Gln Gly Ile	
225 230 235 240	
atg gat ttg caa gag ctt ttg gcc aag atg act gca aaa ctg aat tat	768
Met Asp Leu Gln Glu Leu Leu Ala Lys Met Thr Ala Lys Leu Asn Tyr	
245 250 255	
gca gag acg aga ctt ggt caa ctg gaa aat tgc cac tgt gag aag acc	816
Ala Glu Thr Arg Leu Gly Gln Leu Glu Asn Cys His Cys Glu Lys Thr	
260 265 270	
tgc caa gtg agt ggg ctg ctc tac agg gac caa gac tcc tgg gtg gat	864
Cys Gln Val Ser Gly Leu Leu Tyr Arg Asp Gln Asp Ser Trp Val Asp	
275 280 285	
ggt gac aac tgt ggg aac tgc acg tgc aaa agt ggt gcc gtg gag tgc	912
Gly Asp Asn Cys Gly Asn Cys Thr Cys Lys Ser Gly Ala Val Glu Cys	
290 295 300	
cgc agg atg tcc tgt ccc ccg ctc aac tgt tcc ccg gac tca ctt cct	960
Arg Arg Met Ser Cys Pro Pro Leu Asn Cys Ser Pro Asp Ser Leu Pro	
305 310 315 320	
gtg cac att tcc ggc cag tgt tgt aaa gtt tgc aga cca aaa tgt atc	1008
Val His Ile Ser Gly Gln Cys Cys Lys Val Cys Arg Pro Lys Cys Ile	
325 330 335	
tat gga gga aaa gtt ctt gct gag ggc cag cgg att tta acc aag acc	1056
Tyr Gly Gly Lys Val Leu Ala Glu Gly Gln Arg Ile Leu Thr Lys Thr	
340 345 350	
tgc cgg gaa tgt cga ggt gga gtc ttg gta aaa atc aca gaa gct tgc	1104
Cys Arg Glu Cys Arg Gly Gly Val Leu Val Lys Ile Thr Glu Ala Cys	
355 360 365	

-continued

cct cct ttg aac tgc tca gca aag gat cat att ctt cca gag aat cag	1152
Pro Pro Leu Asn Cys Ser Ala Lys Asp His Ile Leu Pro Glu Asn Gln	
370 375 380	
tgc tgc agg gtc tgc cca ggt cat aac ttc tgt gca gaa gca cct aag	1200
Cys Cys Arg Val Cys Pro Gly His Asn Phe Cys Ala Glu Ala Pro Lys	
385 390 395 400	
tgc gga gaa aac tcg gaa tgc aaa aat tgg aat aca aaa gca acc tgt	1248
Cys Gly Glu Asn Ser Glu Cys Lys Asn Trp Asn Thr Lys Ala Thr Cys	
405 410 415	
gag tgc aag aat gga tac atc tct gtc cag ggc aac tct gca tac tgt	1296
Glu Cys Lys Asn Gly Tyr Ile Ser Val Gln Gly Asn Ser Ala Tyr Cys	
420 425 430	
gaa gat att gat gag tgt gca gct aaa atg cac tat tgt cat gcc aac	1344
Glu Asp Ile Asp Glu Cys Ala Ala Lys Met His Tyr Cys His Ala Asn	
435 440 445	
acc gtg tgt gtc aac ttg ccg ggg ttg tat cgc tgt gac tgc gtc cca	1392
Thr Val Cys Val Asn Leu Pro Gly Leu Tyr Arg Cys Asp Cys Val Pro	
450 455 460	
ggg tac atc cgt gtg gat gac ttc tct tgt acg gag cat gat gat tgt	1440
Gly Tyr Ile Arg Val Asp Asp Phe Ser Cys Thr Glu His Asp Asp Cys	
465 470 475 480	
ggc agc gga caa cac aac tgc gac aaa aat gcc atc tgt acc aac aca	1488
Gly Ser Gly Gln His Asn Cys Asp Lys Asn Ala Ile Cys Thr Asn Thr	
485 490 495	
gtc cag gga cac agc tgc acc tgc cag ccg ggt tac gtg gga aat ggc	1536
Val Gln Gly His Ser Cys Thr Cys Gln Pro Gly Tyr Val Gly Asn Gly	
500 505 510	
acc atc tgc aaa gca ttc tgt gaa gag ggt tgc aga tac gga ggt acc	1584
Thr Ile Cys Lys Ala Phe Cys Glu Glu Gly Cys Arg Tyr Gly Gly Thr	
515 520 525	
tgt gtg gct cct aac aag tgt gtc tgt cct tct gga ttc acg gga agc	1632
Cys Val Ala Pro Asn Lys Cys Val Cys Pro Ser Gly Phe Thr Gly Ser	
530 535 540	
cac tgt gag aaa gat att gat gaa tgc gca gag gga ttc gtt gaa tgc	1680
His Cys Glu Lys Asp Ile Asp Glu Cys Ala Glu Gly Phe Val Glu Cys	
545 550 555 560	
cac aac tac tcc cgc tgt gtt aac ctg cca ggg tgg tac cac tgt gag	1728
His Asn Tyr Ser Arg Cys Val Asn Leu Pro Gly Trp Tyr His Cys Glu	
565 570 575	
tgc aga agc ggt ttc cat gac gat ggg acc tac tca ctg tcc ggg gag	1776
Cys Arg Ser Gly Phe His Asp Asp Gly Thr Tyr Ser Leu Ser Gly Glu	
580 585 590	
tcc tgc att gat atc gat gaa tgt gcc tta aga act cac act tgt tgg	1824
Ser Cys Ile Asp Ile Asp Glu Cys Ala Leu Arg Thr His Thr Cys Trp	
595 600 605	
aat gac tct gcc tgc atc aac tta gca gga gga ttt gac tgc ctg tgt	1872
Asn Asp Ser Ala Cys Ile Asn Leu Ala Gly Gly Phe Asp Cys Leu Cys	
610 615 620	
ccc tct ggg ccc tcc tgc tct ggt gac tgt ccc cac gaa gga ggg ctg	1920
Pro Ser Gly Pro Ser Cys Ser Gly Asp Cys Pro His Glu Gly Gly Leu	
625 630 635 640	
aag cat aat ggg cag gtg tgg att ctg aga gaa gac agg tgt tca gtc	1968
Lys His Asn Gly Gln Val Trp Ile Leu Arg Glu Asp Arg Cys Ser Val	
645 650 655	
tgt tcc tgc aag gat ggg aag ata ttc tgc cgg cgg aca gct tgt gat	2016
Cys Ser Cys Lys Asp Gly Lys Ile Phe Cys Arg Arg Thr Ala Cys Asp	
660 665 670	

-continued

tgc cag aat cca aat gtt gac ctt ttt tgc tgc cca gag tgc gat acc	2064
Cys Gln Asn Pro Asn Val Asp Leu Phe Cys Cys Pro Glu Cys Asp Thr	
675 680 685	
agg gtc acc agc caa tgt tta gat caa agt gga cag aag ctc tat cga	2112
Arg Val Thr Ser Gln Cys Leu Asp Gln Ser Gly Gln Lys Leu Tyr Arg	
690 695 700	
agt gga gac aac tgg acc cac agc tgc cag cag tgc cga tgt ctg gaa	2160
Ser Gly Asp Asn Trp Thr His Ser Cys Gln Gln Cys Arg Cys Leu Glu	
705 710 715 720	
gga gag gca gac tgc tgg cct ctg gct tgc cct agt ttg ggc tgt gaa	2208
Gly Glu Ala Asp Cys Trp Pro Leu Ala Cys Pro Ser Leu Gly Cys Glu	
725 730 735	
tac aca gcc atg ttt gaa ggg gag tgt tgt ccc cga tgt gtc agt gac	2256
Tyr Thr Ala Met Phe Glu Gly Glu Cys Cys Pro Arg Cys Val Ser Asp	
740 745 750	
ccc tgc ctg gct ggt aat att gcc tat gac atc aga aaa act tgc ctg	2304
Pro Cys Leu Ala Gly Asn Ile Ala Tyr Asp Ile Arg Lys Thr Cys Leu	
755 760 765	
gac agc ttt ggt gtt tcg agg ctg agc gga gcc gtg tgg aca atg gct	2352
Asp Ser Phe Gly Val Ser Arg Leu Ser Gly Ala Val Trp Thr Met Ala	
770 775 780	
gga tct cct tgt aca acc tgc aaa tgc aag aat ggg aga gtc tgc tgc	2400
Gly Ser Pro Cys Thr Thr Cys Lys Cys Lys Asn Gly Arg Val Cys Cys	
785 790 795 800	
tct gtg gat ctg gag tgt att gag aat aac tga	2433
Ser Val Asp Leu Glu Cys Ile Glu Asn Asn *	
805 810	

<210> SEQ ID NO 4

<211> LENGTH: 810

<212> TYPE: PRT

<213> ORGANISM: Rattus norvegicus

<400> SEQUENCE: 4

Met Pro Met Asp Val Ile Leu Val Leu Trp Phe Cys Val Cys Thr Ala	
1 5 10 15	
Arg Thr Val Leu Gly Phe Gly Met Asp Pro Asp Leu Gln Leu Asp Ile	
20 25 30	
Ile Ser Glu Leu Asp Leu Val Asn Thr Thr Leu Gly Val Thr Gln Val	
35 40 45	
Ala Gly Leu His Asn Ala Ser Lys Ala Phe Leu Phe Gln Asp Val Gln	
50 55 60	
Arg Glu Ile His Ser Ala Pro His Val Ser Glu Lys Leu Ile Gln Leu	
65 70 75 80	
Phe Arg Asn Lys Ser Glu Phe Thr Phe Leu Ala Thr Val Gln Gln Lys	
85 90 95	
Pro Ser Thr Ser Gly Val Ile Leu Ser Ile Arg Glu Leu Glu His Ser	
100 105 110	
Tyr Phe Glu Leu Glu Ser Ser Gly Pro Arg Glu Glu Ile Arg Tyr His	
115 120 125	
Tyr Ile His Gly Gly Lys Pro Arg Thr Glu Ala Leu Pro Tyr Arg Met	
130 135 140	
Ala Asp Gly Gln Trp His Lys Val Ala Leu Ser Val Ser Ala Ser His	
145 150 155 160	
Leu Leu Leu His Ile Asp Cys Asn Arg Ile Tyr Glu Arg Val Ile Asp	
165 170 175	

-continued

Pro Pro Glu Thr Asn Leu Pro Pro Gly Ser Asn Leu Trp Leu Gly Gln
 180 185 190

Arg Asn Gln Lys His Gly Phe Phe Lys Gly Ile Ile Gln Asp Gly Lys
 195 200 205

Ile Ile Phe Met Pro Asn Gly Phe Ile Thr Gln Cys Pro Asn Leu Asn
 210 215 220

Arg Thr Cys Pro Thr Cys Ser Asp Phe Leu Ser Leu Val Gln Gly Ile
 225 230 235 240

Met Asp Leu Gln Glu Leu Leu Ala Lys Met Thr Ala Lys Leu Asn Tyr
 245 250 255

Ala Glu Thr Arg Leu Gly Gln Leu Glu Asn Cys His Cys Glu Lys Thr
 260 265 270

Cys Gln Val Ser Gly Leu Leu Tyr Arg Asp Gln Asp Ser Trp Val Asp
 275 280 285

Gly Asp Asn Cys Gly Asn Cys Thr Cys Lys Ser Gly Ala Val Glu Cys
 290 295 300

Arg Arg Met Ser Cys Pro Pro Leu Asn Cys Ser Pro Asp Ser Leu Pro
 305 310 315 320

Val His Ile Ser Gly Gln Cys Cys Lys Val Cys Arg Pro Lys Cys Ile
 325 330 335

Tyr Gly Gly Lys Val Leu Ala Glu Gly Gln Arg Ile Leu Thr Lys Thr
 340 345 350

Cys Arg Glu Cys Arg Gly Gly Val Leu Val Lys Ile Thr Glu Ala Cys
 355 360 365

Pro Pro Leu Asn Cys Ser Ala Lys Asp His Ile Leu Pro Glu Asn Gln
 370 375 380

Cys Cys Arg Val Cys Pro Gly His Asn Phe Cys Ala Glu Ala Pro Lys
 385 390 395 400

Cys Gly Glu Asn Ser Glu Cys Lys Asn Trp Asn Thr Lys Ala Thr Cys
 405 410 415

Glu Cys Lys Asn Gly Tyr Ile Ser Val Gln Gly Asn Ser Ala Tyr Cys
 420 425 430

Glu Asp Ile Asp Glu Cys Ala Ala Lys Met His Tyr Cys His Ala Asn
 435 440 445

Thr Val Cys Val Asn Leu Pro Gly Leu Tyr Arg Cys Asp Cys Val Pro
 450 455 460

Gly Tyr Ile Arg Val Asp Asp Phe Ser Cys Thr Glu His Asp Asp Cys
 465 470 475 480

Gly Ser Gly Gln His Asn Cys Asp Lys Asn Ala Ile Cys Thr Asn Thr
 485 490 495

Val Gln Gly His Ser Cys Thr Cys Gln Pro Gly Tyr Val Gly Asn Gly
 500 505 510

Thr Ile Cys Lys Ala Phe Cys Glu Glu Gly Cys Arg Tyr Gly Gly Thr
 515 520 525

Cys Val Ala Pro Asn Lys Cys Val Cys Pro Ser Gly Phe Thr Gly Ser
 530 535 540

His Cys Glu Lys Asp Ile Asp Glu Cys Ala Glu Gly Phe Val Glu Cys
 545 550 555 560

His Asn Tyr Ser Arg Cys Val Asn Leu Pro Gly Trp Tyr His Cys Glu
 565 570 575

-continued

Cys Arg Ser Gly Phe His Asp Asp Gly Thr Tyr Ser Leu Ser Gly Glu
 580 585 590
 Ser Cys Ile Asp Ile Asp Glu Cys Ala Leu Arg Thr His Thr Cys Trp
 595 600 605
 Asn Asp Ser Ala Cys Ile Asn Leu Ala Gly Gly Phe Asp Cys Leu Cys
 610 615 620
 Pro Ser Gly Pro Ser Cys Ser Gly Asp Cys Pro His Glu Gly Gly Leu
 625 630 635 640
 Lys His Asn Gly Gln Val Trp Ile Leu Arg Glu Asp Arg Cys Ser Val
 645 650 655
 Cys Ser Cys Lys Asp Gly Lys Ile Phe Cys Arg Arg Thr Ala Cys Asp
 660 665 670
 Cys Gln Asn Pro Asn Val Asp Leu Phe Cys Cys Pro Glu Cys Asp Thr
 675 680 685
 Arg Val Thr Ser Gln Cys Leu Asp Gln Ser Gly Gln Lys Leu Tyr Arg
 690 695 700
 Ser Gly Asp Asn Trp Thr His Ser Cys Gln Gln Cys Arg Cys Leu Glu
 705 710 715 720
 Gly Glu Ala Asp Cys Trp Pro Leu Ala Cys Pro Ser Leu Gly Cys Glu
 725 730 735
 Tyr Thr Ala Met Phe Glu Gly Glu Cys Cys Pro Arg Cys Val Ser Asp
 740 745 750
 Pro Cys Leu Ala Gly Asn Ile Ala Tyr Asp Ile Arg Lys Thr Cys Leu
 755 760 765
 Asp Ser Phe Gly Val Ser Arg Leu Ser Gly Ala Val Trp Thr Met Ala
 770 775 780
 Gly Ser Pro Cys Thr Thr Cys Lys Cys Lys Asn Gly Arg Val Cys Cys
 785 790 795 800
 Ser Val Asp Leu Glu Cys Ile Glu Asn Asn
 805 810

<210> SEQ ID NO 5
 <211> LENGTH: 2433
 <212> TYPE: DNA
 <213> ORGANISM: Mus musculus
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)...(2433)

<400> SEQUENCE: 5

atg ccg atg gat gtg att tta gtt ttg tgg ttc tgt gtg tgc acc gcc 48
 Met Pro Met Asp Val Ile Leu Val Leu Trp Phe Cys Val Cys Thr Ala
 1 5 10 15
 cag gac agt ggt ggg ctt tgg gat gga ccc tga cct tca gat gga cat 96
 Gln Asp Ser Gly Gly Leu Trp Asp Gly Pro * Pro Ser Asp Gly His
 20 25 30
 cat cac tga act tga cct tgt gaa cac cag ccc tgg gcg tca ctc agg 144
 His His * Thr * Pro Cys Glu His Gln Pro Trp Ala Ser Leu Arg
 35 40 45
 tgg gtg gac tac aca atg cca gta agg cat ttc tgt ttc aag atg tac 192
 Trp Val Asp Tyr Thr Met Pro Val Arg His Phe Cys Phe Lys Met Tyr
 50 55 60
 aga gag aga tcc act cag ccc ctc atg tga gtg aga agc tga tcc agc 240
 Arg Glu Arg Ser Thr Gln Pro Leu Met * Val Arg Ser * Ser Ser
 65 70 75

-continued

tat tcc gga ata aga gtg agt tta cct ttt tgg cta cag tgc agc aga	288
Tyr Ser Gly Ile Arg Val Ser Leu Pro Phe Trp Leu Gln Cys Ser Arg	
80 85 90	
agc cgt cca cct cag ggg tga tac tgt cga tcc ggg agc tgg aac aca	336
Ser Arg Pro Pro Gln Gly * Tyr Cys Arg Ser Gly Ser Trp Asn Thr	
95 100 105	
gct att ttg aac tgg aga gca gtg gcc caa gag aag aga tac gct atc	384
Ala Ile Leu Asn Trp Arg Ala Val Ala Gln Glu Lys Arg Tyr Ala Ile	
110 115 120	
att aca tcc atg gcg gca agc cca gga ctg agg ccc ttc cct acc gca	432
Ile Thr Ser Met Ala Ala Ser Pro Gly Leu Arg Pro Phe Pro Thr Ala	
125 130 135	
tgg ccg atg gac agt ggc aca agg tcg cgc tgt ctg tga gcg cct ctc	480
Trp Pro Met Asp Ser Gly Thr Arg Ser Arg Cys Leu * Ala Pro Leu	
140 145 150	
acc tcc tac tcc atg tcg act gca ata gga ttt atg agc gtg tga tag	528
Thr Ser Tyr Ser Met Ser Thr Ala Ile Gly Phe Met Ser Val * *	
155 160 165	
atc ctc cgg aga cca acc ttc ctc cag gaa gca atc tat ggc ttg ggc	576
Ile Leu Arg Arg Pro Thr Phe Leu Gln Glu Ala Ile Tyr Gly Leu Gly	
170 175 180	
aac gta atc aaa agc atg gct ttt tca aag gaa tca tcc aag atg gca	624
Asn Val Ile Lys Ser Met Ala Phe Ser Lys Glu Ser Ser Lys Met Ala	
185 190 195	
aga tca tct tca tgc cga acg gct tca tca cac agt gcc cca acc taa	672
Arg Ser Ser Ser Cys Arg Thr Ala Ser Ser His Ser Ala Pro Thr *	
200 205 210	
atc gca ctt gcc caa cat gca gtg att tcc tga gcc tgg ttc aag gaa	720
Ile Ala Leu Ala Gln His Ala Val Ile Ser * Ala Trp Phe Lys Glu	
215 220 225	
taa tgg att tgc aag agc ttt tgg cca aga tga ctg caa aac tga att	768
* Trp Ile Cys Lys Ser Phe Trp Pro Arg * Leu Gln Asn * Ile	
230 235 240	
atg cag aga cga gac ttg gtc aac tgg aaa att gcc act gtg aga aga	816
Met Gln Arg Arg Asp Leu Val Asn Trp Lys Ile Ala Thr Val Arg Arg	
245 250 255	
cct gcc aag tga gtg ggc tgc tct aca ggg acc aag act cct ggg tag	864
Pro Ala Lys * Val Gly Cys Ser Thr Gly Thr Lys Thr Pro Gly *	
260 265 270	
atg gtg aca act gca gga act gca cat gca aaa gtg gtg ctg tgg agt	912
Met Val Thr Thr Ala Gly Thr Ala His Ala Lys Val Val Leu Trp Ser	
275 280 285	
gcc gaa gga tgt cct gtc ccc cac tca act gtt ccc cag act cac ttc	960
Ala Glu Gly Cys Pro Val Pro His Ser Thr Val Pro Gln Thr His Phe	
290 295 300	
ctg tgc ata ttt ctg gcc aat gtt gta aag ttt gca gac caa aat gta	1008
Leu Cys Ile Phe Leu Ala Asn Val Val Lys Phe Ala Asp Gln Asn Val	
305 310 315 320	
tct atg gag gaa aag ttc ttg ctg agg gcc agc gga ttt taa cca aga	1056
Ser Met Glu Glu Lys Phe Leu Leu Arg Ala Ser Gly Phe * Pro Arg	
325 330 335	
cct gcc ggg aat gtc gag gtg gag tct tgg taa aaa tca cag aag ctt	1104
Pro Ala Gly Asn Val Glu Val Glu Ser Trp * Lys Ser Gln Lys Leu	
340 345 350	
gcc ctc ctt tga act gct cag aga agg atc ata ttc ttc cgg aga acc	1152
Ala Leu Leu * Thr Ala Gln Arg Arg Ile Ile Phe Phe Arg Arg Thr	
355 360 365	

-continued

agt gct ggg gtc tgc cga ggt cat aac ttc tgt gca gaa gca cct aag	1200
Ser Ala Gly Val Cys Arg Gly His Asn Phe Cys Ala Glu Ala Pro Lys	
370 375 380	
tgt gga gaa aac tcg gaa tgc aaa aat tgg aat aca aaa gcg act tgt	1248
Cys Gly Glu Asn Ser Glu Cys Lys Asn Trp Asn Thr Lys Ala Thr Cys	
385 390 395	
gag tgc aag aat gga tac atc tct gtc cag ggc aac tct gca tac tgt	1296
Glu Cys Lys Asn Gly Tyr Ile Ser Val Gln Gly Asn Ser Ala Tyr Cys	
400 405 410	
gaa gat atc gat gag tgt gca gca aag atg cac tac tgt cat gcc aac	1344
Glu Asp Ile Asp Glu Cys Ala Ala Lys Met His Tyr Cys His Ala Asn	
415 420 425	
acg gtg tgt gtc aac ttg ccg ggg tta tat cgc tgt gac tgc atc cca	1392
Thr Val Cys Val Asn Leu Pro Gly Leu Tyr Arg Cys Asp Cys Ile Pro	
430 435 440 445	
gga tac atc cgt gtg gat gac ttc tct tgt acg gag cat gat gat tgt	1440
Gly Tyr Ile Arg Val Asp Asp Phe Ser Cys Thr Glu His Asp Asp Cys	
450 455 460	
ggc agc gga caa cac aac tgt gac aaa aat gcc atc tgt acc aac aca	1488
Gly Ser Gly Gln His Asn Cys Asp Lys Asn Ala Ile Cys Thr Asn Thr	
465 470 475	
gtc cag gga cac agc tgt acc tgc cag cca ggc tac gtg gga aat ggt	1536
Val Gln Gly His Ser Cys Thr Cys Gln Pro Gly Tyr Val Gly Asn Gly	
480 485 490	
act gtc tgc aaa gca ttc tgt gaa gag ggt tgc aga tac gga ggt acc	1584
Thr Val Cys Lys Ala Phe Cys Glu Glu Gly Cys Arg Tyr Gly Gly Thr	
495 500 505	
tgt gtg gcc cct aac aaa tgt gtc tgt cct tct gga ttc aca gga agc	1632
Cys Val Ala Pro Asn Lys Cys Val Cys Pro Ser Gly Phe Thr Gly Ser	
510 515 520 525	
cac tgt gag aaa gat att gat gaa tgt gca gag gga ttc gtt gag tgc	1680
His Cys Glu Lys Asp Ile Asp Glu Cys Ala Glu Gly Phe Val Glu Cys	
530 535 540	
cac aac cac tcc cgc tgc gtt aac ctt cca ggg tgg tac cac tgt gag	1728
His Asn His Ser Arg Cys Val Asn Leu Pro Gly Trp Tyr His Cys Glu	
545 550 555	
tgc aga agc ggt ttc cat gac gat ggg acc tat tca ctg tcc ggg gag	1776
Cys Arg Ser Gly Phe His Asp Asp Gly Thr Tyr Ser Leu Ser Gly Glu	
560 565 570	
tcc tgc att gat att gat gaa tgt gcc tta aga act cac act tgt tgg	1824
Ser Cys Ile Asp Ile Asp Glu Cys Ala Leu Arg Thr His Thr Cys Trp	
575 580 585	
aat gac tct gcc tgc atc aac tta gca gga gga ttt gac tgc ctg tgt	1872
Asn Asp Ser Ala Cys Ile Asn Leu Ala Gly Phe Asp Cys Leu Cys	
590 595 600 605	
ccc tct ggg ccc tcc tgc tct ggt gac tgt ccc cac gaa ggg ggg ctg	1920
Pro Ser Gly Pro Ser Cys Ser Gly Asp Cys Pro His Glu Gly Gly Leu	
610 615 620	
aag cat aat ggg cag gtg tgg att ctg aga gaa gac agg tgt tca gtc	1968
Lys His Asn Gly Gln Val Trp Ile Leu Arg Glu Asp Arg Cys Ser Val	
625 630 635	
tgt tcc tgt aag gat ggg aag ata ttc tgc cgg cgg aca gct tgt gat	2016
Cys Ser Cys Lys Asp Gly Lys Ile Phe Cys Arg Arg Thr Ala Cys Asp	
640 645 650	
tgc cag aat cca aat gtt gac ctt ttc tgc tgc cca gag tgt gac acc	2064
Cys Gln Asn Pro Asn Val Asp Leu Phe Cys Cys Pro Glu Cys Asp Thr	
655 660 665	

-continued

```

agg gtc act agc caa tgt tta gat caa agc gga cag aag ctc tat cga      2112
Arg Val Thr Ser Gln Cys Leu Asp Gln Ser Gly Gln Lys Leu Tyr Arg
670                      675                      680                      685

agt gga gac aac tgg acc cac agc tgc cag cag tgc cga tgt ctg gaa      2160
Ser Gly Asp Asn Trp Thr His Ser Cys Gln Gln Cys Arg Cys Leu Glu
690                      695                      700

gga gag gca gac tgc tgg cct cta gct tgc cct agt ttg agc tgt gaa      2208
Gly Glu Ala Asp Cys Trp Pro Leu Ala Cys Pro Ser Leu Ser Cys Glu
705                      710                      715

tac aca gcc atc ttt gaa gga gag tgt tgt ccc cgc tgt gtc agt gac      2256
Tyr Thr Ala Ile Phe Glu Gly Glu Cys Cys Pro Arg Cys Val Ser Asp
720                      725                      730

ccc tgc ctg gct gat aat att gcc tat gac atc aga aaa act tgc ctg      2304
Pro Cys Leu Ala Asp Asn Ile Ala Tyr Asp Ile Arg Lys Thr Cys Leu
735                      740                      745

gac agc tct ggt att tcg agg ctg agc ggc gca gtg tgg aca atg gct      2352
Asp Ser Ser Gly Ile Ser Arg Leu Ser Gly Ala Val Trp Thr Met Ala
750                      755                      760                      765

gga tct ccc tgt aca acc tgt caa tgc aag aat ggg aga gtc tgc tgc      2400
Gly Ser Pro Cys Thr Thr Cys Gln Cys Lys Asn Gly Arg Val Cys Cys
770                      775                      780

tct gtg gat ctg gtg tgt ctt gag aat aac tga                          2433
Ser Val Asp Leu Val Cys Leu Glu Asn Asn *
785                      790

```

```

<210> SEQ ID NO 6
<211> LENGTH: 791
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

```

```

<400> SEQUENCE: 6

```

```

Met Pro Met Asp Val Ile Leu Val Leu Trp Phe Cys Val Cys Thr Ala
 1                      5                      10                      15

Gln Asp Ser Gly Gly Leu Trp Asp Gly Pro Pro Ser Asp Gly His His
20                      25                      30

His Thr Pro Cys Glu His Gln Pro Trp Ala Ser Leu Arg Trp Val Asp
35                      40                      45

Tyr Thr Met Pro Val Arg His Phe Cys Phe Lys Met Tyr Arg Glu Arg
50                      55                      60

Ser Thr Gln Pro Leu Met Val Arg Ser Ser Ser Tyr Ser Gly Ile Arg
65                      70                      75                      80

Val Ser Leu Pro Phe Trp Leu Gln Cys Ser Arg Ser Arg Pro Pro Gln
85                      90                      95

Gly Tyr Cys Arg Ser Gly Ser Trp Asn Thr Ala Ile Leu Asn Trp Arg
100                     105                     110

Ala Val Ala Gln Glu Lys Arg Tyr Ala Ile Ile Thr Ser Met Ala Ala
115                     120                     125

Ser Pro Gly Leu Arg Pro Phe Pro Thr Ala Trp Pro Met Asp Ser Gly
130                     135                     140

Thr Arg Ser Arg Cys Leu Ala Pro Leu Thr Ser Tyr Ser Met Ser Thr
145                     150                     155                     160

Ala Ile Gly Phe Met Ser Val Ile Leu Arg Arg Pro Thr Phe Leu Gln
165                     170                     175

Glu Ala Ile Tyr Gly Leu Gly Asn Val Ile Lys Ser Met Ala Phe Ser
180                     185                     190

```

-continued

Lys Glu Ser Ser Lys Met Ala Arg Ser Ser Ser Cys Arg Thr Ala Ser
 195 200 205
 Ser His Ser Ala Pro Thr Ile Ala Leu Ala Gln His Ala Val Ile Ser
 210 215 220
 Ala Trp Phe Lys Glu Trp Ile Cys Lys Ser Phe Trp Pro Arg Leu Gln
 225 230 235 240
 Asn Ile Met Gln Arg Arg Asp Leu Val Asn Trp Lys Ile Ala Thr Val
 245 250 255
 Arg Arg Pro Ala Lys Val Gly Cys Ser Thr Gly Thr Lys Thr Pro Gly
 260 265 270
 Met Val Thr Thr Ala Gly Thr Ala His Ala Lys Val Val Leu Trp Ser
 275 280 285
 Ala Glu Gly Cys Pro Val Pro His Ser Thr Val Pro Gln Thr His Phe
 290 295 300
 Leu Cys Ile Phe Leu Ala Asn Val Val Lys Phe Ala Asp Gln Asn Val
 305 310 315 320
 Ser Met Glu Glu Lys Phe Leu Leu Arg Ala Ser Gly Phe Pro Arg Pro
 325 330 335
 Ala Gly Asn Val Glu Val Glu Ser Trp Lys Ser Gln Lys Leu Ala Leu
 340 345 350
 Leu Thr Ala Gln Arg Arg Ile Ile Phe Phe Arg Arg Thr Ser Ala Gly
 355 360 365
 Val Cys Arg Gly His Asn Phe Cys Ala Glu Ala Pro Lys Cys Gly Glu
 370 375 380
 Asn Ser Glu Cys Lys Asn Trp Asn Thr Lys Ala Thr Cys Glu Cys Lys
 385 390 395 400
 Asn Gly Tyr Ile Ser Val Gln Gly Asn Ser Ala Tyr Cys Glu Asp Ile
 405 410 415
 Asp Glu Cys Ala Ala Lys Met His Tyr Cys His Ala Asn Thr Val Cys
 420 425 430
 Val Asn Leu Pro Gly Leu Tyr Arg Cys Asp Cys Ile Pro Gly Tyr Ile
 435 440 445
 Arg Val Asp Asp Phe Ser Cys Thr Glu His Asp Asp Cys Gly Ser Gly
 450 455 460
 Gln His Asn Cys Asp Lys Asn Ala Ile Cys Thr Asn Thr Val Gln Gly
 465 470 475 480
 His Ser Cys Thr Cys Gln Pro Gly Tyr Val Gly Asn Gly Thr Val Cys
 485 490 495
 Lys Ala Phe Cys Glu Glu Gly Cys Arg Tyr Gly Gly Thr Cys Val Ala
 500 505 510
 Pro Asn Lys Cys Val Cys Pro Ser Gly Phe Thr Gly Ser His Cys Glu
 515 520 525
 Lys Asp Ile Asp Glu Cys Ala Glu Gly Phe Val Glu Cys His Asn His
 530 535 540
 Ser Arg Cys Val Asn Leu Pro Gly Trp Tyr His Cys Glu Cys Arg Ser
 545 550 555 560
 Gly Phe His Asp Asp Gly Thr Tyr Ser Leu Ser Gly Glu Ser Cys Ile
 565 570 575
 Asp Ile Asp Glu Cys Ala Leu Arg Thr His Thr Cys Trp Asn Asp Ser
 580 585 590
 Ala Cys Ile Asn Leu Ala Gly Gly Phe Asp Cys Leu Cys Pro Ser Gly

-continued

595			600			605									
Pro	Ser	Cys	Ser	Gly	Asp	Cys	Pro	His	Glu	Gly	Gly	Leu	Lys	His	Asn
610						615					620				
Gly	Gln	Val	Trp	Ile	Leu	Arg	Glu	Asp	Arg	Cys	Ser	Val	Cys	Ser	Cys
625					630					635					640
Lys	Asp	Gly	Lys	Ile	Phe	Cys	Arg	Arg	Thr	Ala	Cys	Asp	Cys	Gln	Asn
				645					650					655	
Pro	Asn	Val	Asp	Leu	Phe	Cys	Cys	Pro	Glu	Cys	Asp	Thr	Arg	Val	Thr
			660					665					670		
Ser	Gln	Cys	Leu	Asp	Gln	Ser	Gly	Gln	Lys	Leu	Tyr	Arg	Ser	Gly	Asp
		675					680					685			
Asn	Trp	Thr	His	Ser	Cys	Gln	Gln	Cys	Arg	Cys	Leu	Glu	Gly	Glu	Ala
		690					695				700				
Asp	Cys	Trp	Pro	Leu	Ala	Cys	Pro	Ser	Leu	Ser	Cys	Glu	Tyr	Thr	Ala
705					710					715					720
Ile	Phe	Glu	Gly	Glu	Cys	Cys	Pro	Arg	Cys	Val	Ser	Asp	Pro	Cys	Leu
				725					730					735	
Ala	Asp	Asn	Ile	Ala	Tyr	Asp	Ile	Arg	Lys	Thr	Cys	Leu	Asp	Ser	Ser
			740					745					750		
Gly	Ile	Ser	Arg	Leu	Ser	Gly	Ala	Val	Trp	Thr	Met	Ala	Gly	Ser	Pro
		755					760					765			
Cys	Thr	Thr	Cys	Gln	Cys	Lys	Asn	Gly	Arg	Val	Cys	Cys	Ser	Val	Asp
	770					775					780				
Leu	Val	Cys	Leu	Glu	Asn	Asn									
785					790										

<210> SEQ ID NO 7
 <211> LENGTH: 2451
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)...(2451)

<400> SEQUENCE: 7

atg gag tct cgg gtc tta ctg aga aca ttc tgt ttg atc ttc ggt ctc	48
Met Glu Ser Arg Val Leu Leu Arg Thr Phe Cys Leu Ile Phe Gly Leu	
1 5 10 15	
gga gca gtt tgg ggg ctt ggt gtg gac cct tcc cta cag att gac gtc	96
Gly Ala Val Trp Gly Leu Gly Val Asp Pro Ser Leu Gln Ile Asp Val	
20 25 30	
tta aca gag tta gaa ctt ggg gag tcc acg acc gga gtg cgt cag gtc	144
Leu Thr Glu Leu Glu Leu Gly Glu Ser Thr Thr Gly Val Arg Gln Val	
35 40 45	
ccg ggg ctg cat aat ggg acg aaa gcc ttt ctc ttt caa gat act ccc	192
Pro Gly Leu His Asn Gly Thr Lys Ala Phe Leu Phe Gln Asp Thr Pro	
50 55 60	
aga agc ata aaa gca tcc act gct aca gct gaa cag ttt ttt cag aag	240
Arg Ser Ile Lys Ala Ser Thr Ala Thr Ala Glu Gln Phe Phe Gln Lys	
65 70 75 80	
ctg aga aat aaa cat gaa ttt act att ttg gtg acc cta aaa cag acc	288
Leu Arg Asn Lys His Glu Phe Thr Ile Leu Val Thr Leu Lys Gln Thr	
85 90 95	
cac tta aat tca gga gtt att ctc tca att cac cac ttg gat cac agg	336
His Leu Asn Ser Gly Val Ile Leu Ser Ile His His Leu Asp His Arg	
100 105 110	

-continued

tac ctg gaa ctg gaa agt agt ggc cat cgg aat gaa gtc aga ctg cat	384
Tyr Leu Glu Leu Glu Ser Ser Gly His Arg Asn Glu Val Arg Leu His	
115 120 125	
tac cgc tca ggc agt cac cgc cct cac aca gaa gtg ttt cct tac att	432
Tyr Arg Ser Gly Ser His Arg Pro His Thr Glu Val Phe Pro Tyr Ile	
130 135 140	
ttg gct gat gac aag tgg cac aag ctc tcc tta gcc atc agt gct tcc	480
Leu Ala Asp Asp Lys Trp His Lys Leu Ser Leu Ala Ile Ser Ala Ser	
145 150 155 160	
cat ttg att tta cac att gac tgc aat aaa att tat gaa agg gta gta	528
His Leu Ile Leu His Ile Asp Cys Asn Lys Ile Tyr Glu Arg Val Val	
165 170 175	
gaa aag ccc tcc aca gac ttg cct cta ggc aca aca ttt tgg cta gga	576
Glu Lys Pro Ser Thr Asp Leu Pro Leu Gly Thr Thr Phe Trp Leu Gly	
180 185 190	
cag aga aat aat gcg cat gga tat ttt aag ggt ata atg caa gat gtc	624
Gln Arg Asn Asn Ala His Gly Tyr Phe Lys Gly Ile Met Gln Asp Val	
195 200 205	
caa tta ctt gtc atg ccc cag gga ttt att gct cag tgc cca gat ctt	672
Gln Leu Leu Val Met Pro Gln Gly Phe Ile Ala Gln Cys Pro Asp Leu	
210 215 220	
aat cgc acc tgt cca act tgc aat gac ttc cat gga ctt gtg cag aaa	720
Asn Arg Thr Cys Pro Thr Cys Asn Asp Phe His Gly Leu Val Gln Lys	
225 230 235 240	
atc atg gag cta cag gat att tta gcc aaa aca tca gcc aag ctg tct	768
Ile Met Glu Leu Gln Asp Ile Leu Ala Lys Thr Ser Ala Lys Leu Ser	
245 250 255	
cga gct gaa cag cga atg aat aga ttg gat cag tgc tat tgt gaa agg	816
Arg Ala Glu Gln Arg Met Asn Arg Leu Asp Gln Cys Tyr Cys Glu Arg	
260 265 270	
act tgc acc atg aag gga acc acc tac cga gaa ttt gag tcc tgg ata	864
Thr Cys Thr Met Lys Gly Thr Thr Tyr Arg Glu Phe Glu Ser Trp Ile	
275 280 285	
gac ggc tgt aag aac tgc aca tgc ctg aat gga acc atc cag tgt gaa	912
Asp Gly Cys Lys Asn Cys Thr Cys Leu Asn Gly Thr Ile Gln Cys Glu	
290 295 300	
act cta atc tgc cca aat cct gac tgc cca ctt aag tcg gct ctt gcg	960
Thr Leu Ile Cys Pro Asn Pro Asp Cys Pro Leu Lys Ser Ala Leu Ala	
305 310 315 320	
tat gtg gat ggc aaa tgc tgt aag gaa tgc aaa tcg ata tgc caa ttt	1008
Tyr Val Asp Gly Lys Cys Cys Lys Glu Cys Lys Ser Ile Cys Gln Phe	
325 330 335	
caa gga cga acc tac ttt gaa gga gaa aga aat aca gtc tat tcc tct	1056
Gln Gly Arg Thr Tyr Phe Glu Gly Glu Arg Asn Thr Val Tyr Ser Ser	
340 345 350	
tct gga gta tgt gtt ctc tat gag tgc aag gac cag acc atg aaa ctt	1104
Ser Gly Val Cys Val Leu Tyr Glu Cys Lys Asp Gln Thr Met Lys Leu	
355 360 365	
gtt gag agt tca ggc tgt cca gct ttg gat tgt cca gag tct cat cag	1152
Val Glu Ser Ser Gly Cys Pro Ala Leu Asp Cys Pro Glu Ser His Gln	
370 375 380	
ata acc ttg tct cac agc tgt tgc aaa gtt tgt aaa ggt tat gac ttt	1200
Ile Thr Leu Ser His Ser Cys Cys Lys Val Cys Lys Gly Tyr Asp Phe	
385 390 395 400	
tgt tct gaa agg cat aac tgc atg gag aat tcc atc tgc aga aat ctg	1248
Cys Ser Glu Arg His Asn Cys Met Glu Asn Ser Ile Cys Arg Asn Leu	
405 410 415	

-continued

aat gac agg gct gtt tgt agc tgt cga gat ggt ttt agg gct ctt cga	1296
Asn Asp Arg Ala Val Cys Ser Cys Arg Asp Gly Phe Arg Ala Leu Arg	
420 425 430	
gag gat aat gcc tac tgt gaa gac atc gat gag tgt gct gaa ggg cgc	1344
Glu Asp Asn Ala Tyr Cys Glu Asp Ile Asp Glu Cys Ala Glu Gly Arg	
435 440 445	
cat tac tgt cgt gaa aat aca atg tgt gtc aac acc ccg ggt tct ttt	1392
His Tyr Cys Arg Glu Asn Thr Met Cys Val Asn Thr Pro Gly Ser Phe	
450 455 460	
atg tgc atc tgc aaa act gga tac atc aga att gat gat tat tca tgt	1440
Met Cys Ile Cys Lys Thr Gly Tyr Ile Arg Ile Asp Asp Tyr Ser Cys	
465 470 475 480	
aca gaa cat gat gag tgt atc aca aat cag cac aac tgt gat gaa aat	1488
Thr Glu His Asp Glu Cys Ile Thr Asn Gln His Asn Cys Asp Glu Asn	
485 490 495	
gct tta tgc ttc aac act gtt gga gga cac aac tgt gtt tgc aag ccg	1536
Ala Leu Cys Phe Asn Thr Val Gly Gly His Asn Cys Val Cys Lys Pro	
500 505 510	
ggc tat aca ggg aat gga acg aca tgc aaa gca ttt tgc aaa gat ggc	1584
Gly Tyr Thr Gly Asn Gly Thr Thr Cys Lys Ala Phe Cys Lys Asp Gly	
515 520 525	
tgt agg aat gga gga gcc tgt att gcc gct aat gtg tgt gcc tgc cca	1632
Cys Arg Asn Gly Gly Ala Cys Ile Ala Ala Asn Val Cys Ala Cys Pro	
530 535 540	
caa ggc ttc act gga ccc agc tgt gaa acg gac att gat gaa tgc tct	1680
Gln Gly Phe Thr Gly Pro Ser Cys Glu Thr Asp Ile Asp Glu Cys Ser	
545 550 555 560	
gat ggt ttt gtt caa tgt gac agt cgt gct aat tgc att aac ctg cct	1728
Asp Gly Phe Val Gln Cys Asp Ser Arg Ala Asn Cys Ile Asn Leu Pro	
565 570 575	
gga tgg tac cac tgt gag tgc aga gat ggc tac cat gac aat ggg atg	1776
Gly Trp Tyr His Cys Glu Cys Arg Asp Gly Tyr His Asp Asn Gly Met	
580 585 590	
ttt tca cca agt gga gaa tcg tgt gaa gat att gat gag tgt ggg acc	1824
Phe Ser Pro Ser Gly Glu Ser Cys Glu Asp Ile Asp Glu Cys Gly Thr	
595 600 605	
ggg agg cac agc tgt gcc aat gat acc att tgc ttc aat ttg gat ggc	1872
Gly Arg His Ser Cys Ala Asn Asp Thr Ile Cys Phe Asn Leu Asp Gly	
610 615 620	
gga tat gat tgt cga tgt cct cat gga aag aat tgc aca ggg gac tgc	1920
Gly Tyr Asp Cys Arg Cys Pro His Gly Lys Asn Cys Thr Gly Asp Cys	
625 630 635 640	
atc cat gat gga aaa gtt aag cac aat ggt cag att tgg gtg ttg gaa	1968
Ile His Asp Gly Lys Val Lys His Asn Gly Gln Ile Trp Val Leu Glu	
645 650 655	
aat gac agg tgc tct gtg tgc tca tgt cag aat gga ttc gtt atg tgt	2016
Asn Asp Arg Cys Ser Val Cys Ser Cys Gln Asn Gly Phe Val Met Cys	
660 665 670	
cga cgg atg gtc tgt gac tgt gag aat ccc aca gtt gat ctt ttt tgc	2064
Arg Arg Met Val Cys Asp Cys Glu Asn Pro Thr Val Asp Leu Phe Cys	
675 680 685	
tgc cct gaa tgt gac cca agg ctt agt agt cag tgc ctc cat caa aat	2112
Cys Pro Glu Cys Asp Pro Arg Leu Ser Ser Gln Cys Leu His Gln Asn	
690 695 700	
ggg gaa act ttg tat aac agt ggt gac acc tgg gtc cag aat tgt caa	2160
Gly Glu Thr Leu Tyr Asn Ser Gly Asp Thr Trp Val Gln Asn Cys Gln	
705 710 715 720	

-continued

```

cag tgc cgc tgc ttg caa ggg gaa gtt gat tgt tgg ccc ctg cct tgc      2208
Gln Cys Arg Cys Leu Gln Gly Glu Val Asp Cys Trp Pro Leu Pro Cys
              725                      730                      735

cca gat gtg gag tgt gaa ttc agc att ctc cca gag aat gag tgc tgc      2256
Pro Asp Val Glu Cys Glu Phe Ser Ile Leu Pro Glu Asn Glu Cys Cys
              740                      745                      750

ccg cgc tgt gtc aca gac cct tgc cag gct gac acc atc cgc aat gac      2304
Pro Arg Cys Val Thr Asp Pro Cys Gln Ala Asp Thr Ile Arg Asn Asp
              755                      760                      765

atc acc aag act tgc ctg gac gaa atg aat gtg gtt cgc ttc acc ggg      2352
Ile Thr Lys Thr Cys Leu Asp Glu Met Asn Val Val Arg Phe Thr Gly
              770                      775                      780

tcc tct tgg atc aaa cat ggc act gag tgt act ctc tgc cag tgc aag      2400
Ser Ser Trp Ile Lys His Gly Thr Glu Cys Thr Leu Cys Gln Cys Lys
              785                      790                      795                      800

aat ggc cac atc tgt tgc tca gtg gat cca cag tgc ctt cag gaa ctg      2448
Asn Gly His Ile Cys Cys Ser Val Asp Pro Gln Cys Leu Gln Glu Leu
              805                      810                      815

tga
*

```

```

<210> SEQ ID NO 8
<211> LENGTH: 816
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 8

```

```

Met Glu Ser Arg Val Leu Leu Arg Thr Phe Cys Leu Ile Phe Gly Leu
 1              5              10              15

Gly Ala Val Trp Gly Leu Gly Val Asp Pro Ser Leu Gln Ile Asp Val
 20              25              30

Leu Thr Glu Leu Glu Leu Gly Glu Ser Thr Thr Gly Val Arg Gln Val
 35              40              45

Pro Gly Leu His Asn Gly Thr Lys Ala Phe Leu Phe Gln Asp Thr Pro
 50              55              60

Arg Ser Ile Lys Ala Ser Thr Ala Thr Ala Glu Gln Phe Phe Gln Lys
 65              70              75              80

Leu Arg Asn Lys His Glu Phe Thr Ile Leu Val Thr Leu Lys Gln Thr
 85              90              95

His Leu Asn Ser Gly Val Ile Leu Ser Ile His His Leu Asp His Arg
 100             105             110

Tyr Leu Glu Leu Glu Ser Ser Gly His Arg Asn Glu Val Arg Leu His
 115             120             125

Tyr Arg Ser Gly Ser His Arg Pro His Thr Glu Val Phe Pro Tyr Ile
 130             135             140

Leu Ala Asp Asp Lys Trp His Lys Leu Ser Leu Ala Ile Ser Ala Ser
 145             150             155             160

His Leu Ile Leu His Ile Asp Cys Asn Lys Ile Tyr Glu Arg Val Val
 165             170             175

Glu Lys Pro Ser Thr Asp Leu Pro Leu Gly Thr Thr Phe Trp Leu Gly
 180             185             190

Gln Arg Asn Asn Ala His Gly Tyr Phe Lys Gly Ile Met Gln Asp Val
 195             200             205

Gln Leu Leu Val Met Pro Gln Gly Phe Ile Ala Gln Cys Pro Asp Leu

```

-continued

210		215		220											
Asn	Arg	Thr	Cys	Pro	Thr	Cys	Asn	Asp	Phe	His	Gly	Leu	Val	Gln	Lys
225					230					235					240
Ile	Met	Glu	Leu	Gln	Asp	Ile	Leu	Ala	Lys	Thr	Ser	Ala	Lys	Leu	Ser
				245					250					255	
Arg	Ala	Glu	Gln	Arg	Met	Asn	Arg	Leu	Asp	Gln	Cys	Tyr	Cys	Glu	Arg
			260					265					270		
Thr	Cys	Thr	Met	Lys	Gly	Thr	Thr	Tyr	Arg	Glu	Phe	Glu	Ser	Trp	Ile
		275					280					285			
Asp	Gly	Cys	Lys	Asn	Cys	Thr	Cys	Leu	Asn	Gly	Thr	Ile	Gln	Cys	Glu
	290					295					300				
Thr	Leu	Ile	Cys	Pro	Asn	Pro	Asp	Cys	Pro	Leu	Lys	Ser	Ala	Leu	Ala
305					310					315					320
Tyr	Val	Asp	Gly	Lys	Cys	Cys	Lys	Glu	Cys	Lys	Ser	Ile	Cys	Gln	Phe
				325					330					335	
Gln	Gly	Arg	Thr	Tyr	Phe	Glu	Gly	Glu	Arg	Asn	Thr	Val	Tyr	Ser	Ser
			340					345					350		
Ser	Gly	Val	Cys	Val	Leu	Tyr	Glu	Cys	Lys	Asp	Gln	Thr	Met	Lys	Leu
		355					360					365			
Val	Glu	Ser	Ser	Gly	Cys	Pro	Ala	Leu	Asp	Cys	Pro	Glu	Ser	His	Gln
	370					375					380				
Ile	Thr	Leu	Ser	His	Ser	Cys	Cys	Lys	Val	Cys	Lys	Gly	Tyr	Asp	Phe
385					390					395					400
Cys	Ser	Glu	Arg	His	Asn	Cys	Met	Glu	Asn	Ser	Ile	Cys	Arg	Asn	Leu
				405					410					415	
Asn	Asp	Arg	Ala	Val	Cys	Ser	Cys	Arg	Asp	Gly	Phe	Arg	Ala	Leu	Arg
			420					425					430		
Glu	Asp	Asn	Ala	Tyr	Cys	Glu	Asp	Ile	Asp	Glu	Cys	Ala	Glu	Gly	Arg
		435					440					445			
His	Tyr	Cys	Arg	Glu	Asn	Thr	Met	Cys	Val	Asn	Thr	Pro	Gly	Ser	Phe
	450					455					460				
Met	Cys	Ile	Cys	Lys	Thr	Gly	Tyr	Ile	Arg	Ile	Asp	Asp	Tyr	Ser	Cys
465					470					475					480
Thr	Glu	His	Asp	Glu	Cys	Ile	Thr	Asn	Gln	His	Asn	Cys	Asp	Glu	Asn
				485					490					495	
Ala	Leu	Cys	Phe	Asn	Thr	Val	Gly	Gly	His	Asn	Cys	Val	Cys	Lys	Pro
			500					505					510		
Gly	Tyr	Thr	Gly	Asn	Gly	Thr	Thr	Cys	Lys	Ala	Phe	Cys	Lys	Asp	Gly
		515					520					525			
Cys	Arg	Asn	Gly	Gly	Ala	Cys	Ile	Ala	Ala	Asn	Val	Cys	Ala	Cys	Pro
	530					535					540				
Gln	Gly	Phe	Thr	Gly	Pro	Ser	Cys	Glu	Thr	Asp	Ile	Asp	Glu	Cys	Ser
545					550					555					560
Asp	Gly	Phe	Val	Gln	Cys	Asp	Ser	Arg	Ala	Asn	Cys	Ile	Asn	Leu	Pro
				565					570					575	
Gly	Trp	Tyr	His	Cys	Glu	Cys	Arg	Asp	Gly	Tyr	His	Asp	Asn	Gly	Met
			580					585					590		
Phe	Ser	Pro	Ser	Gly	Glu	Ser	Cys	Glu	Asp	Ile	Asp	Glu	Cys	Gly	Thr
		595					600					605			
Gly	Arg	His	Ser	Cys	Ala	Asn	Asp	Thr	Ile	Cys	Phe	Asn	Leu	Asp	Gly
	610					615					620				

-continued

Gly Tyr Asp Cys Arg Cys Pro His Gly Lys Asn Cys Thr Gly Asp Cys
 625 630 635 640
 Ile His Asp Gly Lys Val Lys His Asn Gly Gln Ile Trp Val Leu Glu
 645 650 655
 Asn Asp Arg Cys Ser Val Cys Ser Cys Gln Asn Gly Phe Val Met Cys
 660 665 670
 Arg Arg Met Val Cys Asp Cys Glu Asn Pro Thr Val Asp Leu Phe Cys
 675 680 685
 Cys Pro Glu Cys Asp Pro Arg Leu Ser Ser Gln Cys Leu His Gln Asn
 690 695 700
 Gly Glu Thr Leu Tyr Asn Ser Gly Asp Thr Trp Val Gln Asn Cys Gln
 705 710 715 720
 Gln Cys Arg Cys Leu Gln Gly Glu Val Asp Cys Trp Pro Leu Pro Cys
 725 730 735
 Pro Asp Val Glu Cys Glu Phe Ser Ile Leu Pro Glu Asn Glu Cys Cys
 740 745 750
 Pro Arg Cys Val Thr Asp Pro Cys Gln Ala Asp Thr Ile Arg Asn Asp
 755 760 765
 Ile Thr Lys Thr Cys Leu Asp Glu Met Asn Val Val Arg Phe Thr Gly
 770 775 780
 Ser Ser Trp Ile Lys His Gly Thr Glu Cys Thr Leu Cys Gln Cys Lys
 785 790 795 800
 Asn Gly His Ile Cys Cys Ser Val Asp Pro Gln Cys Leu Gln Glu Leu
 805 810 815

<210> SEQ ID NO 9
 <211> LENGTH: 2451
 <212> TYPE: DNA
 <213> ORGANISM: Rattus norvegicus
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)...(2451)

<400> SEQUENCE: 9

atg gaa tcc cgg gta tta ctg aga acg ttc tgc gtg atc ctc ggg ctc 48
 Met Glu Ser Arg Val Leu Leu Arg Thr Phe Cys Val Ile Leu Gly Leu
 1 5 10 15
 gaa gcg gtt tgg gga ctt ggt gtg gac ccc tcc cta cag att gac gtc 96
 Glu Ala Val Trp Gly Leu Gly Val Asp Pro Ser Leu Gln Ile Asp Val
 20 25 30
 tta tca gag tta gaa ctt ggg gag tcc aca gct gga gtg cgc caa gtc 144
 Leu Ser Glu Leu Glu Leu Gly Glu Ser Thr Ala Gly Val Arg Gln Val
 35 40 45
 cca gga ctg cat aat ggg acg aaa gcc ttc ctc ttc caa gat tcc ccc 192
 Pro Gly Leu His Asn Gly Thr Lys Ala Phe Leu Phe Gln Asp Ser Pro
 50 55 60
 aga agc ata aaa gca ccc att gct aca gct gag cgg ttt ttc cag aag 240
 Arg Ser Ile Lys Ala Pro Ile Ala Thr Ala Glu Arg Phe Phe Gln Lys
 65 70 75 80
 ctg agg aat aaa cac gag ttc aca att ctg gtg acc ctg aaa cag atc 288
 Leu Arg Asn Lys His Glu Phe Thr Ile Leu Val Thr Leu Lys Gln Ile
 85 90 95
 cac tta aat tcg gga gtc att ctc tcc atc cac cac ttg gat cac agg 336
 His Leu Asn Ser Gly Val Ile Leu Ser Ile His His Leu Asp His Arg
 100 105 110

-continued

tac ctg gaa ctg gaa agc agc ggc cac cgg aat gag atc aga ctg cat	384
Tyr Leu Glu Leu Glu Ser Ser Gly His Arg Asn Glu Ile Arg Leu His	
115 120 125	
tac cgc tct gga act cac cgc ccg cac acg gaa gtg ttt cct tat att	432
Tyr Arg Ser Gly Thr His Arg Pro His Thr Glu Val Phe Pro Tyr Ile	
130 135 140	
ttg gct gat gcc aag tgg cac aag ctc tcc tta gcc ttc agt gcc tcc	480
Leu Ala Asp Ala Lys Trp His Lys Leu Ser Leu Ala Phe Ser Ala Ser	
145 150 155 160	
cac tta att tta cac atc gac tgc aac aag atc tat gaa cga gtg gtg	528
His Leu Ile Leu His Ile Asp Cys Asn Lys Ile Tyr Glu Arg Val Val	
165 170 175	
gaa atg cct tct aca gac ttg cct ctg ggc acc aca ttt tgg ttg gga	576
Glu Met Pro Ser Thr Asp Leu Pro Leu Gly Thr Thr Phe Trp Leu Gly	
180 185 190	
cag aga aat aac gca cac ggg tat ttt aag gga ata atg caa gat gtg	624
Gln Arg Asn Asn Ala His Gly Tyr Phe Lys Gly Ile Met Gln Asp Val	
195 200 205	
caa tta ctt gtc atg ccc cag ggg ttc atc gct cag tgc ccg gat ctt	672
Gln Leu Leu Val Met Pro Gln Gly Phe Ile Ala Gln Cys Pro Asp Leu	
210 215 220	
aat cga acc tgt cca aca tgc aac gac ttc cat ggg ctt gtg cag aaa	720
Asn Arg Thr Cys Pro Thr Cys Asn Asp Phe His Gly Leu Val Gln Lys	
225 230 235 240	
atc atg gag ctg cag gac att tta tcg aag acg tca gcc aag ttg tct	768
Ile Met Glu Leu Gln Asp Ile Leu Ser Lys Thr Ser Ala Lys Leu Ser	
245 250 255	
aga gct gaa caa cga atg aac agg ctg gat cag tgc tac tgt gag cgg	816
Arg Ala Glu Gln Arg Met Asn Arg Leu Asp Gln Cys Tyr Cys Glu Arg	
260 265 270	
acg tgc acc atg aag gga gcc acc tac cgg gag ttc gag tcc tgg aca	864
Thr Cys Thr Met Lys Gly Ala Thr Tyr Arg Glu Phe Glu Ser Trp Thr	
275 280 285	
gac ggc tgc aag aac tgc aca tgc ttg aat ggg acc atc cag tgc gag	912
Asp Gly Cys Lys Asn Cys Thr Cys Leu Asn Gly Thr Ile Gln Cys Glu	
290 295 300	
act ctg gtc tgc cct gct ccc gac tgc ccg gct aaa tcg gct cca gcg	960
Thr Leu Val Cys Pro Ala Pro Asp Cys Pro Ala Lys Ser Ala Pro Ala	
305 310 315 320	
tac gtg gat ggc aag tgc tgt aag gag tgc aag tcc acc tgc cag ttc	1008
Tyr Val Asp Gly Lys Cys Cys Lys Glu Cys Lys Ser Thr Cys Gln Phe	
325 330 335	
cag ggg cgg agc tac ttt gag gga gaa agg agc aca gtc ttc tca gct	1056
Gln Gly Arg Ser Tyr Phe Glu Gly Glu Arg Ser Thr Val Phe Ser Ala	
340 345 350	
tcc gga atg tgc gtc ttg tat gaa tgc aag gat cag acc atg aag ctt	1104
Ser Gly Met Cys Val Leu Tyr Glu Cys Lys Asp Gln Thr Met Lys Leu	
355 360 365	
gtt gag aac gcc ggc tgc ccg gct tta gat tgc ccc gag tct cat cag	1152
Val Glu Asn Ala Gly Cys Pro Ala Leu Asp Cys Pro Glu Ser His Gln	
370 375 380	
atc gcc ttg tct cac agc tgc tgc aag gtt tgc aaa ggt tat gac ttc	1200
Ile Ala Leu Ser His Ser Cys Cys Lys Val Cys Lys Gly Tyr Asp Phe	
385 390 395 400	
tgt tct gag aag cat aca tgc atg gag aac tca gtc tgc agg aac ctg	1248
Cys Ser Glu Lys His Thr Cys Met Glu Asn Ser Val Cys Arg Asn Leu	
405 410 415	

-continued

aac gac agg gca gtg tgc agc tgc cgg gat ggt ttc cgg gcc ctc cgg	1296
Asn Asp Arg Ala Val Cys Ser Cys Arg Asp Gly Phe Arg Ala Leu Arg	
420 425 430	
gag gac aat gcc tac tgt gaa gac att gac gag tgt gca gag ggg cgc	1344
Glu Asp Asn Ala Tyr Cys Glu Asp Ile Asp Glu Cys Ala Glu Gly Arg	
435 440 445	
cat tac tgc cgt gag aac acc atg tgt gtg aac aca ccg ggc tct ttc	1392
His Tyr Cys Arg Glu Asn Thr Met Cys Val Asn Thr Pro Gly Ser Phe	
450 455 460	
ctg tgt atc tgc caa aca ggg tac atc aga atc gac gat tac tcg tgt	1440
Leu Cys Ile Cys Gln Thr Gly Tyr Ile Arg Ile Asp Asp Tyr Ser Cys	
465 470 475 480	
acg gaa cat gac gag tgc ctc aca aac cag cac aac tgt gac gag aac	1488
Thr Glu His Asp Glu Cys Leu Thr Asn Gln His Asn Cys Asp Glu Asn	
485 490 495	
gct ttg tgc ttt aac acc gtt gga ggt cac aac tgc gtc tgc aag cct	1536
Ala Leu Cys Phe Asn Thr Val Gly Gly His Asn Cys Val Cys Lys Pro	
500 505 510	
ggg tac act ggg aat gga acc acg tgc aaa gct ttc tgc aaa gac ggc	1584
Gly Tyr Thr Gly Asn Gly Thr Thr Cys Lys Ala Phe Cys Lys Asp Gly	
515 520 525	
tgc aaa aac gga ggt gcc tgc att gct gcc aat gtc tgt gct tgc cca	1632
Cys Lys Asn Gly Gly Ala Cys Ile Ala Ala Asn Val Cys Ala Cys Pro	
530 535 540	
caa ggc ttc acc gga ccc agc tgt gag aca gac att gat gag tgc tct	1680
Gln Gly Phe Thr Gly Pro Ser Cys Glu Thr Asp Ile Asp Glu Cys Ser	
545 550 555 560	
gag ggc ttt gtt cag tgt gac agc cgt gcc aac tgc att aac ctg cct	1728
Glu Gly Phe Val Gln Cys Asp Ser Arg Ala Asn Cys Ile Asn Leu Pro	
565 570 575	
ggg tgg tac cac tgt gag tgc aga gat ggc tac cat gac aat ggg atg	1776
Gly Trp Tyr His Cys Glu Cys Arg Asp Gly Tyr His Asp Asn Gly Met	
580 585 590	
ttt gcg cca ggt gga gaa tcc tgt gaa gat att gat gaa tgt ggg act	1824
Phe Ala Pro Gly Gly Glu Ser Cys Glu Asp Ile Asp Glu Cys Gly Thr	
595 600 605	
ggg agg cac agc tgt gcc aat gac acc att tgc ttc aac ttg gac ggt	1872
Gly Arg His Ser Cys Ala Asn Asp Thr Ile Cys Phe Asn Leu Asp Gly	
610 615 620	
ggc tac gat tgc cgg tgt ccc cat gga aag aac tgc aca ggg gac tgc	1920
Gly Tyr Asp Cys Arg Cys Pro His Gly Lys Asn Cys Thr Gly Asp Cys	
625 630 635 640	
gtg cac gac ggg aaa gtc aaa cac aac ggc cag atc tgg gtg ctg gag	1968
Val His Asp Gly Lys Val Lys His Asn Gly Gln Ile Trp Val Leu Glu	
645 650 655	
aac gac agg tgc tct gtg tgt tcc tgc cag act gga ttt gtt atg tgc	2016
Asn Asp Arg Cys Ser Val Cys Ser Cys Gln Thr Gly Phe Val Met Cys	
660 665 670	
caa cgg atg gtc tgt gac tgc gaa aac ccc aca gtt gac ctc tcc tgc	2064
Gln Arg Met Val Cys Asp Cys Glu Asn Pro Thr Val Asp Leu Ser Cys	
675 680 685	
tgc cct gag tgc gac cca agg ctg agc agc cag tgc ctg cat caa aac	2112
Cys Pro Glu Cys Asp Pro Arg Leu Ser Ser Gln Cys Leu His Gln Asn	
690 695 700	
ggg gaa acc gtg tac aac agc ggt gac acc tgg gcc cag gat tgc cgt	2160
Gly Glu Thr Val Tyr Asn Ser Gly Asp Thr Trp Ala Gln Asp Cys Arg	
705 710 715 720	

-continued

cag tgc cgc tgc ttg caa gaa gaa gtt gac tgc tgg ccc ctg gct tgc	2208
Gln Cys Arg Cys Leu Gln Glu Glu Val Asp Cys Trp Pro Leu Ala Cys	
725 730 735	
cca gag gta gag tgt gaa ttt agt gtc ctt cct gag aac gag tgc tgc	2256
Pro Glu Val Glu Cys Glu Phe Ser Val Leu Pro Glu Asn Glu Cys Cys	
740 745 750	
cca cgc tgt gtc acc gat cct tgt cag gct gac acc atc cgc aat gac	2304
Pro Arg Cys Val Thr Asp Pro Cys Gln Ala Asp Thr Ile Arg Asn Asp	
755 760 765	
atc acc aaa acc tgc ctg gac gag atg aac gtg gtt cgc ttc act ggg	2352
Ile Thr Lys Thr Cys Leu Asp Glu Met Asn Val Val Arg Phe Thr Gly	
770 775 780	
tct tcc tgg atc aag cac ggc acg gag tgc acc ctc tgc cag tgc aag	2400
Ser Ser Trp Ile Lys His Gly Thr Glu Cys Thr Leu Cys Gln Cys Lys	
785 790 795 800	
aac ggc cac gtg tgc tgc tca gtg gac cca cag tgc ctc cag gag ctg	2448
Asn Gly His Val Cys Cys Ser Val Asp Pro Gln Cys Leu Gln Glu Leu	
805 810 815	
tga	2451
*	

<210> SEQ ID NO 10

<211> LENGTH: 816

<212> TYPE: PRT

<213> ORGANISM: Rattus norvegicus

<400> SEQUENCE: 10

Met Glu Ser Arg Val Leu Leu Arg Thr Phe Cys Val Ile Leu Gly Leu	
1 5 10 15	
Glu Ala Val Trp Gly Leu Gly Val Asp Pro Ser Leu Gln Ile Asp Val	
20 25 30	
Leu Ser Glu Leu Glu Leu Gly Glu Ser Thr Ala Gly Val Arg Gln Val	
35 40 45	
Pro Gly Leu His Asn Gly Thr Lys Ala Phe Leu Phe Gln Asp Ser Pro	
50 55 60	
Arg Ser Ile Lys Ala Pro Ile Ala Thr Ala Glu Arg Phe Phe Gln Lys	
65 70 75 80	
Leu Arg Asn Lys His Glu Phe Thr Ile Leu Val Thr Leu Lys Gln Ile	
85 90 95	
His Leu Asn Ser Gly Val Ile Leu Ser Ile His His Leu Asp His Arg	
100 105 110	
Tyr Leu Glu Leu Glu Ser Ser Gly His Arg Asn Glu Ile Arg Leu His	
115 120 125	
Tyr Arg Ser Gly Thr His Arg Pro His Thr Glu Val Phe Pro Tyr Ile	
130 135 140	
Leu Ala Asp Ala Lys Trp His Lys Leu Ser Leu Ala Phe Ser Ala Ser	
145 150 155 160	
His Leu Ile Leu His Ile Asp Cys Asn Lys Ile Tyr Glu Arg Val Val	
165 170 175	
Glu Met Pro Ser Thr Asp Leu Pro Leu Gly Thr Thr Phe Trp Leu Gly	
180 185 190	
Gln Arg Asn Asn Ala His Gly Tyr Phe Lys Gly Ile Met Gln Asp Val	
195 200 205	
Gln Leu Leu Val Met Pro Gln Gly Phe Ile Ala Gln Cys Pro Asp Leu	
210 215 220	

-continued

Asn	Arg	Thr	Cys	Pro	Thr	Cys	Asn	Asp	Phe	His	Gly	Leu	Val	Gln	Lys
225					230					235					240
Ile	Met	Glu	Leu	Gln	Asp	Ile	Leu	Ser	Lys	Thr	Ser	Ala	Lys	Leu	Ser
				245					250					255	
Arg	Ala	Glu	Gln	Arg	Met	Asn	Arg	Leu	Asp	Gln	Cys	Tyr	Cys	Glu	Arg
			260					265					270		
Thr	Cys	Thr	Met	Lys	Gly	Ala	Thr	Tyr	Arg	Glu	Phe	Glu	Ser	Trp	Thr
		275					280					285			
Asp	Gly	Cys	Lys	Asn	Cys	Thr	Cys	Leu	Asn	Gly	Thr	Ile	Gln	Cys	Glu
	290					295					300				
Thr	Leu	Val	Cys	Pro	Ala	Pro	Asp	Cys	Pro	Ala	Lys	Ser	Ala	Pro	Ala
305					310					315					320
Tyr	Val	Asp	Gly	Lys	Cys	Cys	Lys	Glu	Cys	Lys	Ser	Thr	Cys	Gln	Phe
				325					330					335	
Gln	Gly	Arg	Ser	Tyr	Phe	Glu	Gly	Glu	Arg	Ser	Thr	Val	Phe	Ser	Ala
			340					345					350		
Ser	Gly	Met	Cys	Val	Leu	Tyr	Glu	Cys	Lys	Asp	Gln	Thr	Met	Lys	Leu
		355					360					365			
Val	Glu	Asn	Ala	Gly	Cys	Pro	Ala	Leu	Asp	Cys	Pro	Glu	Ser	His	Gln
	370					375					380				
Ile	Ala	Leu	Ser	His	Ser	Cys	Cys	Lys	Val	Cys	Lys	Gly	Tyr	Asp	Phe
385					390					395					400
Cys	Ser	Glu	Lys	His	Thr	Cys	Met	Glu	Asn	Ser	Val	Cys	Arg	Asn	Leu
				405					410					415	
Asn	Asp	Arg	Ala	Val	Cys	Ser	Cys	Arg	Asp	Gly	Phe	Arg	Ala	Leu	Arg
			420					425					430		
Glu	Asp	Asn	Ala	Tyr	Cys	Glu	Asp	Ile	Asp	Glu	Cys	Ala	Glu	Gly	Arg
		435					440					445			
His	Tyr	Cys	Arg	Glu	Asn	Thr	Met	Cys	Val	Asn	Thr	Pro	Gly	Ser	Phe
	450					455					460				
Leu	Cys	Ile	Cys	Gln	Thr	Gly	Tyr	Ile	Arg	Ile	Asp	Asp	Tyr	Ser	Cys
465					470					475					480
Thr	Glu	His	Asp	Glu	Cys	Leu	Thr	Asn	Gln	His	Asn	Cys	Asp	Glu	Asn
			485						490					495	
Ala	Leu	Cys	Phe	Asn	Thr	Val	Gly	Gly	His	Asn	Cys	Val	Cys	Lys	Pro
			500					505					510		
Gly	Tyr	Thr	Gly	Asn	Gly	Thr	Thr	Cys	Lys	Ala	Phe	Cys	Lys	Asp	Gly
		515					520					525			
Cys	Lys	Asn	Gly	Gly	Ala	Cys	Ile	Ala	Ala	Asn	Val	Cys	Ala	Cys	Pro
	530					535					540				
Gln	Gly	Phe	Thr	Gly	Pro	Ser	Cys	Glu	Thr	Asp	Ile	Asp	Glu	Cys	Ser
545					550					555					560
Glu	Gly	Phe	Val	Gln	Cys	Asp	Ser	Arg	Ala	Asn	Cys	Ile	Asn	Leu	Pro
			565						570					575	
Gly	Trp	Tyr	His	Cys	Glu	Cys	Arg	Asp	Gly	Tyr	His	Asp	Asn	Gly	Met
		580						585					590		
Phe	Ala	Pro	Gly	Gly	Glu	Ser	Cys	Glu	Asp	Ile	Asp	Glu	Cys	Gly	Thr
		595					600					605			
Gly	Arg	His	Ser	Cys	Ala	Asn	Asp	Thr	Ile	Cys	Phe	Asn	Leu	Asp	Gly
	610					615					620				

-continued

Gly Tyr Asp Cys Arg Cys Pro His Gly Lys Asn Cys Thr Gly Asp Cys
625 630 635 640

Val His Asp Gly Lys Val Lys His Asn Gly Gln Ile Trp Val Leu Glu
645 650 655

Asn Asp Arg Cys Ser Val Cys Ser Cys Gln Thr Gly Phe Val Met Cys
660 665 670

Gln Arg Met Val Cys Asp Cys Glu Asn Pro Thr Val Asp Leu Ser Cys
675 680 685

Cys Pro Glu Cys Asp Pro Arg Leu Ser Ser Gln Cys Leu His Gln Asn
690 695 700

Gly Glu Thr Val Tyr Asn Ser Gly Asp Thr Trp Ala Gln Asp Cys Arg
705 710 715 720

Gln Cys Arg Cys Leu Gln Glu Glu Val Asp Cys Trp Pro Leu Ala Cys
725 730 735

Pro Glu Val Glu Cys Glu Phe Ser Val Leu Pro Glu Asn Glu Cys Cys
740 745 750

Pro Arg Cys Val Thr Asp Pro Cys Gln Ala Asp Thr Ile Arg Asn Asp
755 760 765

Ile Thr Lys Thr Cys Leu Asp Glu Met Asn Val Val Arg Phe Thr Gly
770 775 780

Ser Ser Trp Ile Lys His Gly Thr Glu Cys Thr Leu Cys Gln Cys Lys
785 790 795 800

Asn Gly His Val Cys Cys Ser Val Asp Pro Gln Cys Leu Gln Glu Leu
805 810 815

<210> SEQ ID NO 11
 <211> LENGTH: 2460
 <212> TYPE: DNA
 <213> ORGANISM: Mus musculus
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)...(2460)
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (1)...(2460)
 <223> OTHER INFORMATION: n = A,T,C or G

<400> SEQUENCE: 11

atg cac gcc atg gaa tcc cgg gtg tta ctg aga acg ttc tgc gtg atc 48
 Met His Ala Met Glu Ser Arg Val Leu Leu Arg Thr Phe Cys Val Ile
 1 5 10 15

ctc ggc ctt gga gcg gtt tgg ggg ctt ggt gtg gac ccc tcc cta cag 96
 Leu Gly Leu Gly Ala Val Trp Gly Leu Gly Val Asp Pro Ser Leu Gln
 20 25 30

att gac gtc tta aca gag tta gaa ctt ggg gag tct aca gat gga gtg 144
 Ile Asp Val Leu Thr Glu Leu Glu Leu Gly Glu Ser Thr Asp Gly Val
 35 40 45

cgc caa gtc ccg gga ctg cat aat ggg acg aaa gcc ttc ctc ttc caa 192
 Arg Gln Val Pro Gly Leu His Asn Gly Thr Lys Ala Phe Leu Phe Gln
 50 55 60

gag tcc ccc aga agc ata aag gca tcc act gct aca gct gag cgg ttt 240
 Glu Ser Pro Arg Ser Ile Lys Ala Ser Thr Ala Thr Ala Glu Arg Phe
 65 70 75 80

ctc cag aag ctg aga aat aaa cac gag ttc aca atc ttg gtg acc tta 288
 Leu Gln Lys Leu Arg Asn Lys His Glu Phe Thr Ile Leu Val Thr Leu
 85 90 95

aaa cag atc cac tta aat tcg gga gtt atc ctc tcc atc cac cac ttg 336

-continued

Lys	Gln	Ile	His	Leu	Asn	Ser	Gly	Val	Ile	Leu	Ser	Ile	His	His	Leu		
			100					105					110				
gat	cac	agg	tac	ctg	gaa	ctg	gaa	agc	agt	ggc	cat	cgg	aat	gag	atc		384
Asp	His	Arg	Tyr	Leu	Glu	Leu	Glu	Ser	Ser	Gly	His	Arg	Asn	Glu	Ile		
		115					120					125					
aga	ctc	cac	tac	cgc	tct	ggc	act	cac	cgc	ccc	cac	acg	gaa	gtg	ttt		432
Arg	Leu	His	Tyr	Arg	Ser	Gly	Thr	His	Arg	Pro	His	Thr	Glu	Val	Phe		
	130					135					140						
cct	tat	att	ttg	gct	gat	gcc	aag	tgg	cac	aag	ctc	tcc	tta	gcc	ttc		480
Pro	Tyr	Ile	Leu	Ala	Asp	Ala	Lys	Trp	His	Lys	Leu	Ser	Leu	Ala	Phe		
	145				150					155					160		
agt	gcc	tct	cac	tta	att	tta	cac	atc	gac	tgc	aat	aag	atc	tat	gaa		528
Ser	Ala	Ser	His	Leu	Ile	Leu	His	Ile	Asp	Cys	Asn	Lys	Ile	Tyr	Glu		
				165					170					175			
cga	gtg	gtg	gaa	atg	ccc	ttc	aca	gac	ttg	gct	ctg	ggc	aca	aca	ttt		576
Arg	Val	Val	Glu	Met	Pro	Phe	Thr	Asp	Leu	Ala	Leu	Gly	Thr	Thr	Phe		
			180					185					190				
tgg	ttg	gga	cag	aga	aat	aat	gca	cat	ggc	tat	ttt	aag	gga	ata	atg		624
Trp	Leu	Gly	Gln	Arg	Asn	Asn	Ala	His	Gly	Tyr	Phe	Lys	Gly	Ile	Met		
		195					200					205					
cag	gat	gtg	cac	gtc	ctt	gtc	atg	cct	cag	ggc	ttc	att	gct	cag	tgc		672
Gln	Asp	Val	His	Val	Leu	Val	Met	Pro	Gln	Gly	Phe	Ile	Ala	Gln	Cys		
	210					215					220						
ccg	gac	ctt	aat	cga	acc	tgt	cca	aca	tgc	aac	gac	ttc	cat	ggg	ctt		720
Pro	Asp	Leu	Asn	Arg	Thr	Cys	Pro	Thr	Cys	Asn	Asp	Phe	His	Gly	Leu		
	225				230					235					240		
gtg	cag	aaa	atc	atg	gag	ctg	cag	gac	att	tta	tca	aag	acg	tca	gcc		768
Val	Gln	Lys	Ile	Met	Glu	Leu	Gln	Asp	Ile	Leu	Ser	Lys	Thr	Ser	Ala		
				245					250					255			
aag	ctg	tcc	cga	gct	gaa	caa	aga	atg	aac	agg	ctg	gat	cag	tgc	tac		816
Lys	Leu	Ser	Arg	Ala	Glu	Gln	Arg	Met	Asn	Arg	Leu	Asp	Gln	Cys	Tyr		
			260					265					270				
tgt	gag	cgg	aca	tgc	act	gtg	aag	gga	acc	acc	tac	cga	gag	tct	gag		864
Cys	Glu	Arg	Thr	Cys	Thr	Val	Lys	Gly	Thr	Thr	Tyr	Arg	Glu	Ser	Glu		
		275					280					285					
tcc	ttg	aca	gac	ggc	tgt	aag	aac	tgc	aca	tgc	ttg	aac	ggg	acc	atc		912
Ser	Trp	Thr	Asp	Gly	Cys	Lys	Asn	Cys	Thr	Cys	Leu	Asn	Gly	Thr	Ile		
	290					295					300						
cag	tgc	gag	act	ctg	gtc	tgc	cct	gct	cct	gac	tgc	cct	cct	aaa	tcg		960
Gln	Cys	Glu	Thr	Leu	Val	Cys	Pro	Ala	Pro	Asp	Cys	Pro	Pro	Lys	Ser		
	305				310					315					320		
gcc	cct	gcg	tat	gtg	gat	ggc	aag	tgc	tgt	aag	gag	tgc	aaa	tca	acc		1008
Ala	Pro	Ala	Tyr	Val	Asp	Gly	Lys	Cys	Cys	Lys	Glu	Cys	Lys	Ser	Thr		
				325					330					335			
tgc	cag	ttc	cag	gga	cgg	agc	tac	ttt	gag	gga	gaa	agg	aac	acg	gca		1056
Cys	Gln	Phe	Gln	Gly	Arg	Ser	Tyr	Phe	Glu	Gly	Glu	Arg	Asn	Thr	Ala		
			340					345					350				
tac	tca	tct	tct	gga	atg	tgt	gtc	tta	tat	gaa	tgc	aag	gat	cag	acc		1104
Tyr	Ser	Ser	Ser	Gly	Met	Cys	Val	Leu	Tyr	Glu	Cys	Lys	Asp	Gln	Thr		
		355					360					365					
atg	aag	ctt	gtt	gag	aac	att	ggc	tgc	cca	ccc	tta	gat	tgt	ccc	gag		1152
Met	Lys	Leu	Val	Glu	Asn	Ile	Gly	Cys	Pro	Pro	Leu	Asp	Cys	Pro	Glu		
		370				375					380						
tct	cat	cag	att	gcc	ttg	tct	cac	agc	tgc	tgc	aag	gtt	tgt	aaa	ggt		1200
Ser	His	Gln	Ile	Ala	Leu	Ser	His	Ser	Cys	Cys	Lys	Val	Cys	Lys	Gly		
				385		390				395					400		
tat	gac	ttc	tgt	tct	gag	aag	cat	acc	tgc	atg	gag	aac	tcg	gtc	tgc		1248

-continued

Tyr	Asp	Phe	Cys	Ser	Glu	Lys	His	Thr	Cys	Met	Glu	Asn	Ser	Val	Cys	
				405					410					415		
agg	aac	ctg	aac	gac	agg	gtt	gtg	tgc	agc	tgc	agg	gat	ggt	ttt	cgg	1296
Arg	Asn	Leu	Asn	Asp	Arg	Val	Val	Cys	Ser	Cys	Arg	Asp	Gly	Phe	Arg	
			420					425					430			
gct	ctc	cga	gag	gac	aac	gcc	tac	tgt	gaa	gac	att	gac	gag	tgt	gca	1344
Ala	Leu	Arg	Glu	Asp	Asn	Ala	Tyr	Cys	Glu	Asp	Ile	Asp	Glu	Cys	Ala	
		435					440					445				
gaa	ggg	cgc	cat	tac	tgc	cgt	gag	aac	acc	atg	tgt	gtg	aat	aca	cct	1392
Glu	Gly	Arg	His	Tyr	Cys	Arg	Glu	Asn	Thr	Met	Cys	Val	Asn	Thr	Pro	
	450					455				460						
ggt	tct	ttc	atg	tgt	gtc	tgc	aaa	act	ggg	tac	atc	agg	atc	gac	gat	1440
Gly	Ser	Phe	Met	Cys	Val	Cys	Lys	Thr	Gly	Tyr	Ile	Arg	Ile	Asp	Asp	
465					470				475					480		
tac	tca	tgt	aca	gaa	cat	gat	gag	tgt	ctc	aca	acc	cag	cac	aat	tgt	1488
Tyr	Ser	Cys	Thr	Glu	His	Asp	Glu	Cys	Leu	Thr	Thr	Gln	His	Asn	Cys	
				485					490					495		
gat	gaa	aac	gct	ttg	tgc	ttt	aac	act	ggt	gga	gga	cac	aac	tgt	gtc	1536
Asp	Glu	Asn	Ala	Leu	Cys	Phe	Asn	Thr	Val	Gly	Gly	His	Asn	Cys	Val	
			500					505					510			
tgc	aag	cct	ggc	tac	acc	ggg	aat	gga	acc	acg	tgc	aaa	gct	ttc	tgc	1584
Cys	Lys	Pro	Gly	Tyr	Thr	Gly	Asn	Gly	Thr	Thr	Cys	Lys	Ala	Phe	Cys	
		515					520					525				
aaa	gat	ggc	tgt	aga	aac	gga	gga	gcg	tgc	att	gct	gcc	aat	gtg	tgt	1632
Lys	Asp	Gly	Cys	Arg	Asn	Gly	Gly	Ala	Cys	Ile	Ala	Ala	Asn	Val	Cys	
	530					535					540					
gcc	tgc	cca	caa	ggc	ttc	acg	gga	ccc	agc	tgt	gag	aca	gac	att	gac	1680
Ala	Cys	Pro	Gln	Gly	Phe	Thr	Gly	Pro	Ser	Cys	Glu	Thr	Asp	Ile	Asp	
545				550					555					560		
gag	tgc	tct	gag	ggc	ttt	ggt	cag	tgt	gac	agc	cgt	gcc	aac	tgc	atc	1728
Glu	Cys	Ser	Glu	Gly	Phe	Val	Gln	Cys	Asp	Ser	Arg	Ala	Asn	Cys	Ile	
				565					570					575		
aac	ctg	cct	ggg	tgg	tat	cac	tgt	gag	tgc	aga	gac	ggc	tac	cat	gac	1776
Asn	Leu	Pro	Gly	Trp	Tyr	His	Cys	Glu	Cys	Arg	Asp	Gly	Tyr	His	Asp	
			580					585					590			
aat	ggg	atg	ttt	gcg	cca	ggc	gga	gaa	tcc	tgt	gaa	gat	att	gac	gaa	1824
Asn	Gly	Met	Phe	Ala	Pro	Gly	Gly	Glu	Ser	Cys	Glu	Asp	Ile	Asp	Glu	
		595				600						605				
tgc	ggg	act	ggg	agg	cac	agc	tgc	acc	aac	gac	acc	att	tgc	ttc	aac	1872
Cys	Gly	Thr	Gly	Arg	His	Ser	Cys	Thr	Asn	Asp	Thr	Ile	Cys	Phe	Asn	
	610					615					620					
ttg	gac	ggg	gga	tac	gat	tgc	cgg	tgt	ccc	cat	ggg	aag	aac	tgc	act	1920
Leu	Asp	Gly	Gly	Tyr	Asp	Cys	Arg	Cys	Pro	His	Gly	Lys	Asn	Cys	Thr	
625					630					635				640		
ggg	gac	tgc	gtg	cac	gag	ggg	aaa	gtg	aag	cac	acc	ggc	cag	atc	tgg	1968
Gly	Asp	Cys	Val	His	Glu	Gly	Lys	Val	Lys	His	Thr	Gly	Gln	Ile	Trp	
				645					650					655		
gtg	ctg	gaa	aac	gac	agg	tgc	tcc	gtg	tgt	tcc	tgg	cag	act	ggg	ttt	2016
Val	Leu	Glu	Asn	Asp	Arg	Cys	Ser	Val	Cys	Ser	Trp	Gln	Thr	Gly	Phe	
			660					665						670		
gtc	atg	tgt	cga	cgg	atg	gtc	tgc	gac	tgc	gaa	aac	ccc	aca	gat	gac	2064
Val	Met	Cys	Arg	Arg	Met	Val	Cys	Asp	Cys	Glu	Asn	Pro	Thr	Asp	Asp	
		675					680					685				
ctt	tcc	tgc	tgc	cct	gag	tgt	gac	cca	agg	ctg	agc	agt	cag	tgc	ctg	2112
Leu	Ser	Cys	Cys	Pro	Glu	Cys	Asp	Pro	Arg	Leu	Ser	Ser	Gln	Cys	Leu	
	690					695					700					
cat	caa	aac	ggg	gaa	acc	gtg	tac	aac	agc	ggc	gac	acc	tgg	gtc	cag	2160

-continued

His	Gln	Asn	Gly	Glu	Thr	Val	Tyr	Asn	Ser	Gly	Asp	Thr	Trp	Val	Gln	
705					710					715					720	
gat tgc cgt cag tgc cgc tgc ttg caa gga gaa gtt gac tgt tgg ccc 2208																
Asp	Cys	Arg	Gln	Cys	Arg	Cys	Leu	Gln	Gly	Glu	Val	Asp	Cys	Trp	Pro	
			725						730					735		
ctg gct tgc cca gag gta gaa tgt gaa ttt agc gtc ctt cct gag aac 2256																
Leu	Ala	Cys	Pro	Glu	Val	Glu	Cys	Glu	Phe	Ser	Val	Leu	Pro	Glu	Asn	
			740					745						750		
gag tgc tgc cca cgc tgt gtc acc gat cct tgt cag gcc gac acc atc 2304																
Glu	Cys	Cys	Pro	Arg	Cys	Val	Thr	Asp	Pro	Cys	Gln	Ala	Asp	Thr	Ile	
		755					760					765				
cgc aat gac atc acc aaa acc tgc ctg gac gag atg aac gtg gtt cgc 2352																
Arg	Asn	Asp	Ile	Thr	Lys	Thr	Cys	Leu	Asp	Glu	Met	Asn	Val	Val	Arg	
	770					775					780					
ttc acc ggg tct tcc tgg atc aag cac ggc acg gag tgt acc ctc tgc 2400																
Phe	Thr	Gly	Ser	Ser	Trp	Ile	Lys	His	Gly	Thr	Glu	Cys	Thr	Leu	Cys	
785					790				795						800	
cag tgc aag aat ggc cat ttg tgc tgc tca gtg gat cca cag tgc ctt 2448																
Gln	Cys	Lys	Asn	Gly	His	Leu	Cys	Cys	Ser	Val	Asp	Pro	Gln	Cys	Leu	
			805					810						815		
cag gag ctg tga 2460																
Gln	Glu	Leu	*													

<210> SEQ ID NO 12

<211> LENGTH: 819

<212> TYPE: PRT

<213> ORGANISM: Mus musculus

<400> SEQUENCE: 12

Met	His	Ala	Met	Glu	Ser	Arg	Val	Leu	Leu	Arg	Thr	Phe	Cys	Val	Ile	
1				5					10					15		
Leu Gly Leu Gly Ala Val Trp Gly Leu Gly Val Asp Pro Ser Leu Gln																
			20					25					30			
Ile Asp Val Leu Thr Glu Leu Glu Leu Gly Glu Ser Thr Asp Gly Val																
		35				40					45					
Arg Gln Val Pro Gly Leu His Asn Gly Thr Lys Ala Phe Leu Phe Gln																
		50				55				60						
Glu Ser Pro Arg Ser Ile Lys Ala Ser Thr Ala Thr Ala Glu Arg Phe																
65				70					75						80	
Leu Gln Lys Leu Arg Asn Lys His Glu Phe Thr Ile Leu Val Thr Leu																
			85					90						95		
Lys Gln Ile His Leu Asn Ser Gly Val Ile Leu Ser Ile His His Leu																
		100					105						110			
Asp His Arg Tyr Leu Glu Leu Glu Ser Ser Gly His Arg Asn Glu Ile																
		115				120						125				
Arg Leu His Tyr Arg Ser Gly Thr His Arg Pro His Thr Glu Val Phe																
		130				135						140				
Pro Tyr Ile Leu Ala Asp Ala Lys Trp His Lys Leu Ser Leu Ala Phe																
145				150					155						160	
Ser Ala Ser His Leu Ile Leu His Ile Asp Cys Asn Lys Ile Tyr Glu																
			165					170						175		
Arg Val Val Glu Met Pro Phe Thr Asp Leu Ala Leu Gly Thr Thr Phe																
			180					185						190		
Trp Leu Gly Gln Arg Asn Asn Ala His Gly Tyr Phe Lys Gly Ile Met																
		195				200							205			

-continued

Gln Asp Val His Val Leu Val Met Pro Gln Gly Phe Ile Ala Gln Cys
 210 215 220

Pro Asp Leu Asn Arg Thr Cys Pro Thr Cys Asn Asp Phe His Gly Leu
 225 230 235 240

Val Gln Lys Ile Met Glu Leu Gln Asp Ile Leu Ser Lys Thr Ser Ala
 245 250 255

Lys Leu Ser Arg Ala Glu Gln Arg Met Asn Arg Leu Asp Gln Cys Tyr
 260 265 270

Cys Glu Arg Thr Cys Thr Val Lys Gly Thr Thr Tyr Arg Glu Ser Glu
 275 280 285

Ser Trp Thr Asp Gly Cys Lys Asn Cys Thr Cys Leu Asn Gly Thr Ile
 290 295 300

Gln Cys Glu Thr Leu Val Cys Pro Ala Pro Asp Cys Pro Pro Lys Ser
 305 310 315 320

Ala Pro Ala Tyr Val Asp Gly Lys Cys Cys Lys Glu Cys Lys Ser Thr
 325 330 335

Cys Gln Phe Gln Gly Arg Ser Tyr Phe Glu Gly Glu Arg Asn Thr Ala
 340 345 350

Tyr Ser Ser Ser Gly Met Cys Val Leu Tyr Glu Cys Lys Asp Gln Thr
 355 360 365

Met Lys Leu Val Glu Asn Ile Gly Cys Pro Pro Leu Asp Cys Pro Glu
 370 375 380

Ser His Gln Ile Ala Leu Ser His Ser Cys Cys Lys Val Cys Lys Gly
 385 390 395 400

Tyr Asp Phe Cys Ser Glu Lys His Thr Cys Met Glu Asn Ser Val Cys
 405 410 415

Arg Asn Leu Asn Asp Arg Val Val Cys Ser Cys Arg Asp Gly Phe Arg
 420 425 430

Ala Leu Arg Glu Asp Asn Ala Tyr Cys Glu Asp Ile Asp Glu Cys Ala
 435 440 445

Glu Gly Arg His Tyr Cys Arg Glu Asn Thr Met Cys Val Asn Thr Pro
 450 455 460

Gly Ser Phe Met Cys Val Cys Lys Thr Gly Tyr Ile Arg Ile Asp Asp
 465 470 475 480

Tyr Ser Cys Thr Glu His Asp Glu Cys Leu Thr Thr Gln His Asn Cys
 485 490 495

Asp Glu Asn Ala Leu Cys Phe Asn Thr Val Gly Gly His Asn Cys Val
 500 505 510

Cys Lys Pro Gly Tyr Thr Gly Asn Gly Thr Thr Cys Lys Ala Phe Cys
 515 520 525

Lys Asp Gly Cys Arg Asn Gly Gly Ala Cys Ile Ala Ala Asn Val Cys
 530 535 540

Ala Cys Pro Gln Gly Phe Thr Gly Pro Ser Cys Glu Thr Asp Ile Asp
 545 550 555 560

Glu Cys Ser Glu Gly Phe Val Gln Cys Asp Ser Arg Ala Asn Cys Ile
 565 570 575

Asn Leu Pro Gly Trp Tyr His Cys Glu Cys Arg Asp Gly Tyr His Asp
 580 585 590

Asn Gly Met Phe Ala Pro Gly Gly Glu Ser Cys Glu Asp Ile Asp Glu
 595 600 605

-continued

Cys Gly Thr Gly Arg His Ser Cys Thr Asn Asp Thr Ile Cys Phe Asn
 610 615 620

Leu Asp Gly Gly Tyr Asp Cys Arg Cys Pro His Gly Lys Asn Cys Thr
 625 630 635 640

Gly Asp Cys Val His Glu Gly Lys Val Lys His Thr Gly Gln Ile Trp
 645 650 655

Val Leu Glu Asn Asp Arg Cys Ser Val Cys Ser Trp Gln Thr Gly Phe
 660 665 670

Val Met Cys Arg Arg Met Val Cys Asp Cys Glu Asn Pro Thr Asp Asp
 675 680 685

Leu Ser Cys Cys Pro Glu Cys Asp Pro Arg Leu Ser Ser Gln Cys Leu
 690 695 700

His Gln Asn Gly Glu Thr Val Tyr Asn Ser Gly Asp Thr Trp Val Gln
 705 710 715 720

Asp Cys Arg Gln Cys Arg Cys Leu Gln Gly Glu Val Asp Cys Trp Pro
 725 730 735

Leu Ala Cys Pro Glu Val Glu Cys Glu Phe Ser Val Leu Pro Glu Asn
 740 745 750

Glu Cys Cys Pro Arg Cys Val Thr Asp Pro Cys Gln Ala Asp Thr Ile
 755 760 765

Arg Asn Asp Ile Thr Lys Thr Cys Leu Asp Glu Met Asn Val Val Arg
 770 775 780

Phe Thr Gly Ser Ser Trp Ile Lys His Gly Thr Glu Cys Thr Leu Cys
 785 790 795 800

Gln Cys Lys Asn Gly His Leu Cys Cys Ser Val Asp Pro Gln Cys Leu
 805 810 815

Gln Glu Leu

<210> SEQ ID NO 13
 <211> LENGTH: 2453
 <212> TYPE: DNA
 <213> ORGANISM: Gallus gallus
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)...(2453)

<400> SEQUENCE: 13

atg gag tcc ggc tgc ggc tta ggc acg ctt tgc ctt ctc ctc tgc ctg	48
Met Glu Ser Gly Cys Gly Leu Gly Thr Leu Cys Leu Leu Leu Cys Leu	
1 5 10 15	
ggg cca gtc gta ggc ttc ggc gtg gac ccc tcg ctg cag atc gac gtg	96
Gly Pro Val Val Gly Phe Gly Val Asp Pro Ser Leu Gln Ile Asp Val	
20 25 30	
ctg tcc gag ctg ggc ctg ccg ggc tac gcg gcg ggc gtg cgc cag gtg	144
Leu Ser Glu Leu Gly Leu Pro Gly Tyr Ala Ala Gly Val Arg Gln Val	
35 40 45	
ccg ggc ctg cac aac ggc agc aaa gcc ttc ctc ttc cca gat act tca	192
Pro Gly Leu His Asn Gly Ser Lys Ala Phe Leu Phe Pro Asp Thr Ser	
50 55 60	
aga agt gta aag gcg tct cca gaa aca gct gaa atc ttt ttt cag aag	240
Arg Ser Val Lys Ala Ser Pro Glu Thr Ala Glu Ile Phe Phe Gln Lys	
65 70 75 80	
ttg aga aat aaa tat gaa ttc aca atc ctg gtg acc tta aaa caa gcc	288
Leu Arg Asn Lys Tyr Glu Phe Thr Ile Leu Val Thr Leu Lys Gln Ala	
85 90 95	

-continued

cat tta aat tca ggg gtt att ttc tct att cat cac tta gat cac agg	336
His Leu Asn Ser Gly Val Ile Phe Ser Ile His His Leu Asp His Arg	
100 105 110	
tat ctg gaa ttg gaa agc agc ggt cat cga aat gaa atc agg ttg cat	384
Tyr Leu Glu Leu Glu Ser Ser Gly His Arg Asn Glu Ile Arg Leu His	
115 120 125	
tac cgt aca ggc agt cat cgc tcc cac aca gaa gta ttc cca tac atc	432
Tyr Arg Thr Gly Ser His Arg Ser His Thr Glu Val Phe Pro Tyr Ile	
130 135 140	
ctg gca gac gat aag tgg cac agg ctt tcc tta gca atc agt gcc tct	480
Leu Ala Asp Asp Lys Trp His Arg Leu Ser Leu Ala Ile Ser Ala Ser	
145 150 155 160	
cac ttg att tta cac gtg gac tgc aat aaa atc tat gaa aga gtt gtg	528
His Leu Ile Leu His Val Asp Cys Asn Lys Ile Tyr Glu Arg Val Val	
165 170 175	
gag aag ccc ttc atg gac tta cct gtg ggt aca acc ttt tgg cta gga	576
Glu Lys Pro Phe Met Asp Leu Pro Val Gly Thr Thr Phe Trp Leu Gly	
180 185 190	
cag agg aat aat gca cac ggt tat ttt aag ggc ata atg caa gat gtg	624
Gln Arg Asn Asn Ala His Gly Tyr Phe Lys Gly Ile Met Gln Asp Val	
195 200 205	
caa tta ctt gtc atg cct caa gga ttt att tct cag tgc cca gat ctt	672
Gln Leu Leu Val Met Pro Gln Gly Phe Ile Ser Gln Cys Pro Asp Leu	
210 215 220	
aat cgg aca tgc cca act tgt aat gat ttc cat gga ctt gtg cag aaa	720
Asn Arg Thr Cys Pro Thr Cys Asn Asp Phe His Gly Leu Val Gln Lys	
225 230 235 240	
att atg gaa ctg caa gac att tta gct aaa acg tca gct aag ctg tcg	768
Ile Met Glu Leu Gln Asp Ile Leu Ala Lys Thr Ser Ala Lys Leu Ser	
245 250 255	
caa gct gag cag agg atg aac aag ttg gat cag tgc tat tgt gaa agg	816
Gln Ala Glu Gln Arg Met Asn Lys Leu Asp Gln Cys Tyr Cys Glu Arg	
260 265 270	
acc tgc aca atg aaa ggc atg aca tac aga gaa ttt gaa tcc tgg aca	864
Thr Cys Thr Met Lys Gly Met Thr Tyr Arg Glu Phe Glu Ser Trp Thr	
275 280 285	
gat ggt tgt aag aac tgc act tgc atg aat ggc act gtg cag tgt gaa	912
Asp Gly Cys Lys Asn Cys Thr Cys Met Asn Gly Thr Val Gln Cys Glu	
290 295 300	
gct ttg att tgc tcc ctc tct gac tgt cca cct aat tct gcc ctg tca	960
Ala Leu Ile Cys Ser Leu Ser Asp Cys Pro Pro Asn Ser Ala Leu Ser	
305 310 315 320	
tac gtg gat ggc aag tgc tgc aaa gaa tgt caa tcg gtg tgc ata ttt	1008
Tyr Val Asp Gly Lys Cys Cys Lys Glu Cys Gln Ser Val Cys Ile Phe	
325 330 335	
gaa ggc aga acc tac ttt gaa gga caa aga gaa acg gtg tat tca agc	1056
Glu Gly Arg Thr Tyr Phe Glu Gly Gln Arg Glu Thr Val Tyr Ser Ser	
340 345 350	
tca ggg gac tgt gtt ctg ttt gag tgc aag gac cac aaa atg cag cgt	1104
Ser Gly Asp Cys Val Leu Phe Glu Cys Lys Asp His Lys Met Gln Arg	
355 360 365	
att cca aaa gac agt tgt gca act ttg aac tgc ccg gaa tct caa cag	1152
Ile Pro Lys Asp Ser Cys Ala Thr Leu Asn Cys Pro Glu Ser Gln Gln	
370 375 380	
atc cca tta tct cac agt tgc tgc aaa atc tgt aaa ggc cat gac ttt	1200
Ile Pro Leu Ser His Ser Cys Cys Lys Ile Cys Lys Gly His Asp Phe	
385 390 395 400	

-continued

tgc act gaa gga cat aac tgt atg gag cat tct gtc tgc cga aac cta	1248
Cys Thr Glu Gly His Asn Cys Met Glu His Ser Val Cys Arg Asn Leu	
405 410 415	
gat gac aga gct gtc tgt agc tgc cga gat ggc ttc cgg gcc ctt cgg	1296
Asp Asp Arg Ala Val Cys Ser Cys Arg Asp Gly Phe Arg Ala Leu Arg	
420 425 430	
gag gac aat gcc tac tgt gaa gat gtt gat gag tgt gcc gag ggg cag	1344
Glu Asp Asn Ala Tyr Cys Glu Asp Val Asp Glu Cys Ala Glu Gly Gln	
435 440 445	
cac tac tgt cgg gag aac acc atg tgt gta aat aca cca gga tcc ttc	1392
His Tyr Cys Arg Glu Asn Thr Met Cys Val Asn Thr Pro Gly Ser Phe	
450 455 460	
atg tgc atc tgc aaa aca gga tat ata cgc att gat gac tat tca tgt	1440
Met Cys Ile Cys Lys Thr Gly Tyr Ile Arg Ile Asp Asp Tyr Ser Cys	
465 470 475 480	
aca gag cac gat gaa tgt gta aca aac cag cac aac tgt gat gaa aat	1488
Thr Glu His Asp Glu Cys Val Thr Asn Gln His Asn Cys Asp Glu Asn	
485 490 495	
gcg cta tgt ttc aac acg gtg ggt ggg cac aac tgt gtc tgc aag ctg	1536
Ala Leu Cys Phe Asn Thr Val Gly Gly His Asn Cys Val Cys Lys Leu	
500 505 510	
ggt tac aca gga aat ggg acg gtg tgt aaa gca ttt tgc aaa gat ggg	1584
Gly Tyr Thr Gly Asn Gly Thr Val Cys Lys Ala Phe Cys Lys Asp Gly	
515 520 525	
tgc agg aat gga gga gcc tgt att gct tcc aac gtg tgt gcc tgc cca	1632
Cys Arg Asn Gly Gly Ala Cys Ile Ala Ser Asn Val Cys Ala Cys Pro	
530 535 540	
caa ggc ttc act ggc ccc agc tgt gaa act gac att gat gaa tgc tct	1680
Gln Gly Phe Thr Gly Pro Ser Cys Glu Thr Asp Ile Asp Glu Cys Ser	
545 550 555 560	
gat ggc ttt gtg cag tgt gac agc cgt gct aat tgc atc aat ctg cca	1728
Asp Gly Phe Val Gln Cys Asp Ser Arg Ala Asn Cys Ile Asn Leu Pro	
565 570 575	
ggg tgg tac cac tgt gaa tgc agg gat ggc tac cat gac aat ggg atg	1776
Gly Trp Tyr His Cys Glu Cys Arg Asp Gly Tyr His Asp Asn Gly Met	
580 585 590	
ttt tca cca agt gga gaa tcc tgt gaa gac att gat gaa tgt gca act	1824
Phe Ser Pro Ser Gly Glu Ser Cys Glu Asp Ile Asp Glu Cys Ala Thr	
595 600 605	
gga agg cat agc tgt gcc aat gac act gtt tgc ttt aac ctg gat ggt	1872
Gly Arg His Ser Cys Ala Asn Asp Thr Val Cys Phe Asn Leu Asp Gly	
610 615 620	
ggg tat gac tgt cga tgt cca cat ggc aag aac tgc aca gga gac tgt	1920
Gly Tyr Asp Cys Arg Cys Pro His Gly Lys Asn Cys Thr Gly Asp Cys	
625 630 635 640	
atc cat gaa gac aaa atc aag cac aat ggt cag att tgg gtg ctg gag	1968
Ile His Glu Asp Lys Ile Lys His Asn Gly Gln Ile Trp Val Leu Glu	
645 650 655	
aac gac aga tgc tct gtc tgc tca tgc cag agt gga tac gtg atg tgc	2016
Asn Asp Arg Cys Ser Val Cys Ser Cys Gln Ser Gly Tyr Val Met Cys	
660 665 670	
cgg cga atg gtc tgt gac tgt gaa aat ccc act gtt gac ctc ttt tgc	2064
Arg Arg Met Val Cys Asp Cys Glu Asn Pro Thr Val Asp Leu Phe Cys	
675 680 685	
tgt cct gag tgt gac cca agg ctc agc agt caa tgt tta cat cag agt	2112
Cys Pro Glu Cys Asp Pro Arg Leu Ser Ser Gln Cys Leu His Gln Ser	
690 695 700	

-continued

ggg gag ctt tcc tac aac agt ggt gac tcc tgg ata caa aac tgt cag	2160
Gly Glu Leu Ser Tyr Asn Ser Gly Asp Ser Trp Ile Gln Asn Cys Gln	
705 710 715 720	
cag tgt cgc tgc ttg caa gga gag gtt gac tgt tgg ccc tta ccg tgc	2208
Gln Cys Arg Cys Leu Gln Gly Glu Val Asp Cys Trp Pro Leu Pro Cys	
725 730 735	
cca gag gta gac tgt gag ttc agt gtc ctc cct gag aat gag tgc tgc	2256
Pro Glu Val Asp Cys Glu Phe Ser Val Leu Pro Glu Asn Glu Cys Cys	
740 745 750	
cca cgc tgt gtc act gac ccc tgc caa gcg gac acc atc cgt aat gac	2304
Pro Arg Cys Val Thr Asp Pro Cys Gln Ala Asp Thr Ile Arg Asn Asp	
755 760 765	
atc acc aaa acc tgc ctg gat gaa acc aat gtt gtt cgc ttc act gga	2352
Ile Thr Lys Thr Cys Leu Asp Glu Thr Asn Val Val Arg Phe Thr Gly	
770 775 780	
tct tct tgg att aag cat ggc aca gag tgc aca ctc tgc caa tgt aag	2400
Ser Ser Trp Ile Lys His Gly Thr Glu Cys Thr Leu Cys Gln Cys Lys	
785 790 795 800	
aat ggc cac gtc tgt tgc tca gtg gat cca cag tgc ctt cag gaa ctg	2448
Asn Gly His Val Cys Cys Ser Val Asp Pro Gln Cys Leu Gln Glu Leu	
805 810 815	
tga ca	2453
*	

<210> SEQ ID NO 14

<211> LENGTH: 816

<212> TYPE: PRT

<213> ORGANISM: Gallus gallus

<400> SEQUENCE: 14

Met Glu Ser Gly Cys Gly Leu Gly Thr Leu Cys Leu Leu Leu Cys Leu	
1 5 10 15	
Gly Pro Val Val Gly Phe Gly Val Asp Pro Ser Leu Gln Ile Asp Val	
20 25 30	
Leu Ser Glu Leu Gly Leu Pro Gly Tyr Ala Ala Gly Val Arg Gln Val	
35 40 45	
Pro Gly Leu His Asn Gly Ser Lys Ala Phe Leu Phe Pro Asp Thr Ser	
50 55 60	
Arg Ser Val Lys Ala Ser Pro Glu Thr Ala Glu Ile Phe Phe Gln Lys	
65 70 75 80	
Leu Arg Asn Lys Tyr Glu Phe Thr Ile Leu Val Thr Leu Lys Gln Ala	
85 90 95	
His Leu Asn Ser Gly Val Ile Phe Ser Ile His His Leu Asp His Arg	
100 105 110	
Tyr Leu Glu Leu Glu Ser Ser Gly His Arg Asn Glu Ile Arg Leu His	
115 120 125	
Tyr Arg Thr Gly Ser His Arg Ser His Thr Glu Val Phe Pro Tyr Ile	
130 135 140	
Leu Ala Asp Asp Lys Trp His Arg Leu Ser Leu Ala Ile Ser Ala Ser	
145 150 155 160	
His Leu Ile Leu His Val Asp Cys Asn Lys Ile Tyr Glu Arg Val Val	
165 170 175	
Glu Lys Pro Phe Met Asp Leu Pro Val Gly Thr Thr Phe Trp Leu Gly	
180 185 190	
Gln Arg Asn Asn Ala His Gly Tyr Phe Lys Gly Ile Met Gln Asp Val	

-continued

195					200					205					
Gln	Leu	Leu	Val	Met	Pro	Gln	Gly	Phe	Ile	Ser	Gln	Cys	Pro	Asp	Leu
210						215					220				
Asn	Arg	Thr	Cys	Pro	Thr	Cys	Asn	Asp	Phe	His	Gly	Leu	Val	Gln	Lys
225					230					235					240
Ile	Met	Glu	Leu	Gln	Asp	Ile	Leu	Ala	Lys	Thr	Ser	Ala	Lys	Leu	Ser
				245					250					255	
Gln	Ala	Glu	Gln	Arg	Met	Asn	Lys	Leu	Asp	Gln	Cys	Tyr	Cys	Glu	Arg
			260					265					270		
Thr	Cys	Thr	Met	Lys	Gly	Met	Thr	Tyr	Arg	Glu	Phe	Glu	Ser	Trp	Thr
		275					280					285			
Asp	Gly	Cys	Lys	Asn	Cys	Thr	Cys	Met	Asn	Gly	Thr	Val	Gln	Cys	Glu
	290					295					300				
Ala	Leu	Ile	Cys	Ser	Leu	Ser	Asp	Cys	Pro	Pro	Asn	Ser	Ala	Leu	Ser
305					310					315					320
Tyr	Val	Asp	Gly	Lys	Cys	Cys	Lys	Glu	Cys	Gln	Ser	Val	Cys	Ile	Phe
				325					330					335	
Glu	Gly	Arg	Thr	Tyr	Phe	Glu	Gly	Gln	Arg	Glu	Thr	Val	Tyr	Ser	Ser
			340					345					350		
Ser	Gly	Asp	Cys	Val	Leu	Phe	Glu	Cys	Lys	Asp	His	Lys	Met	Gln	Arg
	355						360					365			
Ile	Pro	Lys	Asp	Ser	Cys	Ala	Thr	Leu	Asn	Cys	Pro	Glu	Ser	Gln	Gln
370						375						380			
Ile	Pro	Leu	Ser	His	Ser	Cys	Cys	Lys	Ile	Cys	Lys	Gly	His	Asp	Phe
385					390					395					400
Cys	Thr	Glu	Gly	His	Asn	Cys	Met	Glu	His	Ser	Val	Cys	Arg	Asn	Leu
				405					410					415	
Asp	Asp	Arg	Ala	Val	Cys	Ser	Cys	Arg	Asp	Gly	Phe	Arg	Ala	Leu	Arg
			420					425					430		
Glu	Asp	Asn	Ala	Tyr	Cys	Glu	Asp	Val	Asp	Glu	Cys	Ala	Glu	Gly	Gln
		435					440					445			
His	Tyr	Cys	Arg	Glu	Asn	Thr	Met	Cys	Val	Asn	Thr	Pro	Gly	Ser	Phe
	450					455					460				
Met	Cys	Ile	Cys	Lys	Thr	Gly	Tyr	Ile	Arg	Ile	Asp	Asp	Tyr	Ser	Cys
465					470					475					480
Thr	Glu	His	Asp	Glu	Cys	Val	Thr	Asn	Gln	His	Asn	Cys	Asp	Glu	Asn
				485					490					495	
Ala	Leu	Cys	Phe	Asn	Thr	Val	Gly	Gly	His	Asn	Cys	Val	Cys	Lys	Leu
			500					505					510		
Gly	Tyr	Thr	Gly	Asn	Gly	Thr	Val	Cys	Lys	Ala	Phe	Cys	Lys	Asp	Gly
		515					520					525			
Cys	Arg	Asn	Gly	Gly	Ala	Cys	Ile	Ala	Ser	Asn	Val	Cys	Ala	Cys	Pro
	530					535					540				
Gln	Gly	Phe	Thr	Gly	Pro	Ser	Cys	Glu	Thr	Asp	Ile	Asp	Glu	Cys	Ser
545					550					555					560
Asp	Gly	Phe	Val	Gln	Cys	Asp	Ser	Arg	Ala	Asn	Cys	Ile	Asn	Leu	Pro
				565					570					575	
Gly	Trp	Tyr	His	Cys	Glu	Cys	Arg	Asp	Gly	Tyr	His	Asp	Asn	Gly	Met
			580					585					590		
Phe	Ser	Pro	Ser	Gly	Glu	Ser	Cys	Glu	Asp	Ile	Asp	Glu	Cys	Ala	Thr
		595					600					605			

-continued

Gly Arg His Ser Cys Ala Asn Asp Thr Val Cys Phe Asn Leu Asp Gly
610 615 620

Gly Tyr Asp Cys Arg Cys Pro His Gly Lys Asn Cys Thr Gly Asp Cys
625 630 635 640

Ile His Glu Asp Lys Ile Lys His Asn Gly Gln Ile Trp Val Leu Glu
645 650 655

Asn Asp Arg Cys Ser Val Cys Ser Cys Gln Ser Gly Tyr Val Met Cys
660 665 670

Arg Arg Met Val Cys Asp Cys Glu Asn Pro Thr Val Asp Leu Phe Cys
675 680 685

Cys Pro Glu Cys Asp Pro Arg Leu Ser Ser Gln Cys Leu His Gln Ser
690 695 700

Gly Glu Leu Ser Tyr Asn Ser Gly Asp Ser Trp Ile Gln Asn Cys Gln
705 710 715 720

Gln Cys Arg Cys Leu Gln Gly Glu Val Asp Cys Trp Pro Leu Pro Cys
725 730 735

Pro Glu Val Asp Cys Glu Phe Ser Val Leu Pro Glu Asn Glu Cys Cys
740 745 750

Pro Arg Cys Val Thr Asp Pro Cys Gln Ala Asp Thr Ile Arg Asn Asp
755 760 765

Ile Thr Lys Thr Cys Leu Asp Glu Thr Asn Val Val Arg Phe Thr Gly
770 775 780

Ser Ser Trp Ile Lys His Gly Thr Glu Cys Thr Leu Cys Gln Cys Lys
785 790 795 800

Asn Gly His Val Cys Cys Ser Val Asp Pro Gln Cys Leu Gln Glu Leu
805 810 815

What is claimed is:

1. A method of expressing a functional peptide in an insect cell, said method comprising:

providing a nucleic acid construct including at least a nucleic acid encoding at least a NELL1 peptide in frame with a nucleic acid encoding an insect secretory signal peptide;

transfecting an insect cell with said nucleic acid construct;

culturing said insect cell under conditions that permit expression of the NELL1 peptide;

optionally collecting NELL1 peptide secreted from the cell line;

optionally substantially purifying the NELL1 peptide; and

optionally testing the activity of the NELL1 peptide.

2. The method of claim 1, wherein said insect cell is a high five cell.

3. The method of claim 1, wherein said insect secretory signal peptide is a melittin signal sequence.

4. The method of claim 1, wherein the nucleic acid encoding NELL1 is selected from the group comprising: SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5.

5. The method of claim 1, wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6.

6. A nucleic acid construct for expressing a NELL1 peptide in an insect cell, said nucleic acid construct comprising at least a nucleic acid encoding at least a NELL1 peptide in frame with a nucleic acid encoding an insect secretory signal peptide.

7. The nucleic acid of claim 5, wherein said insect secretory signal peptide is a melittin signal sequence.

8. The nucleic acid of claim 5, wherein the nucleic acid encoding NELL1 is selected from the group comprising: SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5.

9. The nucleic acid of claim 5, wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6.

10. A cell line for expressing a functional NELL1 peptide, said cell line including a nucleic acid construct comprising at least a nucleic acid encoding at least a NELL1 peptide in frame with a nucleic acid encoding an insect secretory signal peptide.

11. The cell of claim 10, wherein said cell is an insect cell.

12. The cell of claim 11, wherein said cell is a high five cell.

13. The cell of claim 10, wherein said cell secretes said NELL1 peptide.

14. The cell of claim 10, wherein said secretory signal peptide is a melittin signal sequence.

15. The cell of claim 10, wherein the nucleic acid encoding NELL1 peptide is selected from the group comprising: SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5.

16. The method of claim 1, wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6.

17. A polypeptide comprising a NELL1 peptide and an insect secretory signal peptide.

18. The polypeptide of claim 16, wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6.

19. The polypeptide of claim 17, wherein said secretory signal peptide is a melittin signal sequence.

20. A method of expressing a functional peptide in a mammalian cell, said method comprising:

providing a nucleic acid construct including at least a nucleic acid encoding at least a NELL1 peptide in frame with a nucleic acid encoding a secretory signal peptide;

transfecting a mammalian cell with said nucleic acid construct;

culturing said mammalian cell under conditions that permit expression of the NELL1 peptide;

optionally collecting NELL1 peptide secreted from the cell line;

optionally substantially purifying the NELL1 peptide; and

optionally testing the activity of the NELL1 peptide to induce bone formation.

21. The method of claim 20, wherein said insect cell is a COS7 cell.

22. The method of claim 20, wherein said insect secretory signal peptide is a NELL peptide signal sequence.

23. The method of claim 20, wherein the nucleic acid encoding NELL1 is selected from the group comprising: SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5.

24. The method of claim 20, wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6.

25. A nucleic acid construct for expressing a NELL1 peptide in a mammalian cell, said nucleic acid construct comprising at least a nucleic acid encoding at least a NELL1 peptide in frame with a nucleic acid encoding a secretory signal peptide.

26. The nucleic acid of claim 24, wherein said insect secretory signal peptide is a NELL peptide signal sequence.

27. The nucleic acid of claim 24, wherein the nucleic acid encoding NELL1 is selected from the group comprising: SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5.

28. The nucleic acid of claim 24, wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6.

29. A cell line for expressing a functional NELL1 peptide, said cell line including a nucleic acid construct comprising at least a nucleic acid encoding at least a NELL1 peptide in frame with a nucleic acid encoding a secretory signal peptide.

30. The cell of claim 29, wherein said cell is a mammalian cell.

31. The cell of claim 30, wherein said cell is a COS7 cell.

32. The cell of claim 29, wherein said cell secretes said NELL1 peptide.

33. The cell of claim 29, wherein said secretory signal peptide is a NELL peptide signal sequence.

34. The cell of claim 29, wherein the nucleic acid encoding NELL1 peptide is selected from the group comprising: SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5.

35. The method of claim 20, wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6.

36. A polypeptide comprising a NELL1 peptide and a secretory signal peptide.

37. The polypeptide of claim 35, wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6.

38. The polypeptide of claim 35, wherein said secretory signal peptide is a NELL peptide signal sequence.

39. A method of expressing a functional peptide in an insect cell, said method comprising:

providing a nucleic acid construct including at least a nucleic acid encoding at least a NELL2 peptide and an insect secretory signal peptide in frame with the NELL2 peptide;

transfecting an insect cell with said nucleic acid construct;

culturing said insect cell under conditions that permit expression of the NELL2 peptide;

optionally collecting NELL2 peptide secreted from the cell line;

optionally substantially purifying the NELL2 peptide; and

optionally testing the activity of the NELL2 peptide.

40. The method of claim 39, wherein said insect cell is a high five cell.

41. The method of claim 39, wherein said insect secretory signal peptide is a melittin signal sequence.

42. The method of claim 39, wherein the nucleic acid encoding NELL2 is selected from the group comprising: SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11 or SEQ ID NO:13.

43. The method of claim 39, wherein the NELL2 peptide is selected from the group comprising: SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12 or SEQ ID NO: 14.

44. A nucleic acid construct for expressing a NELL2 peptide in an insect cell, said nucleic acid construct comprising at least a nucleic acid encoding at least a NELL2 peptide in frame with a nucleic acid encoding an insect secretory signal peptide.

45. The nucleic acid of claim 43, wherein said insect secretory signal peptide is a melittin signal sequence.

46. The nucleic acid of claim 43, wherein the nucleic acid encoding NELL2 is selected from the group comprising: SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11 or SEQ ID NO:13.

47. The nucleic acid of claim 43, wherein the NELL2 peptide is selected from the group comprising: SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12 or SEQ ID NO:14.

48. A cell line for expressing a functional NELL2 peptide, said cell line including a nucleic acid construct comprising at least a nucleic acid encoding at least a NELL2 peptide in frame with a nucleic acid encoding an insect secretory signal peptide.

49. The cell of claim 48, wherein said cell is an insect cell.

50. The cell of claim 49, wherein said cell is a high five cell.

51. The cell of claim 48, wherein said cell secretes said NELL2 peptide.

52. The cell of claim 48, wherein said secretory signal peptide is a melittin signal sequence.

53. The cell of claim 48, wherein the nucleic acid encoding NELL2 peptide is selected from the group comprising: SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, or SEQ ID NO:13.

54. The method of claim 39, wherein the NELL2 peptide is selected from the group comprising: SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14.

55. A polypeptide comprising a NELL2 peptide and an insect secretory signal peptide.

56. The polypeptide of claim 55, wherein the NELL2 peptide is selected from the group comprising: SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14.

57. The polypeptide of claim 55, wherein said secretory signal peptide is a melittin signal sequence.

58. A method of expressing a functional peptide in a mammalian cell, said method comprising:

providing a nucleic acid construct including at least a nucleic acid encoding at least a NELL2 peptide and a nucleic acid encoding a secretory signal peptide in frame with the NELL2 peptide;

transfecting an insect cell with said nucleic acid construct; culturing said insect cell under conditions that permit expression of the NELL2 peptide;

optionally collecting NELL2 peptide secreted from the cell line;

optionally substantially purifying the NELL2 peptide; and

optionally testing the activity of the NELL2 peptide to promote neuronal cell survival.

59. The method of claim 58, wherein said mammalian cell is a COS7 cell.

60. The method of claim 58, wherein said mammalian secretory signal peptide is a NELL peptide signal sequence.

61. The method of claim 58, wherein the nucleic acid encoding NELL1 is selected from the group comprising: SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, or SEQ ID NO:13.

62. The method of claim 58, wherein the NELL2 peptide is selected from the group comprising: SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14.

63. A nucleic acid construct for expressing a NELL2 peptide in a mammalian cell, said nucleic acid construct comprising at least a nucleic acid encoding at least a NELL2 peptide in frame with a nucleic acid encoding a secretory signal peptide.

64. The nucleic acid of claim 63, wherein said mammalian secretory signal peptide is a NELL peptide signal sequence.

65. The nucleic acid of claim 63, wherein the nucleic acid encoding NELL2 is selected from the group comprising: SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, or SEQ ID NO:13.

66. The nucleic acid of claim 63, wherein the NELL2 peptide is selected from the group comprising: SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14.

67. A cell line for expressing a functional NELL2 peptide, said cell line including a nucleic acid construct comprising at least a nucleic acid encoding at least a NELL2 peptide in frame with a nucleic acid encoding a secretory signal peptide.

68. The cell of claim 67, wherein said cell is a mammalian cell.

69. The cell of claim 68, wherein said cell is a COS7 cell.

70. The cell of claim 67, wherein said cell secretes said NELL2 peptide.

71. The cell of claim 67, wherein said secretory signal peptide is a NELL peptide signal sequence.

72. The cell of claim 67, wherein the nucleic acid encoding NELL2 peptide is selected from the group comprising: SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, or SEQ ID NO:13.

73. The method of claim 58, wherein the NELL2 peptide is selected from the group comprising: SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12 or SEQ ID NO:14.

74. A method of increasing osteogenic cell differentiation comprising:

increasing the concentration of a NELL1 gene product in an osteogenic cell;

optionally applying a second osteogenic agent; and

inducing the expression of cellular marker of osteoblastic differentiation.

75. The method of claim 74, wherein the increasing the concentration of a NELL1 gene product comprises applying a NELL1 peptide to an osteogenic cell.

76. The method of claim 74 wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO: 4, or SEQ ID NO:6.

77. The method of claim 74, wherein the increasing the concentration of a NELL1 gene product comprises inducing the expression of an endogenous NELL1 gene.

78. The method of claim 77 wherein increasing the concentration of a NELL1 gene product comprises increasing cellular levels of Cbfa1.

79. The method of claim 74, wherein the increasing the concentration of a NELL1 gene product comprises transfecting the osteogenic cell with a nucleic acid construct encoding a NELL1 peptide.

80. The method of claim 74 wherein the nucleic acid construct encoding a NELL1 peptide comprises at least one selected from the group: SEQ ID NO:1, SEQ ID NO: 3, or SEQ ID NO:5.

81. The method of claim 74 wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO: 4, or SEQ ID NO:6.

82. The method of claim 74 wherein the osteogenic cell is selected from the group comprising: an osteoblast, a mesenchymal cell, a fibroblast, fetal embryonic cell, a stem cell, a bone marrow cell, a dura cell, a chondrocytes, a chondroblast, primary calvarial cells, stem cells, adipose stem cells.

83. The method of claim 74, wherein the second osteogenic peptide is selected from the group comprising: TGF- β , BMP2, BMP4, BMP7, bFGF, collagen.

84. The method of claim 74 wherein the induced cellular marker of osteoblastic differentiation is selected from the group comprising: alkaline phosphatase activity, osteocalcin mRNA expression, osteoponin mRNA expression, decorin expression, and laminin B expression.

85. A method of increasing osteoblastic mineralization comprising:

increasing the concentration of a NELL1 gene product in an osteogenic cell;

optionally applying an agent to the osteogenic cell; and

inducing the expression of cellular marker of mineralization.

86. The method of claim 85, wherein the increasing the concentration of a NELL1 gene product comprises applying a NELL1 peptide to an osteogenic cell.

87. The method of claim 85 wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO: 4, or SEQ ID NO:6.

88. The method of claim 85, wherein the increasing the concentration of a NELL1 gene product comprises inducing the expression of an endogenous NELL1 gene.

89. The method of claim 88 wherein increasing the concentration of a NELL1 gene product comprises increasing cellular levels of Cbfa1.

90. The method of claim 85, wherein the increasing the concentration of a NELL1 gene product comprises transfecting the osteogenic cell with a nucleic acid construct encoding a NELL1 peptide.

91. The method of claim 85 wherein the nucleic acid construct encoding a NELL1 peptide comprises at least one selected from the group: SEQ ID NO:1, SEQ ID NO: 3, or SEQ ID NO:5.

92. The method of claim 85 wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO: 4, or SEQ ID NO:6.

93. The method of claim 85 wherein the osteogenic cell is selected from the group comprising: an osteoblast, a mesenchymal cell, a fibroblast, fetal embryonic cell, a stem cell, a bone marrow cell, a dura cell, a chondrocytes, a chondroblast, primary calvarial cells, stem cells, adipose stem cells.

94. The method of claim 85, wherein the second osteogenic agent is selected from the group comprising: TGF- β , BMP2, BMP4, BMP7, bFGF, collagen.

95. The method of claim 85 wherein the induced cellular marker of mineralization is selected from the group comprising: calcium incorporation.

96. A method of increasing intramembraneous bone formation comprising:

increasing the concentration of a NELL1 gene product in a region where bone formation is desired;

optionally applying a second agent to approximately the same region where bone formation is desired; and

inducing the formation of intramembraneous bone formation.

97. The method of claim 96, wherein the increasing the concentration of a NELL1 gene product comprises applying a NELL1 peptide to the region where bone formation is desired.

98. The method of claim 96 wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO: 4, or SEQ ID NO:6.

99. The method of claim 96, wherein the increasing the concentration of a NELL1 gene product comprises inducing the expression of an endogenous NELL1 gene.

100. The method of claim 96, wherein the increasing the concentration of a NELL1 gene product comprises transfecting cell with a nucleic acid construct encoding a NELL1 peptide, and applying the cells in proximity to the region where bone formation is desired

101. The method of claim 96 wherein the nucleic acid construct encoding a NELL1 peptide comprises at least one selected from the group: SEQ ID NO:1, SEQ ID NO: 3, or SEQ ID NO:5.

102. The method of claim 96 wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO: 4, or SEQ ID NO:6.

103. The method of claim 96, wherein the agent is selected from the group comprising: TGF- β , BMP2, BMP4, BMP7, bFGF, collagen, bone, matrix, ligament matrix, tendon matrix, osteogenic cells or osteoblastic cells.

104. The method of claim 96 wherein inducing the formation of intramembraneous bone is evaluated by CT, gene expression, histology, mechanical testing.

105. A method of increasing endochondral bone formation comprising:

increasing the concentration of a NELL1 gene product in a region where bone formation and or healing and or regeneration is desired;

optionally applying an agent to the region where bone formation is desired; and

at least inducing hypertrophy of chondroblast in the region where bone formation is desired.

106. The method of claim 105, wherein bone formation includes bone healing or bone regeneration.

107. The method of claim 105, wherein the increasing the concentration of a NELL1 gene product comprises applying a NELL1 peptide to the region where bone formation is desired.

108. The method of claim 105 wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO: 4, or SEQ ID NO:6.

109. The method of claim 105, wherein the increasing the concentration of a NELL1 gene product comprises inducing the expression of an endogenous NELL1 gene.

110. The method of claim 105, wherein the increasing the concentration of a NELL1 gene product comprises transfecting cell with a nucleic acid construct encoding a NELL1 peptide, and applying the cells in proximity to the region where bone formation is desired

111. The method of claim 110 wherein the nucleic acid construct encoding a NELL1 peptide comprises at least one selected from the group: SEQ ID NO:1, SEQ ID NO: 3, or SEQ ID NO:5.

112. The method of claim 110 wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO: 4, or SEQ ID NO:6.

113. The method of claim 105, wherein the agent is selected from the group comprising: TGF- β , BMP2, BMP4, BMP7, bFGF, collagen, bone, matrix, ligament matrix, tendon matrix, osteogenic cells or osteoblastic cells.

114. The method of claim 105 wherein inducing the chondroblast hypertrophy causes an increase in apoptotic chondroblasts

115. A method of increasing bone formation in proximity to a vertebra, comprising:

increasing the concentration of a NELL1 gene product proximate to a vertebra where spinal fusion is desired;

optionally applying an additional active agent proximate to a vertebra where spinal fusion is desired; and

inducing chondroblast hypertrophy or osteoblast differentiation in the region where spinal fusion is desired.

116. The method of claim 115, further including increasing osteoblastic differentiation.

117. The method of claim 115, further including increasing osteoblastic mineralization.

118. The method of claim 115, further including inducing membranous bone formation.

119. The method of claim 115, wherein the increasing the concentration of a NELL1 gene product comprises applying a NELL1 peptide to the region where spinal fusion is desired.

120. The method of claim 115 wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO: 4, or SEQ ID NO:6.

121. The method of claim 115, wherein the increasing the concentration of a NELL1 gene product comprises inducing the expression of an endogenous NELL1 gene.

122. The method of claim 115, wherein the increasing the concentration of a NELL1 gene product comprises transfecting cell with a nucleic acid construct encoding a NELL1 peptide, and applying the cells in proximity to the region where spinal fusion is desired

123. The method of claim 122 wherein the nucleic acid construct encoding a NELL1 peptide comprises at least one selected from the group: SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5.

124. The method of claim 122 wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO: 4, or SEQ ID NO:6.

125. The method of claim 115, wherein the agent is selected from the group comprising: TGF- β , BMP2, BMP4, BMP7, bFGF, collagen, bone, matrix, ligament matrix, tendon matrix, osteogenic cells or osteoblastic cells.

126. A composition for inducing bone formation comprising:

An effective amount of a first agent to induce bone formation selected from the group comprising: a NELL1 peptide, and an agent that alters expression of NELL1 peptide, or an agent that alters the activity of a NELL1 peptide; and

optionally a carrier.

127. The composition of claim 126 wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO: 4, or SEQ ID NO:6.

128. The composition of claim 126 wherein the agent is selected from the group comprising: TGF- β , BMP2, BMP4, BMP7, bFGF, collagen.

129. The composition of claim 126 wherein the agent is selected from the group comprising: bone matrix, tendon matrix or ligament matrix, osteogenic cells or osteoblastic cells.

130. The composition of claim 126, where the carrier is degradable by enzymatic or hydrolytic mechanisms.

131. The composition of claim 126, where the carrier is comprised a synthetic polymers selected from the group comprising: poly(α -hydroxy acids) such as poly(L-lactide), poly(D, L-lactide), polyglycolide, poly(lactide-co-glycolide), poly(-caprolactone), poly(trimethylene carbonate), poly(p-dioxanone), poly(-caprolactone-co-glycolide), poly(glycolide-co-trimethylene carbonate) poly(D, L-lactide-co-trimethylene carbonate), polyarylates, polyhydroxybutyrate, polyanhydrides, poly(anhydride-co-imide), propylene-co-fumarates, polylactones, polyesters, polycarbonates, polyanionic polymers, polyanhydrides, polyester-amides, poly(amino-acids), homopolypeptides, poly(phosphazenes),

poly (glaxanone), polysaccharides, and poly(orthoesters), polyglactin, polyglactic acid, polyaldonic acid, polyacrylic acids, polyalkanoates.

132. The composition of claim 126, where the carrier is comprised of a cellulosic polymer selected from the group comprising: to alkylcellulose, hydroxyalkylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, carboxymethylcellulose, and their cationic salts.

133. The composition of claim 126, where the carrier is comprised of a synthetic or natural bioceramic selected from the group comprising: calcium carbonate, calcium phosphate, apatite, bioactive glass material, and coral-derived apatite.

134. The composition of claim 126, where the carrier is selected from the group including: collagen, hyaluronan, fibrin, chitosan, alginate, and gelatin.

135. The composition of claim 126, further comprising heparin-binding agents selected from the group comprising dextran sulfate, chondroitin sulfate, heparan sulfate, fucan, alginate.

136. The composition of claim 126, where the carrier is in the form a flowable gel.

137. The composition of claim 126, where the carrier is photopolymerizable.

138. The composition of claim 126, where the carrier is temperature sensitive.

139. The composition of claim 126, where the composition further includes a sequestering agent selected from the group comprising: collagen, gelatin, hyaluronic acid, alginate, poly(ethylene glycol), alkylcellulose (including hydroxyalkylcellulose), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, blood, fibrin, polyoxyethylene oxide, calcium sulfate hemihydrate, apatites, carboxyvinyl polymer, or poly(vinyl alcohol).

140. The composition of claim 126, where the composition further includes a surfactant selected from the group comprising: polysorbate 80, polysorbate 20 or Pluronic F-68.

141. The composition of claim 126, wherein the composition further includes a buffering agent selected from the group comprising: glycine, glutamic acid hydrochloride, sodium chloride, guanidine, heparin, glutamic acid hydrochloride, acetic acid, succinic acid, polysorbate, dextran sulfate, sucrose, and amino acids.

142. A method of treating a patient to increase intramembraneous bone formation, comprising administering NELL1 peptide at a therapeutically effective dose in an effective dosage form at a selected interval to enhance bone formation.

143. The method of claim 142, further comprising administering at least one agent in the region where bone formation is desired selected from the group comprising: TGF- β , BMP2, BMP4, BMP7, bFGF, collagen, bone matrix, tendon matrix or ligament matrix.

144. A method of treating a patient to induce bone formation comprising:

harvesting mammalian osteogenic cells;

increasing the concentration of NELL1 peptide in contact with the osteogenic cells;

administering the osteogenic cells to a region where bone formation is desired.

145. The method of claim 144 wherein the increasing the concentration of expression of NELL1 peptide in contact with the osteogenic cells comprises applying a composition including a NELL1 peptide to the osteogenic cells.

146. The method of claim 144 wherein increasing the concentration of expression of NELL1 peptide in contact with the osteogenic cells comprises inducing the endogenous expression of NELL1 peptide.

147. The method of claim 144 wherein increasing the concentration of expression of NELL1 peptide in contact with the osteogenic cells comprises transfecting the cells with a nucleic acid construct expressing NELL1 peptide.

148. The method of claims **145**, **146** or **147**, wherein the NELL1 peptide is selected from the group comprising: SEQ ID NO:2, SEQ ID NO: 4, or SEQ ID NO:6.

149. The method of claim 145, 146 or **147**, further comprising administering at least one agent in the region where bone formation is desired selected from the group comprising: TGF- β , BMP2, BMP4, BMP7, bFGF, collagen, bone, matrix, ligament matrix, tendon matrix, osteogenic cells or osteoblastic cells.

150. An implant for use in the human body comprising, a substrate wherein the substrate includes NELL1 in an amount sufficient to induce bone formation proximate to the implant.

151. An implant for use in the human body comprising, a substrate having a surface, wherein at least a portion of the surface includes NELL1 in an amount sufficient to induce bone formation proximate to the implant.

152. An implant for use in the human body comprising: a substrate having a surface, wherein at least a portion of the surface includes osteogenic cells, and the substrate comprises NELL1 in an amount sufficient to induce bone formation.

153. The implant of claim 145, 146 or **147**, wherein the substrate is formed into the shape of a mesh, pin, screw, plate, or prosthetic joint.

154. The implant of 145, 146 or 147, wherein the substrate is resorbable.

155. The implant of claim 145, 146 or **147**, wherein the substrate comprises collagen.

* * * * *